timestamp,question,success,status_code,response_time,error,response_id,answer_length,answer_preview,qa_score,qa_combination,qa_badge,qa_directly_answers,qa_addresses_question,qa_grounded_in_context,qa_assessment,qa_assessment_length,source_count,source_unique_docs,source_avg_length,source_total_length,source_titles,source_uris,answer_llm,eval_llm,customer
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 1, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'pediatric patients size in the United States diagnosed with cutaneous lupus erythematosus at initial diagnosis between 2015 and 2024', 'role': 'user'}]}",True,200.0,23.339011907577515,,076f498f-54f2-4f21-8597-420af3ad878a,399.0,Published literature does not report the count of pediatric patients in the United States specifical...,2.0,F/T/T,2.0,False,True,True,"The context does not directly answer the question, as neither study provides data specific to pediatric cutaneous lupus erythematosus at initial diagnosis between 2015 and 2024; both focus on systemic lupus erythematosus or are outside the requested time frame. However, the context addresses the general topic and substantiates the AI's statement that such data is not reported in the referenced literature. The AI's answer is completely grounded in the provided context and does not introduce external information.",516,2,2,258.5,517,"Epidemiology of Childhood-Onset Systemic Lupus Erythematosus: A Population-Based Study: A Lupus Midwest Network (LUMEN) Study; Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population",https://pmc.ncbi.nlm.nih.gov/articles/PMC9038612/; https://pubmed.ncbi.nlm.nih.gov/22847366/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 4, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Exacerbations in ASthmatics on biologics', 'role': 'user'}]}",True,200.0,27.05763030052185,,338b5d13-4a3e-484b-9eb8-4c0cddb6b722,835.0,All approved anti‑T2 biologics substantially reduce severe asthma exacerbation rates versus standard...,3.0,T/T/T,3.0,True,True,True,"The AI's answer directly addresses the question regarding exacerbations in asthmatics on biologics, providing detailed findings on exacerbation rate reductions with specific IRRs for each biologic as reported in the context. It also summarizes additional context information about the comparative efficacy, real-world reductions in exacerbations, and findings from claims analyses, all of which are present in the provided context. No external facts or hallucination is evident; statements are appropriately referenced to the studies given. Thus, all three evaluation criteria are met.",585,4,4,229.25,917,"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma - PubMed; Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis - PubMed; Real-world benefits of biologics for asthma: Exacerbation events and systemic corticosteroid use - PMC; Comparative Impact of Asthma Biologics: A Nationwide US Claim-Based Analysis - PubMed",https://pubmed.ncbi.nlm.nih.gov/32034960/; https://pubmed.ncbi.nlm.nih.gov/35772597/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8585664/; https://pubmed.ncbi.nlm.nih.gov/38423294/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 6, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the prevalence of dyslipidemia in patients aged 65 years and older in the US', 'role': 'user'}]}",True,200.0,28.083946704864502,,1706d05c-2743-47e8-b9d3-dfaaab10b02e,249.0,Estimated prevalence of dyslipidemia among U.S. adults aged ≥65 years is 60.3% (NHANES 1999–2004). [...,3.0,T/T/T,3.0,True,True,True,"The AI's answer correctly states that the prevalence of dyslipidemia among U.S. adults aged 65 and older is 60.3%, which is taken directly from the context (NHANES 1999–2004 data). The secondary reference to general lipid abnormalities in all adults (53%) is contextual and also accurately reflects the provided data, with proper clarification that this statistic is not age-specific. No unsupported claims or hallucinations were introduced; both main points in the answer are grounded in the context provided.",510,2,2,124.0,248,"Prevalence, Awareness, and Management of Hypertension, Dyslipidemia, and Diabetes Among United States Adults Aged 65 and Older; Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006",https://pmc.ncbi.nlm.nih.gov/articles/PMC2655011/; https://pubmed.ncbi.nlm.nih.gov/22836069/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 7, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population size of patients with Cutaneous lupus erythematosus who are pediatric at the time of index diagnosis and are diagnosed between 2015 to 2024 in US', 'role': 'user'}]}",True,200.0,29.628860235214233,,86edc818-937e-4f8d-9926-01eb6051b353,877.0,No published study was identified that reports the national count of US patients with cutaneous lupu...,2.0,F/T/T,2.0,False,True,True,"The provided context does not contain a direct answer or national population size for pediatric cutaneous lupus erythematosus cases diagnosed in the US between 2015 and 2024. However, the context is highly relevant and addresses the question by summarizing related incidence, prevalence, and single-centre data, and clearly states the absence of national counts for the specified period. The AI's answer accurately reflects this information and does not introduce claims beyond what is presented in the context.",511,4,4,197.25,789,Epidemiology of Childhood-Onset Systemic Lupus Erythematosus: A Population-Based Study: A Lupus Midwest Network (LUMEN) Study; Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States; Demographic and clinical characteristics of cutaneous lupus erythematosus at a paediatric dermatology referral centre; Cutaneous Lupus Erythematosus in Children,https://pmc.ncbi.nlm.nih.gov/articles/PMC9038612/; https://pubmed.ncbi.nlm.nih.gov/25369985/; https://pmc.ncbi.nlm.nih.gov/articles/PMC4764050/; https://pubmed.ncbi.nlm.nih.gov/33655840/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 0, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'pediatric patients in the United States diagnosed with cutaneous lupus erythematosus at initial diagnosis between 2015 and 2024', 'role': 'user'}]}",True,200.0,30.538661241531372,,5d60d364-1b8b-42b9-9196-7332ae54c62f,466.0,The published literature does not report the number of pediatric patients in the United States first...,2.0,F/T/T,2.0,False,True,True,"The context does not provide specific numbers or incidence/prevalence data for pediatric cutaneous lupus erythematosus (CLE) in the United States between 2015 and 2024. The sources mention a lack of epidemiologic data for pediatric CLE, and population-based studies focus on systemic lupus erythematosus (SLE) rather than CLE. The AI's answer accurately reflects the absence of direct data and is appropriately grounded in the context, but the context itself does not provide a direct answer to the question.",508,3,3,214.66666666666666,644,Cutaneous Lupus Erythematosus in Children - PubMed; Epidemiology of Childhood-Onset Systemic Lupus Erythematosus: A Population-Based Study - PMC; Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries - PMC,https://pubmed.ncbi.nlm.nih.gov/33655840/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9038612/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8685969/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 9, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Do patients with high blood pressure have higher incidence of stroke during follow up, compared to patients with normal blood pressure', 'role': 'user'}]}",True,200.0,30.659071445465088,,80fa705f-1f4a-4f1b-9698-29fc139f1d8c,424.0,Yes. Prospective meta-analyses found higher blood pressure (including prehypertension) is associated...,3.0,T/T/T,3.0,True,True,True,"The context directly answers the question by providing evidence from large cohort meta-analyses that increased blood pressure, specifically prehypertension, is associated with increased stroke incidence compared to optimal/normal blood pressure. The studies cited report a roughly 1.66-fold increase in stroke risk for those with prehypertension versus those with optimal blood pressure, which is directly relevant to the question about stroke incidence during follow-up in patients with higher vs. normal blood pressure. The AI's answer accurately summarizes and uses only the information found in the provided context, making it grounded, relevant, and directly addressing the question.",688,2,2,186.5,373,Prehypertension and the risk of stroke: a meta-analysis; Prehypertension and risk of cardiovascular diseases: a meta-analysis of 47 cohort studies,https://pubmed.ncbi.nlm.nih.gov/24623843/; https://pubmed.ncbi.nlm.nih.gov/31335511/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 5, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What proportion of patients takins statins for primary prevention achieve LDL goal', 'role': 'user'}]}",True,200.0,32.1899893283844,,cabd7e8f-a944-4a81-9cf7-702aaf6514a8,523.0,Proportions vary by cohort and target definition: a large primary-care cohort found 26.0% of patient...,3.0,T/T/T,3.0,True,True,True,"The context provides explicit data on the proportion of patients achieving LDL goals with statins for primary prevention, referencing studies showing 26%, 7.4-10.7%, and 42% (in diabetics) achieving different guideline-defined targets. The AI's answer summarizes these findings, gives the same proportions, and notes the variation according to cohort and definitions, which reflects what is in the provided context. There is no evidence of hallucination, and the answer is fully grounded in and supported by the context.",520,3,3,138.33333333333334,415,Achievement of LDL-Cholesterol Goals in Patients Receiving LLT in Primary Care: TERESA-AP Study: LDL-Cholesterol Goals in Primary Care; Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes - PubMed; Adherence to Statin Therapy and Attainment of LDL Cholesterol Goal Among Patients with Type 2 Diabetes and Dyslipidemia - PMC,https://pmc.ncbi.nlm.nih.gov/articles/PMC11236467/; https://pubmed.ncbi.nlm.nih.gov/34271920/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6916674/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 12, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'How many patients has CKD stage 2 and hypertension, and CKD stage 3 and hypertension?', 'role': 'user'}]}",True,200.0,9.606975555419922,,9a886080-7b67-463f-a85f-0882439c62d1,259.0,"I don’t have enough context to answer — please specify the population or dataset (e.g., your clinic,...",1.0,F/F/T,1.0,False,False,True,"The provided context is empty and does not supply any specific or relevant evidence to directly answer the question regarding the number of patients with CKD stage 2 and hypertension, or CKD stage 3 and hypertension. Therefore, it neither answers nor addresses the question. However, the AI assistant's answer is appropriately grounded in the available (nonexistent) context, as it does not introduce external facts or make unsupported claims—instead, it requests necessary additional information.",497,0,0,0.0,0,,,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 13, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with chronic kidney disease and hypertension, Cohort_1: chronic kidney disease stage 2 and hypertension, Cohort_2: chronic kidney disease stage 3 and hypertension', 'role': 'user'}]}",True,200.0,12.278562545776367,,c93ed143-82f5-4909-a553-dfe3d43805bb,388.0,Please clarify which outcome(s) you want compared between Cohort_1 (CKD stage 2 + hypertension) and ...,1.0,F/F/T,1.0,False,False,True,"The context provided is empty, offering no information about the cohorts or comparisons relevant to the question. The AI's answer is therefore not based on any evidence from the context and simply asks for clarification, not making any unsupported or hallucinated claims. The answer does not address or answer the question using the context, as none was given.",360,0,0,0.0,0,,,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 3, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'True Out of pocket in asthma biologics', 'role': 'user'}]}",True,200.0,39.38807249069214,,0f73e68c-9336-4602-9869-7e0dffbbd8c1,955.0,"Limitations: published literature does not report a single ""true"" patient out-of-pocket (OOP) amount...",3.0,T/T/T,3.0,True,True,True,"The AI's answer uses information drawn directly from the provided context, accurately summarizing variability in out-of-pocket (OOP) costs for asthma biologics according to insurance type, coverage benefit, and recent Medicare policy changes. It acknowledges that a single 'true' OOP amount is not reported, consistent with the context. The references to high drug prices, impact of coverage type on OOP, and differences in access by insurance status are also grounded in the context. Thus, the answer is well-grounded, directly addresses, and is relevant to the question.",572,4,4,225.5,902,The Effectiveness and Value of Biologic Therapies for the Treatment of Uncontrolled Asthma: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council - PMC; The Inflation Reduction Act: Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma - PubMed; Trends and Disparities in Asthma Biologic Use in the United States - PMC; Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals - PubMed,https://pmc.ncbi.nlm.nih.gov/articles/PMC10397880/; https://pubmed.ncbi.nlm.nih.gov/38465800/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7012665/; https://pubmed.ncbi.nlm.nih.gov/33556592/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 2, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Character (role):\n You are a senior Real-World Data Analyst specializing in patient affordability.\n \n Objective (business question):\n Quantify and benchmark True Out-of-Pocket (T-OOP) costs (patient-paid deductible + co-pay + co-insurance) among asthma patients newly treated with FDA-approved biologic therapies, using IQVIA’s ELAAD → FIA (fill-level integrated adjudicated claims) dataset.\n \n Request (tasks):\n \n  Cohort definition\n \n  Identify patients with ≥ 2 encounters coded for asthma (ICD-10 J45.x) [LOOK-BACK WINDOW: 12 months] before index date.\n \n  Index = first fill of any biologic asthma therapy: omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab \n \n  Require continuous enrollment in FIA for [BASELINE = 6 mo] pre-index and [FOLLOW-UP = 12 mo] post-index.\n \n  Outcome construction\n \n  For each patient, sum patient-paid amounts (deductible + co-pay + co-insurance) on all claims for the index biologic during follow-up.\n \n  Report: mean, median, IQR, SD, and % patients with annual T-OOP ≥ $500, ≥ $1 000, ≥ $2 000.\n \n  Break out results by payer channel (Commercial, Medicare Advantage, Medicare Part D, Medicaid, Other) and by biologic agent.\n \n  Sensitivity / sub-analyses\n \n  Restrict to patients with high eosinophilic phenotype (ICD-10 D72.18 or blood eos ≥ 300/mm³ in lab feed) \n  Exclude patients with concomitant biologic use for non-asthma indications .\n \n  Repeat outcome using patient-year and claim-level units.\n \n  Output format\n \n  Return three tables (Overall, By Payer, By Biologic) plus a brief narrative (< 250 words) summarizing key cost drivers and any notable payer/agent disparities.\n \n  Include an appendix with SQL-style pseudocode for cohort and outcome logic.\n \n Examples (optional):\n \n  “Example of desired table layout attached below.” \n \n Adjustments / refinements:\n \n  Apply IQVIA standard inflation adjustment to 2025 USD.\n \n  Flag if > 10 % of fills lack patient-paid fields (possible data quality issue).\n \n  Use exact drug NDCs; i', 'role': 'user'}]}",True,200.0,39.63543725013733,,5ca6c660-b37a-48a3-bdfd-4f315b9cb86f,546.0,The published literature does not contain an answer to this question (no study reports IQVIA ELAAD→F...,1.0,F/F/T,1.0,False,False,True,"There is no context provided to answer or even address the business question. The AI's answer is grounded in the absence of context; it does not make unsupported claims but does not fulfill the user's request due to lack of data or evidence. Consequently, the answer cannot be directly linked to the question or even said to address it with supporting context.",360,0,0,0.0,0,,,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 8, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the estimated number of pediatric patients in the United States who were diagnosed with Cutaneous Lupus Erythematosus (CLE) at the time of their initial diagnosis between 2015 and 2024?', 'role': 'user'}]}",True,200.0,41.99728488922119,,ff427f30-ac3b-40dd-b1e1-208f0ec27387,472.0,Published literature does not provide a national estimate of the number of pediatric Cutaneous Lupus...,3.0,T/T/T,3.0,True,True,True,"The context makes clear that pediatric CLE data are sparse and mostly limited to case series, not national or population-based estimates, which directly answers the question: no national estimate for pediatric CLE exists in the US for 2015-2024. The AI answer explicitly cites these limitations and accurately summarizes the content, staying grounded in the context. The context is directly relevant, directly responsive, and there are no hallucinated or unsupported statements in the AI answer.",495,3,3,210.33333333333334,631,Cutaneous Lupus Erythematosus in Children; Cutaneous Lupus Erythematosus in Children: Experience from a Tertiary Care Pediatric Dermatology Clinic; Epidemiology of Childhood-Onset Systemic Lupus Erythematosus: A Population-Based Study (LUMEN),https://pubmed.ncbi.nlm.nih.gov/33655840/; https://pubmed.ncbi.nlm.nih.gov/27001318/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9038612/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 11, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what proportion of patients with CKD stage 2 and hypertension, and CKD stage 3 and hypertension, treated with SLGT2 along, MRA along, SGLT2 and MRA together, or none?', 'role': 'user'}]}",True,200.0,42.36114764213562,,e5ed117f-e78b-4de7-922b-46e090d82d84,826.0,No published study was identified that reports the proportion of patients with (a) CKD stage 2 plus ...,2.0,F/T/T,2.0,False,True,True,"The context does not provide direct, specific proportions of patients with CKD stage 2 or stage 3 and hypertension treated with SGLT2 inhibitors alone, MRA alone, both, or neither. The AI’s answer accurately summarizes the scope and limitations of the provided literature, including the lack of relevant published data for the requested breakdown. The response is appropriately grounded in the context: it references specific findings regarding high prevalence of hypertension among CKD patients, some granular data on SGLT2 use by CKD stage, and the acknowledged lack of population-level data for MRAs. The answer does not introduce information beyond what the sources supply. Therefore, while the context does not answer the question directly, it does address it by indicating the absence of data and providing related, relevant statistics.",842,3,3,171.66666666666666,515,Patient Management and Clinical Outcomes Associated with a Recorded Diagnosis of Stage 3 Chronic Kidney Disease: The REVEAL-CKD Study; Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study; Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease,https://pmc.ncbi.nlm.nih.gov/articles/PMC10219868/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11794911/; https://pubmed.ncbi.nlm.nih.gov/36422853/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 15, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with type 1 diabetes and have multiple (i.e., more than 2) c-peptide records within one year before the first T1D diagnosis and within one year after first T1D diagnosis. The multiple c-peptide records (in both pre- and post-diagnosis windows) can be any number of days apart (e.g., 1 day, 7 days, 30 days), but should not be on the same day, Outcomes: Number of patients in the cohort and how many c peptide records are present on average for this population cohort before index and after index', 'role': 'user'}]}",True,200.0,18.177984952926636,,83b33b6c-b07e-46d8-a22c-a100c6fa98e0,442.0,Unable to produce the requested cohort counts and mean numbers of C‑peptide records because the requ...,1.0,F/F/T,1.0,False,False,True,"The provided context is empty, offering no information about the patient cohort or c-peptide measurements either before or after T1D diagnosis. Thus, the context neither directly answers the question nor even addresses it. The AI's response is grounded in the context, as it correctly notes the lack of information and does not introduce unsupported claims or facts.",366,0,0,0.0,0,,,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 10, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'In patients with BMI 30 or higher, is there a difference in use of GLP1-RA in those with vs without a recorded obesity diagnosis?\u200b', 'role': 'user'}]}",True,200.0,53.750468492507935,,bc2eb3dd-1b7c-49e9-8aad-bfeec5aa437a,1062.0,Published observational studies show prescribing of GLP-1 receptor agonists is common among patients...,2.0,F/T/T,2.0,False,True,True,"The context discusses that GLP-1 RA prescribing occurs both in patients with BMI ≥30 with and without a recorded obesity diagnosis. It highlights that some patients do not have an obesity code yet still receive the drug, and there are disparities in prescribing among those who are BMI-eligible but lack an obesity diagnosis code. However, the context does not provide quantitative or direct comparative data on the *difference* in GLP-1 RA use itself between those with versus without a recorded obesity diagnosis within the BMI ≥30 population. Thus, the context is relevant and the answer remains grounded in it, but the context does not answer the question directly with specific evidence about comparative rates or differences in use.",738,4,4,228.5,914,"Prescribing patterns of glucagon-like peptide-1 receptor agonists in the Swedish capital region-a register-based cross-sectional study; Prescribing GLPs for Obesity Treatment for Adults at a University Based Health Maintenance Organization by Race, Ethnicity, and Socioeconomic Status; Trends in glucagon-like peptide 1 receptor agonist prescribing patterns; Trends in obesity and glucagon-like peptide-1 receptor agonist prescriptions in type 1 diabetes in the United States",https://pubmed.ncbi.nlm.nih.gov/40074942/; https://pubmed.ncbi.nlm.nih.gov/40588707/; https://pubmed.ncbi.nlm.nih.gov/40829097/; https://pubmed.ncbi.nlm.nih.gov/40028670/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 17, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: ATTR patients identified by the above confirmed cohort definitions, Cohort_1: ATTR-PN (confirmed with nerve conduction studies and specific peripheral neuropathy diagnosis codes) and exclude stem cell transplant, chemotherapy , Cohort_2: ATTR-CM (confirmed with cardiac imaging evidence and additional cardiomyopathy diagnosis codes), and exclude stem cell transplant, chemotherapy , Cohort_3: ATTR - Mixed (confirmed with nerve conduction studies, specific peripheral neuropathy, or cardiomyopathy diagnosis) and exclude stem cell transplant and chemotherapy , Outcomes: first recorded ATTR diagnosis based on diagnosis and procedure records in 2024 and 2025 separately', 'role': 'user'}]}",True,200.0,24.467613220214844,,9689a43d-2d3d-4e90-89c1-a6fd8ac33260,512.0,The published literature does not report counts of first-recorded ATTR diagnoses in 2024 and 2025 fo...,2.0,F/T/T,2.0,False,True,True,"The provided context states that published literature does not include year-specific counts for 2024–2025 or the precise cohort definitions requested. It describes broader prevalence, heterogeneity, knowledge gaps, and increased diagnosis rates, but none of the references offer direct cohort- and year-specific outcome data as outlined in the question. The AI's answer accurately summarizes these shortcomings and grounds its response in the available context, without introducing unsupported claims.",501,3,3,219.0,657,Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review - PMC; Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review - PubMed; Changes in the diagnostic trajectory of transthyretin cardiac amyloidosis over six years - PubMed,https://pmc.ncbi.nlm.nih.gov/articles/PMC11740649/; https://pubmed.ncbi.nlm.nih.gov/39819351/; https://pubmed.ncbi.nlm.nih.gov/38710807/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 20, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'average c peptide levels of patients before and after first diagnosis of T1D', 'role': 'user'}]}",True,200.0,24.76611638069153,,1b24a2ea-09f1-4184-b12f-73d2fa60b776,763.0,Reported endogenous C‑peptide at first clinical diagnosis of type 1 diabetes varies by cohort and me...,3.0,T/T/T,3.0,True,True,True,"The AI's answer is well-grounded in the provided context. It cites specific values for C-peptide at diagnosis from multiple references and mentions post-diagnosis changes, which are present in the context. The answer synthesizes the information directly provided in the context, accurately reporting both the at-diagnosis and early post-diagnosis levels shown in the references. Therefore, it directly answers the question about average C-peptide levels before and after first T1D diagnosis, the context is highly relevant, and the answer does not introduce information unsupported by the given documents.",605,4,4,141.75,567,Pubertal stage significantly and independently impacts C‑peptide levels at type 1 diabetes diagnosis along with body mass index and age; C‑peptide in the classification of diabetes in children and adolescents; Prediction of clinical remission using the C‑peptide level in type 1 diabetes in children; C‑peptide decline in type 1 diabetes has two phases: an initial exponential fall and a subsequent stable phase,https://pmc.ncbi.nlm.nih.gov/articles/PMC11872750/; https://pubmed.ncbi.nlm.nih.gov/21910810/; https://pubmed.ncbi.nlm.nih.gov/17880810/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6027962/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 22, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with hypertension, Intervention: patients with uncontrolled blood pressure (SBP>130mmHg and on 2 antihypertensive medications), Control: patients with controlled blood pressure (SBP<130mmHg and on 2 antihypertensive medications), Outcomes: ischemic stroke, myocardial infarction', 'role': 'user'}]}",True,200.0,25.53844690322876,,1cbd55d5-2c61-4ea9-bdf7-11782738b028,476.0,"In hypertensive patients who are receiving two antihypertensive drugs, achieving a systolic BP <130 ...",3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: True. The context specifically addresses the outcomes of ischemic stroke and myocardial infarction in patients with hypertension controlled to SBP <130 mmHg versus higher SBP, including patients on antihypertensive medication. The studies cited report a lower risk of stroke with tighter control and either non-significant or variable MI outcomes, directly addressing the question components.

2. context_addresses_question: True. The context is highly relevant, focusing precisely on blood pressure targets, population, and outcomes that match the question.

3. answer_grounded_in_context: True. The AI's answer summarizes and integrates the findings reported in the supplied publications without adding unsupported claims, correctly referencing variability in the effect on MI and a consistent reduction in stroke with SBP <130 mmHg.",873,3,3,227.33333333333334,682,Tight versus standard blood pressure control on the incidence of myocardial infarction and stroke: an observational retrospective cohort study in the general ambulatory setting; Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis; Achieved Blood Pressure and Outcomes in the Secondary Prevention of Small Subcortical Strokes Trial,https://pmc.ncbi.nlm.nih.gov/articles/PMC7231410/; https://pubmed.ncbi.nlm.nih.gov/28564682/; https://pubmed.ncbi.nlm.nih.gov/26553236/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 14, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with Type 1 Diabetes with a clearly identifiable first diagnosis date and at least two c-peptide laboratory test records within one year before and one year after diagnosis, Outcomes: count and average number of c-peptide laboratory test records', 'role': 'user'}]}",True,200.0,40.18834042549133,,1af062af-86e3-4ce5-be0c-a03e8201a488,635.0,Published studies do not report the requested EHR-style summary (per‑patient count and mean number o...,2.0,F/T/T,2.0,False,True,True,"The provided context makes it clear that none of the referenced studies report the per-patient count or mean number of C-peptide laboratory records within ±1 year of diagnosis, which is the information requested by the question. The AI's answer accurately reflects this and is grounded solely in the context provided; no unsupported claims are included. However, because the context does not directly provide the requested counts or averages, it does not directly answer the question, but it is relevant to the topic asked.",523,3,3,248.66666666666666,746,C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet - PubMed; C-peptide in the natural history of type 1 diabetes - PubMed; Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants - PubMed,https://pubmed.ncbi.nlm.nih.gov/32457058/; https://pubmed.ncbi.nlm.nih.gov/19267337/; https://pubmed.ncbi.nlm.nih.gov/20032282/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 23, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with hypertension , Intervention: uncontrolled hypertension (SBP>130mmHg and on at least 2 antihypertensive medications), Control: controlled hypertension (SBP<130mmHg and on at least 2 antihypertensive medications), Outcomes: ischemic stroke and myocardial infarction', 'role': 'user'}]}",True,200.0,28.00887632369995,,b266006d-b317-4290-9c5a-af498e8de11f,1337.0,"Available observational and trial data show that, among treated hypertensive patients, higher on‑tre...",3.0,T/T/T,3.0,True,True,True,"The context directly contains data comparing outcomes (stroke, MI) between patients with lower (SBP <130 mmHg) and higher (SBP >130 mmHg) on-treatment systolic blood pressure, often on at least two antihypertensive medications. The AI’s answer accurately describes several studies cited in the context: multicenter retrospective and prospective studies, as well as randomized trials, all indicating higher incidence of ischemic stroke and myocardial infarction with uncontrolled hypertension compared to controlled hypertension. The answer makes an effort to specify relevant study populations (older adults, people with diabetes, etc.) and acknowledges limitations present in the context regarding population differences and exact match to the PICO criteria. All claims are grounded in the provided context. Therefore, all three criteria are met.",847,4,4,224.5,898,Cardiovascular outcomes according to on-treatment systolic blood pressure in older hypertensive patients: a multicenter cohort using a common data model - PubMed; Association Between Early Hypertension Control and Cardiovascular Disease Incidence in Veterans With Diabetes - PubMed; Outcomes in adults with systolic blood pressure between 130 and 139 mmHg in Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial and Systolic Blood Pressure Intervention Trial - PubMed; Uncontrolled Hypertension and Increased Risk for Incident Heart Failure in Older Adults with Hypertension: Findings from a Propensity-Matched Prospective Population Study - PMC,https://pubmed.ncbi.nlm.nih.gov/37965799/; https://pubmed.ncbi.nlm.nih.gov/31515207/; https://pubmed.ncbi.nlm.nih.gov/32371767/; https://pmc.ncbi.nlm.nih.gov/articles/PMC2914566/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 24, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Do patients taking spironolactone have higher rates of hyperkalemia than patients taking eplerenone?', 'role': 'user'}]}",True,200.0,30.936312198638916,,937d5857-610b-49b2-ab9a-ec05c28472d0,453.0,Available randomized and review evidence show no consistent signal that spironolactone causes higher...,3.0,T/T/T,3.0,True,True,True,"The AI's answer accurately reflects the context provided. The randomized study cited in context [2] directly compares rates of hyperkalemia between the two drugs, showing similar rates. The safety profile review [3] also states hyperkalemia is common with both drugs and that there are no greater rates of hyperkalemia-induced withdrawals for one over the other according to clinical trial data. The systematic review/meta-analysis [1] is referenced regarding overall safety, though it does not specifically mention hyperkalemia rates directly. Thus, the answer is well-grounded in the provided context, directly addresses the question, and does not add unsupported claims.",673,3,3,218.0,654,Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis; Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism; Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone,https://pubmed.ncbi.nlm.nih.gov/39271992/; https://pubmed.ncbi.nlm.nih.gov/18312153/; https://pubmed.ncbi.nlm.nih.gov/26404748/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 16, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: COPD, Intervention: Breztri, Control: Trelegy, Outcomes: % with COPD-Related Hospitalization', 'role': 'user'}]}",True,200.0,43.09204411506653,,349b73e8-82f2-4c40-97e7-dfcc25b35599,1158.0,No randomized head-to-head trial reporting the percentage with COPD‑related hospitalization for Brez...,2.0,F/T/T,2.0,False,True,True,"The context does not provide a direct percentage of COPD-related hospitalizations for Breztri versus Trelegy, so the AI's answer is correct in stating that this information is not reported in head-to-head randomized trials. The context does address the question by providing relevant comparative data: hazard ratios for severe exacerbations leading to hospitalization and noting that neither direct percentages nor RCTs addressing this outcome exist. The AI's answer sticks closely to the evidence from the context, summarizes the findings accurately without introducing external information, and does not claim unsupported results. However, because the exact outcome asked for (the percentage with hospitalization) is not reported, the context does not directly answer the question.",783,3,3,270.3333333333333,811,Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study; Comparative Effectiveness of FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up From Dual Therapy; Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching‑adjusted indirect comparison based on ETHOS and IMPACT,https://pubmed.ncbi.nlm.nih.gov/39797646/; https://pubmed.ncbi.nlm.nih.gov/40619503/; https://pubmed.ncbi.nlm.nih.gov/37583267/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 21, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Pulmonologists caring for adult patients who are maintenance therapy–naive and newly diagnosed with either chronic obstructive pulmonary disease (COPD) or asthma., Intervention: Prescribing triple inhaled therapy (fluticasone+umeclidinium+vilanterol or budesonide+glycopyrolate+formoterol)) to maintenance-naive COPD patients., Control: Prescribing triple inhaled therapy (fluticasone+umeclidinium+vilanterol or budesonide+glycopyrolate+formoterol) to maintenance-naive asthma patients., Outcomes: Likelihood (rate or proportion) of fluticasone+umeclidinium+vilanterol or budesonide+glycopyrolate+formoterol initiation among maintenance-naive asthma patients compared to maintenance-naive COPD patients by pulmonologists who already prescribe triple therapy to maintenance-naive COPD patients.', 'role': 'user'}]}",True,200.0,38.72752499580383,,456cfa90-5114-4b8d-9903-d98a7f9b5822,1232.0,No published study directly compares the likelihood that pulmonologists who already prescribe triple...,2.0,F/T/T,2.0,False,True,True,"The context includes studies evaluating the use of single-inhaler triple therapy as initial maintenance in both COPD and asthma patients. It provides data about the prevalence and outcomes of initiating triple therapy in maintenance-naive COPD and asthma populations separately. However, there is no direct comparison or information about the likelihood or rate that pulmonologists who prescribe triple therapy to maintenance-naive COPD patients will also do so for maintenance-naive asthma patients. The AI's answer correctly reflects this gap, notes the lack of direct comparative data, and grounds its discussion in the context provided without introducing external or unsupported claims. Therefore, the answer is context-grounded, covers the relevant context, but does not provide a direct answer to the question since the necessary comparative data is missing.",865,4,4,294.0,1176,Clinical and Economic Evaluation of Fluticasone Furoate/Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol Therapy in Maintenance Treatment‑Naive Patients with COPD in the US; Adherence and Persistence to Single‑Inhaler Versus Multiple‑Inhaler Triple Therapy for Asthma Management; Single‑Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real‑World Comparative Effectiveness and Safety; Impact of the IMPACT Trial,https://pubmed.ncbi.nlm.nih.gov/39968202/; https://pubmed.ncbi.nlm.nih.gov/35752431/; https://pubmed.ncbi.nlm.nih.gov/36065315/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6296790/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 25, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'do patients with uncontrolled hypertension have higher rates of cardiovascular outcomes compared to patients with controlled hypertension?', 'role': 'user'}]}",True,200.0,37.278265953063965,,69bb7690-62e2-40a1-9c04-0547a29c19ce,747.0,Yes. Randomized-trial meta-analyses show that lower (intensive) BP targets reduce major cardiovascul...,3.0,T/T/T,3.0,True,True,True,"The context directly and specifically addresses the question of whether patients with uncontrolled hypertension have higher rates of cardiovascular outcomes compared to patients with controlled hypertension. The provided studies show that uncontrolled hypertension is associated with higher cardiovascular and all-cause mortality (with specific hazard ratios given), as well as increased rates of major adverse cardiovascular events and incident heart failure, relative to controlled hypertension. The AI's answer closely mirrors these findings, referencing specific evidence and numeric outcomes directly from the supplied context, without introducing unsupported claims. Thus, all criteria are fulfilled.",706,4,4,209.0,836,Impact of Intensive Blood Pressure Control Versus Standard Control on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - PubMed; Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study - PubMed; Association of hypertension treatment and control with all-cause and cardiovascular disease mortality among US adults with hypertension - PubMed; Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study - PubMed,https://pubmed.ncbi.nlm.nih.gov/40772210/; https://pubmed.ncbi.nlm.nih.gov/29925884/; https://pubmed.ncbi.nlm.nih.gov/19851295/; https://pubmed.ncbi.nlm.nih.gov/20374948/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 19, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'In patients with BMI 30 or higher, is there a difference in use of GLP1-RA in those with vs without a recorded obesity diagnosis?\u200b\n \n \u200b\n \n \u200b\n \n \u200b\n \u200b', 'role': 'user'}]}",True,200.0,53.50785160064697,,e77a7647-5a93-4815-a91b-7c64a2ef20ca,508.0,No published study was identified that directly compares GLP‑1 receptor agonist use among adults wit...,2.0,F/T/T,2.0,False,True,True,"The provided context includes studies examining GLP-1 RA prescribing patterns in adults with BMI ≥30, but specifically notes that none of them compare GLP-1 RA use based on presence versus absence of a recorded obesity diagnosis. Thus, the context does not directly answer the question but is still relevant because it describes related study parameters and explicitly states the absence of a direct comparison. The AI's answer appropriately reflects these limitations, does not introduce unsupported claims, and is grounded solely in the provided context.",556,3,3,302.3333333333333,907,"Prescribing GLPs for Obesity Treatment for Adults at a University Based Health Maintenance Organization by Race, Ethnicity, and Socioeconomic Status - PubMed; Trends in glucagon-like peptide 1 receptor agonist prescribing patterns - PubMed; Trends in obesity and glucagon-like peptide-1 receptor agonist prescriptions in type 1 diabetes in the United States - PubMed",https://pubmed.ncbi.nlm.nih.gov/40588707/; https://pubmed.ncbi.nlm.nih.gov/40829097/; https://pubmed.ncbi.nlm.nih.gov/40028670/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 26, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with hypertension, Intervention: controlled hypertension (SBP<130mmHg and on 2 antihypertensive medications), Outcomes: ischemic stroke', 'role': 'user'}]}",True,200.0,33.65507102012634,,afd77789-4443-4c3c-aa64-0698d2b8f89f,485.0,"In patients with hypertension, intensive blood‑pressure control (SBP target <130 mmHg) is associated...",3.0,T/T/T,3.0,True,True,True,"The provided context specifically addresses the effect of intensive versus standard blood pressure control on recurrent ischemic stroke in hypertensive patients. Meta-analyses and clinical trial evidence cited in the context make it clear that while intensive BP control (<130 mmHg) reduces overall recurrent stroke and hemorrhagic stroke, it has little or no significant effect on reducing ischemic stroke risk (with reported relative risks close to 1 and confidence intervals crossing 1). The AI's answer accurately summarizes these findings and is appropriately grounded in the evidence from the provided articles, with no apparent introduction of external or unsupported claims. The answer is both relevant and directly addresses the nuanced aspect of ischemic stroke specified in the question.",798,3,3,259.6666666666667,779,Optimal blood pressure target for patients with prior stroke: A systematic review and meta-analysis - PubMed; Association Between Magnitude of Differential Blood Pressure Reduction and Secondary Stroke Prevention: A Meta-analysis and Meta-Regression - PubMed; Intensive or standard blood pressure control in patients with a history of ischemic stroke: RESPECT post hoc analysis - PubMed,https://pubmed.ncbi.nlm.nih.gov/40097615/; https://pubmed.ncbi.nlm.nih.gov/36939729/; https://pubmed.ncbi.nlm.nih.gov/35241817/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 18, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with type 1 diabetes, Outcomes: type 2 diabetes', 'role': 'user'}]}",True,200.0,56.54318714141846,,c3e505bd-b4c1-4e10-abea-260ba935f01d,535.0,Published literature does not describe type 1 diabetes “converting” into type 2 diabetes; instead pe...,2.0,F/T/T,2.0,False,True,True,"The context does not directly answer whether patients with type 1 diabetes can develop type 2 diabetes—the outcome in question—but instead discusses the concept of 'double diabetes', which describes type 1 diabetes with insulin resistance and metabolic-syndrome features that resemble type 2 diabetes. The information in the context is clearly relevant and addresses the spirit of the question by discussing phenomena closely related to the outcome, but does not provide direct evidence that type 1 diabetes patients develop type 2 diabetes per se. The AI's answer appropriately restricts itself to what is present in the context, describing 'double diabetes' and not making unsupported claims about the conversion of type 1 to type 2 diabetes. Therefore, only the criteria for context relevance and grounding in context are met.",829,3,3,212.0,636,"Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?; Double diabetes: A Growing Problem Requiring Solutions; Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: ""double diabetes"" in the Diabetes Control and Complications Trial",https://pubmed.ncbi.nlm.nih.gov/23613085/; https://pubmed.ncbi.nlm.nih.gov/33636739/; https://pubmed.ncbi.nlm.nih.gov/17327345/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 29, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: prescribers identified through retrospective EHR or claims data, Cohort_1: prescribers of maintenance naive chronic obstructive pulmonary disease inhaled ics/lama/laba, Cohort_2: prescribers of maintenance naive asthma inhaled ics/laba/lama', 'role': 'user'}]}",True,200.0,25.72824192047119,,9ec8323c-6bf4-4762-9355-6eba7c451d01,570.0,The published literature does not contain studies that identify and compare prescribers (via retrosp...,3.0,T/T/T,3.0,True,True,True,"The context explicitly indicates that available studies focus on patient-level data regarding prescription patterns and adherence for COPD and asthma, not prescriber-level cohort comparisons as specified in the question. The AI's answer accurately reflects this evidence, noting the lack of direct comparisons of prescriber cohorts, and appropriately cites the context to support this claim. The answer does not introduce unsupported information and is fully grounded in the context provided.",492,3,3,259.0,777,Pattern and Adherence to Maintenance Medication Use in Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease: 2008-2013; Analysis of adherence to ICS/LAMA/LABA in patients with asthma: a retrospective observational cohort study using medical claims data; Prescription patterns and effectiveness of medications for chronic obstructive pulmonary disease: A retrospective study of real-world settings,https://pmc.ncbi.nlm.nih.gov/articles/PMC5870736/; https://pubmed.ncbi.nlm.nih.gov/40328074/; https://pubmed.ncbi.nlm.nih.gov/38857214/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 28, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: COPD patients with Mucus plug, Intervention: fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Outcomes: % with COPD related Hospitalization', 'role': 'user'}]}",True,200.0,28.27189302444458,,f6c4e11d-3d59-4cd9-b1bb-aac2cb79f44b,965.0,No published study was identified that reports hospitalization rates specifically for COPD patients ...,2.0,F/T/T,2.0,False,True,True,"The context addresses the broader question of outcomes with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) in COPD patients, including effects on exacerbation rates and hospital readmissions. However, it does not provide direct or specific data about the percentage of COPD patients with mucus plugs who experience COPD-related hospitalization. The AI answer correctly notes the absence of direct evidence for this subpopulation, accurately summarizes the available evidence, and does not introduce unsupported claims.",528,3,3,185.0,555,Fluticasone Furoate/Umeclidinium/Vilanterol Initiation Following a COPD Exacerbation: Benefits of Prompt Initiation on COPD Outcomes; Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation; Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies,https://pubmed.ncbi.nlm.nih.gov/39453592/; https://pubmed.ncbi.nlm.nih.gov/35281476/; https://pubmed.ncbi.nlm.nih.gov/26117292/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 27, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Are primary care physicians who prescribe triple therapy to maintenance naive asthma patients more likely to prescribe triple therapy to maintenance naive copd patients?', 'role': 'user'}]}",True,200.0,39.660489320755005,,07d4404b-9169-4294-b559-ff220631e339,493.0,No published study was identified that directly asks whether individual primary care physicians who ...,2.0,F/T/T,2.0,False,True,True,"The provided context does not directly answer whether primary care physicians who prescribe triple therapy to maintenance-naive asthma patients are more likely to prescribe triple therapy to maintenance-naive COPD patients. None of the excerpts compare prescribing behavior between asthma and COPD within the same physician. The context, however, does address related aspects, such as primary care physicians' patterns in COPD and factors influencing triple therapy prescriptions. The AI's answer accurately limits itself to what the context supports and does not introduce unsupported claims, grounding its statement in the actual provided studies.",649,3,3,209.66666666666666,629,Trends and Characteristics of Global Initiative for Chronic Obstructive Lung Disease Guidelines-Discordant Prescribing of Triple Therapy Among Patients with COPD; An Exploratory Study of Physician Decision-Making When Treating Uncontrolled COPD; Treatment Patterns for Chronic Obstructive Pulmonary Disease (COPD) in the United States: Results from an Observational Cross-Sectional Physician and Patient Survey,https://pmc.ncbi.nlm.nih.gov/articles/PMC9166325/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11193463/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8995154/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 31, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'STUDY DESIGN\n  Title: Difference in all-cause hospitalization rates between Breztri Aerosphere and Trelegy Ellipta users in US commercial + Medicare claims\n  Data Source: ATROPOS-claims (open adjudicated + Pharmetrics, 2019-2024)\n  Study Period: 01-Jan-2020 to 31-Dec-2023\n  Follow-up Window: index date → earliest of 12 months, death, plan disenrollment, or end of data\n  \n COHORT 1 (Breztri)\n  Index Event:\n  first dispensing or administration of Breztri Aerosphere (NDC or J-code list)\n  Continuous Enrollment:\n  ≥6 months pre-index medical + pharmacy\n  ≥1 day post-index enrollment\n  Exclusions:\n  any Trelegy (NDC/J-code) dispensing in the 6 months pre-index\n  \n COHORT 2 (Trelegy)\n  Index Event:\n  first dispensing or administration of Trelegy Ellipta\n  Continuous Enrollment:\n  ≥6 months pre-index medical + pharmacy\n  ≥1 day post-index enrollment\n  Exclusions:\n  any Breztri dispensing in the 6 months pre-index\n  \n BASELINE COVARIATES (look-back = 6 months pre-index)\n  Age, Sex, Region, Insurance Type\n  Quan-Charlson Comorbidity Index\n  COPD severity proxy: # COPD exacerbations, OCS bursts, prior hospitalizations\n  Respiratory comedications: LABA, LAMA, ICS, SABA, OCS\n  Health-care utilization: total inpatient stays, ER visits, office visits, total cost\n  \n OUTCOME\n  All-cause inpatient hospitalization (IP stay with admission date within follow-up)\n  \n ANALYSES\n  1. Crude incidence rate\n  numerator: patients with ≥1 hospitalization\n  denominator: person-years of follow-up\n  output: incidence rate/100 PY, 95 % CI\n  2. Time-to-first hospitalization\n  Kaplan–Meier curve, log-rank p-value\n  3. Adjusted hazard ratio\n  Cox PH model: treatment (Breztri vs Trelegy) + baseline covariates\n  4. Propensity score IPTW sensitivity\n  PS estimated via logistic regression on baseline covariates\n  apply stabilized weights; run weighted Cox model\n  \n OUTPUTS\n  • Table 1: baseline characteristics by cohort (unweighted and weighted) \n  • Incidence rate table \n  • KM plot', 'role': 'user'}]}",True,200.0,30.739203929901123,,6aeb8b83-2c8a-4644-ad40-ea7919d69e64,444.0,"The proposed observational claims study design (new-user cohorts, 6‑month baseline, 12‑month follow-...",2.0,F/T/T,2.0,False,True,True,"The context summarizes studies comparing FF/UMEC/VI and BUD/GLY/FORM (which correspond to Trelegy Ellipta and Breztri Aerosphere), using similar methods such as new-user designs, claims data, baseline covariates, KM analysis, Cox models, and IPTW/weighting. However, while the context is highly relevant to the question of study design alignment, it does not provide specific evidence or direct statements that the proposed design is exactly the same as published studies. Thus, the context addresses the question's topic (study design comparison) and the AI's answer is grounded in the context, but there is no direct evidence in the context that ""substantially answers"" the question as posed (i.e., demonstrating explicit design matching).",741,3,3,233.33333333333334,700,Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study - PubMed; Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol among US Patients with Chronic Obstructive Pulmonary Disease - PubMed; Comparative Effectiveness of FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up From Dual Therapy - PubMed,https://pubmed.ncbi.nlm.nih.gov/39797646/; https://pubmed.ncbi.nlm.nih.gov/39731707/; https://pubmed.ncbi.nlm.nih.gov/40619503/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 33, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the prevalence of heart failure across different age brackets?', 'role': 'user'}]}",True,200.0,30.940186738967896,,c8c93ffb-7769-4581-ae04-2a7f67491a77,349.0,Reported prevalence rises steeply with age: 45–54 years ~0.3%; 55–64 years ~0.9%; 65–74 years ~2.5%;...,3.0,T/T/T,3.0,True,True,True,"The AI's answer directly extracts and synthesizes age-specific prevalence data from the provided context, citing data for various age brackets (45–54, 55–64, 65–74, ≥75, 50s, 80s, 65–70), and the overall adult prevalence, matching the figures and sources in the context. No external information or unsupported claims are introduced. The answer is highly relevant, directly addresses the question about heart failure prevalence across age groups, and is fully grounded in the supplied context.",492,3,3,147.0,441,"Real world heart failure epidemiology and outcome: A population-based analysis of 88,195 patients; Epidemiology of heart failure; Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America",https://pmc.ncbi.nlm.nih.gov/articles/PMC5325273/; https://pubmed.ncbi.nlm.nih.gov/2000773/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10864030/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 32, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'do GLP1s improve outcomes for Asthma patients?', 'role': 'user'}]}",True,200.0,31.61182403564453,,1da14858-313f-4299-9704-622649506031,380.0,Available human evidence indicates GLP‑1 receptor agonists are associated with improved asthma contr...,3.0,T/T/T,3.0,True,True,True,"The context includes multiple studies and analyses indicating that GLP-1 receptor agonists are associated with improved asthma control, fewer exacerbations, and a trend toward reduced respiratory events, directly addressing the question about outcome improvement in asthma patients. The AI's answer reflects these findings accurately and also notes the limitation regarding causality due to a lack of prospective randomized trials specifically in asthma, which is supported by the context. All three criteria are met.",517,5,5,217.4,1087,The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity - PubMed; Glucagon-like Peptide-1 Receptor Agonists in Asthma Exacerbations: An Application of High-Dimensional Iterative Causal Forest to Identify Subgroups - PubMed; Glucagon-like Peptide 1 Receptor Agonists and Asthma Exacerbations: Which Patients Benefit Most? - PubMed; The Association between GLP-1 Receptor-Based Agonists and the Incidence of Asthma in Patients with Type 2 Diabetes and/or Obesity: A Meta-Analysis - PubMed; Evaluating the glucagon-like peptide-1 receptor in managing asthma - PubMed,https://pubmed.ncbi.nlm.nih.gov/40198520/; https://pubmed.ncbi.nlm.nih.gov/40717037/; https://pubmed.ncbi.nlm.nih.gov/39012183/; https://pubmed.ncbi.nlm.nih.gov/38988111/; https://pubmed.ncbi.nlm.nih.gov/34772827/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 37, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: outpatients with transthyretin (ATTR) amyloidosis, Intervention: silencer therapy, Outcomes: duration of silencer therapy', 'role': 'user'}]}",True,200.0,22.79872989654541,,5f0af871-848d-4ffd-b9b9-08b1044473af,377.0,Silencer therapies used in outpatients with ATTR include the siRNA patisiran (IV 0.3 mg/kg every 3 w...,3.0,T/T/T,3.0,True,True,True,"The context provides specific information on the duration of silencer therapies in outpatients with ATTR amyloidosis. For patisiran, the context mentions an 18-month trial and at least 2 years of stable TTR knockdown in extension data. For inotersen, the context mentions a median treatment exposure of 3 years (up to 6.2 years). The AI's answer accurately reflects these data, citing both therapies and matching duration outcomes directly with the facts in the provided sources. No unsupported claims or external knowledge are introduced. Thus, the response meets all three evaluation criteria.",595,5,5,136.2,681,"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis; Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran; Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation; Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update; Inotersen therapy of transthyretin amyloid cardiomyopathy",https://pubmed.ncbi.nlm.nih.gov/29972753/; https://pubmed.ncbi.nlm.nih.gov/31701435/; https://pubmed.ncbi.nlm.nih.gov/35213769/; https://pubmed.ncbi.nlm.nih.gov/35908242/; https://pubmed.ncbi.nlm.nih.gov/31713445/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 35, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with heart failure, Intervention: NT-proBNP measured post-diagnosis, Outcomes: NT-proBNP level >4000 pg/mL', 'role': 'user'}]}",True,200.0,30.422162532806396,,1b63344e-326b-496a-9626-f7c1438fa577,821.0,"In patients with heart failure, NT-proBNP measured post-diagnosis above 4000 pg/mL is associated wit...",3.0,T/T/T,3.0,True,True,True,"The AI's answer is well grounded in the provided context. It directly addresses the research question by stating that, in patients with heart failure, NT-proBNP levels measured post-diagnosis above 4000 pg/mL are associated with a significantly higher risk of mortality and heart failure rehospitalization, as supported by multiple cited studies in the context. The answer also includes details of hazard ratios and additional clinical correlations that are present in the context. There are no claims made that are not substantiated by the context. Overall, the answer is accurate, relevant, and well supported.",612,4,4,223.75,895,Quantitative Profiling of Serum Carnitines Facilitates the Etiology Diagnosis and Prognosis Prediction in Heart Failure; Clinical and Demographic Characteristics of Patients Hospitalized for Decompensated Heart Failure with Extremely High NT‑proBNP Levels; Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction; Routinely measured cardiac troponin I and N‑terminal pro‑B‑type natriuretic peptide as predictors of mortality in haemodialysis patients,https://pmc.ncbi.nlm.nih.gov/articles/PMC10384279/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11592870/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10531735/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8934949/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 34, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'In patients with BMI 30 or higher, is there a difference in use of GLP1-RA in those with vs without a recorded obesity diagnosis?', 'role': 'user'}]}",True,200.0,38.31027340888977,,fae29fda-5c3e-48d6-8721-762551492685,69.0,The published literature does not contain an answer to this question.,0.0,F/F/F,1.0,False,False,False,"There is no context provided, so it does not directly answer the question, does not address the question, and the AI's answer cannot be considered grounded in the context. The AI's statement is an assertion not supported or refuted by the nonexistent context.",259,0,0,0.0,0,,,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 39, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the prevalence of heart failure', 'role': 'user'}]}",True,200.0,26.77638030052185,,794051f1-586b-457b-8a7d-a0c8e7bfb2eb,324.0,Global prevalence: ~56 million people living with heart failure (2019 Global Burden of Disease estim...,3.0,T/T/T,3.0,True,True,True,"The context provides explicit, quantitative data on the global prevalence of heart failure (56.19 million cases in 2019, 711.90 per 100,000 population, and 1–3% prevalence range worldwide), as well as a US-specific estimate. The AI's answer accurately summarizes these key data points, citing the global tally, the prevalence percentage, and the US estimate. While the mention of ""Western countries"" is not directly stated in the context, the AI does not give a prevalence outside the supplied 1–3% range. The answer remains grounded in the provided evidence and does not introduce unsupported claims. Context both directly answers and addresses the question. Therefore, all three criteria are satisfied.",704,3,3,196.33333333333334,589,"Burden, Trends, and Inequalities of Heart Failure Globally, 1990 to 2019: A Secondary Analysis Based on the Global Burden of Disease 2019 Study; Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America; Epidemiology and risk profile of heart failure",https://pmc.ncbi.nlm.nih.gov/articles/PMC10111559/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10864030/; https://pubmed.ncbi.nlm.nih.gov/21060326/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 36, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Among heart failure patients, what proportion have NT-proBNP levels exceeding 4000 pg/mL at any point after diagnosis?', 'role': 'user'}]}",True,200.0,32.50878119468689,,35f4314c-6749-4bef-be90-78d85a64f3ad,233.0,"In a large US HFrEF cohort with post-diagnosis NT‑proBNP testing, 25.5% had values >4000 pg/mL at an...",3.0,T/T/T,3.0,True,True,True,"The context provides a direct answer to the question, specifically stating that 25.5% of HFrEF (heart failure with reduced ejection fraction) patients had NT-proBNP levels exceeding 4000 pg/mL at some point after diagnosis. It further breaks down the percentages for subgroups, matching the details in the AI-generated answer. The answer is fully grounded in the provided context and contains no unsupported claims.",415,2,2,195.5,391,N‑terminal pro‑B‑type natriuretic peptide testing patterns in patients with heart failure with reduced ejection fraction; Vericiguat and NT‑proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial,https://pmc.ncbi.nlm.nih.gov/articles/PMC8787988/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9773767/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 38, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what is the prevalence of HF', 'role': 'user'}]}",True,200.0,32.5784649848938,,8e57aa2c-3646-4779-9fc5-ab7b050b17e5,252.0,"Global prevalence: ~55.5 million people living with heart failure in 2021. [1]
United States: ~6.7 m...",3.0,T/T/T,3.0,True,True,True,"The context provides specific figures about the global and US prevalence of heart failure (HF): 55.5 million people globally and 6.7 million US adults affected, along with prevalence percentages and future projections. The AI's answer accurately uses this data, specifying global and US prevalence and citing anticipated trends. All statements in the answer are directly grounded in the provided context and address the prevalence question directly and specifically.",466,2,2,182.0,364,"Global burden of heart failure and its underlying causes in 204 countries and territories, 1990-2021; Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America - PMC",https://pubmed.ncbi.nlm.nih.gov/39774847/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10864030/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 30, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: COPD, Intervention: budesonide-glycopyrrolate-formoterol, Control: fluticasone-umeclidinium-vilanterol, Outcomes: % Hospitalization', 'role': 'user'}]}",True,200.0,56.31261658668518,,349e23aa-2c48-4f3f-993d-109bb7ea4126,891.0,Limitations: absolute percent hospitalized on each drug is not reported in the abstracts; available ...,3.0,T/T/T,3.0,True,True,True,"The context directly answers the question by providing comparative data on hospitalization risk: it states that in a cohort study, budesonide–glycopyrrolate–formoterol had a 29% higher hazard of severe COPD exacerbation (hospitalization) compared to fluticasone–umeclidinium–vilanterol. The AI answer correctly cites this, notes limitations (such as lack of absolute rates), accurately reflects the information about pneumonia rates, and references supporting network meta-analysis and observational data. All information in the answer is grounded in the given context and does not introduce unsupported claims.",611,3,3,219.66666666666666,659,Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study; Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis; Fluticasone Furoate/Umeclidinium/Vilanterol Initiation Following a COPD Exacerbation: Benefits of Prompt Initiation on COPD Outcomes - PubMed,https://pubmed.ncbi.nlm.nih.gov/39797646/; https://pubmed.ncbi.nlm.nih.gov/33929661/; https://pubmed.ncbi.nlm.nih.gov/39453592/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 43, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: COPD, Intervention: budesonide-glycopyrrolate-formoterol, Control: fluticasone-umeclidinium-vilanterol, Outcomes: % with COPD-related hospitalization', 'role': 'user'}]}",True,200.0,28.589250564575195,,adacc0f3-5f57-4772-aeab-e81e5321243c,1489.0,No randomized head-to-head trial reporting the percent of patients with COPD-related hospitalization...,2.0,F/T/T,2.0,False,True,True,"The context does not provide a direct head-to-head percentage comparison of COPD-related hospitalization rates between the two interventions (budesonide-glycopyrrolate-formoterol vs fluticasone-umeclidinium-vilanterol). However, the context is relevant as it discusses each therapy's effects on exacerbation rates, respiratory hospitalizations, and related real-world outcomes, including comparative and observational meta-analyses. The AI's answer accurately reflects the evidence from the context and does not introduce unsupported claims, clearly noting the absence of a direct comparison and summarizing the existing evidence appropriately.",644,4,4,215.0,860,Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis - PubMed; Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis - PubMed; Fluticasone Furoate/Umeclidinium/Vilanterol Initiation Following a COPD Exacerbation: Benefits of Prompt Initiation on COPD Outcomes - PubMed; Triple inhaled therapy of formoterol/glycopyrrolate/budesonide reduces the use of oral corticosteroids and antibiotics during COPD exacerbations in real-world conditions - PubMed,https://pubmed.ncbi.nlm.nih.gov/33929661/; https://pubmed.ncbi.nlm.nih.gov/35849317/; https://pubmed.ncbi.nlm.nih.gov/39453592/; https://pubmed.ncbi.nlm.nih.gov/39827764/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 41, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma, Intervention: Dupixent, Control: Fasenra, Outcomes: % of asthma related ED visit', 'role': 'user'}]}",True,200.0,41.617390632629395,,0beb73eb-d18b-471e-a734-10878eda14a5,697.0,No head-to-head randomized trials report percent of asthma-related ED visits for Dupixent (dupilumab...,2.0,F/T/T,2.0,False,True,True,"The provided context does not include a direct report of the percent of asthma-related ED visits for Dupixent versus Fasenra, which is what the original question asks. Instead, it offers data on the relative reduction in risk or hazard of asthma exacerbations (which may include, but are broader than, ED visits) and does not specify the outcome as a percentage, nor does it strictly isolate ED visits versus other forms of exacerbation. The context is relevant as it addresses comparative effectiveness between Dupixent and Fasenra on exacerbation rates (including those that result in ED visits), so it is relevant to the question. The AI answer is grounded in the context, restating the provided data points and accurately clarifying the lack of direct head-to-head or percent-based outcomes, without introducing outside information.",836,3,3,174.0,522,"Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma - PubMed; Real-world effectiveness of dupilumab versus benralizumab and mepolizumab - PubMed; Comparative Effectiveness of Dupilumab Versus Mepolizumab and Benralizumab in Asthma: A Multinational Retrospective Cohort Study - PubMed",https://pubmed.ncbi.nlm.nih.gov/40261563/; https://pubmed.ncbi.nlm.nih.gov/38760161/; https://pubmed.ncbi.nlm.nih.gov/40250559/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 42, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Lupus , Cohort_1: Hydroxychloroquine, Cohort_2: Steroid, Outcomes: ED visit', 'role': 'user'}]}",True,200.0,38.92508316040039,,de9e3554-0eac-4f0c-b2b3-1702a750dafd,1047.0,No published study was identified that directly compares hydroxychloroquine versus corticosteroid-tr...,2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False. The context does not provide direct evidence or data comparing rates of emergency department (ED) visits between hydroxychloroquine- and steroid-treated lupus cohorts. The answer correctly notes this absence.

2. context_addresses_question: True. The context discusses studies about ED use in lupus, hydroxychloroquine outcomes, and steroid adverse events, making it generally relevant to the question even though it lacks the direct comparison requested.

3. answer_grounded_in_context: True. The answer correctly summarizes the provided context and does not introduce unsupported claims, sticking closely to the findings and limitations from the cited studies.",707,4,4,153.75,615,Frequent use of the emergency department among persons with systemic lupus erythematosus; Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort; Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: A systematic review and meta-analysis of cohort studies; Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis,https://pubmed.ncbi.nlm.nih.gov/20391487/; https://pubmed.ncbi.nlm.nih.gov/30103646/; https://pubmed.ncbi.nlm.nih.gov/36325952/; https://pubmed.ncbi.nlm.nih.gov/26749299/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 45, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the incidence of cdiff in immunocompromised patients?', 'role': 'user'}]}",True,200.0,32.203532218933105,,3663fb22-6550-46bc-924a-64fa7b404a8c,592.0,Incidence varies by type of immunocompromise: reported rates range from about 6–33% in hematology–on...,3.0,T/T/T,3.0,True,True,True,"The provided context gives specific incidence rates for C. difficile infection in various subpopulations of immunocompromised patients, such as hematology-oncology patients, lung transplant recipients, people living with HIV, and HSCT (hematopoietic stem cell transplant) recipients. The AI's answer accurately paraphrases these statistics and appropriately differentiates by subgroup, while also mentioning recurrence rates found in the context. There are no unsupported claims or hallucinations; all provided numbers come directly from the given context. The answer both directly and substantially addresses the question with exact data from the source material.",664,3,3,198.33333333333334,595,"Clostridium difficile in Immunocompromised Hosts: A Review of Epidemiology, Risk Factors, Treatment, and Prevention - PubMed; Prevalence of Clostridium difficile Infection in the Hematopoietic Transplantation Setting: Update of Systematic Review and Meta-Analysis - PubMed; The incidence and impact of clostridioides difficile infection on transplant outcomes in acute leukemia and MDS after allogeneic hematopoietic cell transplant-a CIBMTR study - PubMed",https://pubmed.ncbi.nlm.nih.gov/30281082/; https://pubmed.ncbi.nlm.nih.gov/35265530/; https://pubmed.ncbi.nlm.nih.gov/36543999/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 48, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'suggest some novel indications for existing AstraZeneca drugs', 'role': 'user'}]}",True,200.0,32.61669611930847,,8b084403-d510-4a64-ad24-ea04b2a8a744,398.0,Recommend repurposing AstraZeneca's SGLT2 inhibitor dapagliflozin (Farxiga) for treatment of nonalco...,3.0,T/T/T,3.0,True,True,True,"The context provided consists of multiple randomized controlled trials and systematic reviews demonstrating dapagliflozin's effects on NAFLD and MASH, such as reductions in liver fat, improvement in liver enzymes, and beneficial histological outcomes. The AI's answer directly suggests these as novel indications for dapagliflozin, which is consistent with the provided evidence. No unsupported claims or external information were introduced. The context addresses and directly answers the question, and the answer is grounded entirely in the context supplied.",560,4,4,184.0,736,"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial; Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis; Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial - PubMed; Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease",https://pubmed.ncbi.nlm.nih.gov/40467095/; https://pubmed.ncbi.nlm.nih.gov/35202771/; https://pubmed.ncbi.nlm.nih.gov/39625600/; https://pubmed.ncbi.nlm.nih.gov/37722211/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 47, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'do GLP1 affect COPD exacerbation rates?', 'role': 'user'}]}",True,200.0,38.96696901321411,,947a2461-60a9-4c99-b136-d1786e04d71d,705.0,Observational studies and systematic reviews report that GLP‑1 receptor agonist (GLP‑1RA) use is ass...,3.0,T/T/T,3.0,True,True,True,"The AI's answer accurately reflects the content provided in the context. The context directly answers the question by referencing observational studies and systematic reviews showing that GLP-1 receptor agonists are associated with decreased rates of COPD exacerbations compared to other antidiabetic drugs, with no randomized controlled trial evidence. The answer is appropriately cautious, highlights the nonrandomized nature of the supporting studies, and closely matches the statistical findings and recommendations in the provided sources. No unsupported claims or external information are introduced.",606,4,4,254.0,1016,"Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes; Efficacy of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Moderate-to-Severe COPD Exacerbations Among Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis; Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study; Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic review",https://pubmed.ncbi.nlm.nih.gov/37647574/; https://pubmed.ncbi.nlm.nih.gov/41011208/; https://pubmed.ncbi.nlm.nih.gov/36318979/; https://pubmed.ncbi.nlm.nih.gov/40480531/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 50, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients diagnosed with severe acute kidney injury, Intervention: Encounter for care involving renal dialysis, Control: patients diagnosed with severe acute kidney injury not receiving renal replacement therapy, Outcomes: death', 'role': 'user'}]}",True,200.0,34.42541742324829,,6c2402c5-9854-449f-9876-5b1e2a6cfdb3,1205.0,Limitations: No randomized trials directly compare ‘encounter for dialysis’ versus no renal replacem...,3.0,T/T/T,3.0,True,True,True,"The AI's answer is well grounded in the provided context. It accurately summarizes the observational evidence from the cited studies, which report higher mortality among severe AKI patients treated with RRT compared to those not receiving RRT, noting specific mortality rates and hazard ratios found in the studies. It also correctly notes the lack of randomized controlled trials directly comparing RRT to no RRT in severe AKI, accurately reflecting the limitations and data presented in the context. The answer refrains from over-interpreting causality due to confounding by severity, in line with the limitations of the observational data provided. All statements and interpretations correspond to and are supported by the information given in the context.",759,4,4,151.5,606,High-dose renal replacement therapy for acute kidney injury: Systematic review and meta-analysis; Incidence and Outcomes of Acute Kidney Injury Requiring Renal Replacement Therapy: A Retrospective Cohort Study; Long-term outcome in ICU patients with acute kidney injury treated with renal replacement therapy: a prospective cohort study; Acute kidney injury treated with renal replacement therapy and 5-year mortality after myocardial infarction-related cardiogenic shock: a nationwide population-based cohort study,https://pubmed.ncbi.nlm.nih.gov/20308884/; https://pubmed.ncbi.nlm.nih.gov/27380264/; https://pubmed.ncbi.nlm.nih.gov/27520553/; https://pubmed.ncbi.nlm.nih.gov/26715162/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 40, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma, Intervention: Airsupra, Control: Albuterol, Outcomes: % with asthma related ED visit', 'role': 'user'}]}",True,200.0,65.57728266716003,,8e81ca53-6f8f-4786-bc72-d07eb2592d85,717.0,No published randomized trial was found that directly compares Airsupra (albuterol+budesonide) versu...,2.0,F/T/T,2.0,False,True,True,"The provided context does not directly answer the question about the percentage of asthma-related ED visits comparing Airsupra to albuterol; it does not present head-to-head randomized trial data on this outcome. The context is relevant to the question, discussing Airsupra, albuterol, and studies on adding budesonide to albuterol-containing regimens, which relates to the intervention and comparator. The AI's answer is appropriately grounded in the context, citing the lack of direct comparative data and referencing the available studies without importing unsupported facts.",578,3,3,155.0,465,"AIRSUPRA (albuterol sulfate and budesonide) aerosol, metered - DailyMed search results; New Combination Asthma Drug - PubMed; Nebulized budesonide added to standard pediatric emergency department treatment of acute asthma: a randomized, double-blind trial - PubMed",https://dailymed.nlm.nih.gov/dailymed/search.cfm?_escaped_fragment_=&audience=professional&labeltype=all&page=1&pagesize=100&query=Corticosteroid&searchdb=class&sortby=rel&vfile=; https://pubmed.ncbi.nlm.nih.gov/37077014/; https://pubmed.ncbi.nlm.nih.gov/21762229/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 54, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with type 2 diabetes and chronic obstructive pulmonary disease, Intervention: glucagon-like peptide-1 agonists, Control: dipeptidyl peptidase-4 inhibitors, Outcomes: hospitalisation for chronic obstructive pulmonary disease exacerbations', 'role': 'user'}]}",True,200.0,19.535605669021606,,5a61a8b2-b369-4ab5-ad87-4e4963465ce9,799.0,"Observational evidence indicates that, among patients with type 2 diabetes and chronic obstructive p...",3.0,T/T/T,3.0,True,True,True,"The provided context includes three studies directly comparing GLP-1 receptor agonists with DPP-4 inhibitors in patients with type 2 diabetes and COPD, with measured outcomes being hospitalizations or exacerbations for COPD or related respiratory conditions. The AI's answer accurately summarizes these findings: reporting the pooled incidence rate ratio from a systematic review, the adjusted hazard ratio from a population cohort, and similar findings from an EHR study. Furthermore, the AI properly notes the observational nature of these data and the absence of randomized trial evidence for the specified comparison. All claims in the AI answer are grounded in the provided context, which is relevant and directly addresses the original question.",751,3,3,183.0,549,Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic review; Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes; Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes,https://pubmed.ncbi.nlm.nih.gov/40480531/; https://pubmed.ncbi.nlm.nih.gov/33875487/; https://pubmed.ncbi.nlm.nih.gov/37647574/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 53, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'do GLP1s reduce the risk of COPD exacerbations', 'role': 'user'}]}",True,200.0,31.9683780670166,,640d610b-34cd-4c42-9522-0a47e4de764c,590.0,Observational studies and systematic reviews show GLP‑1 receptor agonist (GLP‑1RA) use is associated...,3.0,T/T/T,3.0,True,True,True,"The context directly addresses the question by describing observational evidence and systematic reviews indicating that GLP-1 receptor agonists are associated with lower rates of COPD exacerbations in patients with type 2 diabetes, when compared with sulfonylureas and DPP-4 inhibitors. The context specifically states results of network meta-analysis and cohort studies, providing quantitative measures (e.g., reduced risk and incidence rate ratios) and noting that the evidence is based on observational studies only, with no randomized controlled trials identified. The AI's answer accurately reflects and is grounded in the context, discusses the limitations (i.e., lack of RCTs and causal inference), and does not introduce unsupported claims.",748,4,4,224.0,896,"Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes; Efficacy of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Moderate-to-Severe COPD Exacerbations Among Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis; Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic review; Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD",https://pubmed.ncbi.nlm.nih.gov/37647574/; https://pubmed.ncbi.nlm.nih.gov/41011208/; https://pubmed.ncbi.nlm.nih.gov/40480531/; https://pubmed.ncbi.nlm.nih.gov/39353727/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 49, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'In patients with BMI 30 or higher, is there a difference in use of GLP1-RA in those with vs without a recorded obesity diagnosis?', 'role': 'user'}]}",True,200.0,51.85750675201416,,91db6f15-fdc1-4374-b26e-d1ca4849b683,1525.0,Limitations: No published study was found that directly compares GLP-1 RA prescribing among patients...,2.0,F/T/T,2.0,False,True,True,"The context does not contain direct evidence comparing GLP1-RA use in patients with BMI ≥30 with versus without a recorded obesity diagnosis. However, it does address elements relevant to the question: (1) One study focuses only on those with a recorded obesity diagnosis; (2) Higher BMI is associated with greater GLP1-RA use among patients with both obesity and T2D; (3) Obesity is under-diagnosed in clinical records even in patients with BMI ≥30, and anti-obesity medications are still prescribed to some without a recorded diagnosis. The AI's answer accurately synthesizes and summarizes these points without introducing unsupported claims or external information, and explicitly states that a direct comparison study is lacking. Thus, the output is fully grounded in the context and addresses the question, but does not answer it directly.",845,3,3,208.33333333333334,625,"Factors Associated With Semaglutide Initiation Among Adults With Obesity; Trends in Glucagon-Like Peptide-1 Agonist Use and BMI Among Obese Adults With Type 2 Diabetes: Analysis of the 2010-2015 National Ambulatory Medical Care Survey (NAMCS), Adjusted for Cardiovascular Comorbidity - PMC; Knowledge, attitudes, and practices in obesity among trained and in-training primary care providers in an urban safety-net hospital system - PMC",https://pubmed.ncbi.nlm.nih.gov/39836425/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12432795/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12182768/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 52, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'do GLP1 reduce COPD exacerbation rates?', 'role': 'user'}]}",True,200.0,40.77764320373535,,866acec9-2f27-4659-aa36-a36b48741f60,733.0,Observational evidence and a recent systematic review/meta-analysis of retrospective studies indicat...,3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: True. The context provides direct evidence from observational studies and a systematic review/meta-analysis showing that GLP-1RA use is associated with lower COPD exacerbation rates compared to sulfonylureas and DPP-4 inhibitors. 

2. context_addresses_question: True. The context is highly relevant, focusing specifically on GLP-1RA effects on COPD exacerbations, and includes both observational and randomized trial data. 

3. answer_grounded_in_context: True. The AI answer accurately reflects the findings of the context, summarizes the results of the provided studies, and correctly states that high-quality prospective trials are lacking. No claims are made beyond what is in the context.",732,3,3,227.0,681,Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic review; Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes - PubMed; Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease - PubMed,https://pubmed.ncbi.nlm.nih.gov/40480531/; https://pubmed.ncbi.nlm.nih.gov/37647574/; https://pubmed.ncbi.nlm.nih.gov/35237033/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 55, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Do GLP1 reduce risk of COPD exacerbation in non T1 or T2 diabetes patients?', 'role': 'user'}]}",True,200.0,35.49565577507019,,3852607e-16d5-48d2-aac9-c27ed859124e,533.0,No high-quality evidence addresses whether GLP-1 receptor agonists reduce COPD exacerbations in pati...,2.0,F/T/T,2.0,False,True,True,"The context does not directly answer whether GLP-1 reduces the risk of COPD exacerbation in non-diabetic (non-T1 or T2 diabetes) patients, as the studies cited all focus on populations with diabetes or use genetic proxies rather than clinical outcomes in non-diabetic patients. However, the context is relevant to the question since it discusses GLP-1RA and COPD exacerbations, and addresses the populations studied. The AI's answer accurately summarizes the scope and limitations of the contextual evidence and does not introduce unsupported claims.",550,3,3,216.33333333333334,649,Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic review; Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes; Association of GLP1RAs with risk of chronic obstructive pulmonary disease: evidence from drug target Mendelian randomization,https://pubmed.ncbi.nlm.nih.gov/40480531/; https://pubmed.ncbi.nlm.nih.gov/37647574/; https://pubmed.ncbi.nlm.nih.gov/40722198/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 58, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients identified in retrospective electronic health record or claims data with a minimum 12 months of continuous enrollment prior to the index diagnosis, Intervention: patients with a diagnosis of rheumatoid arthritis, Control: patients with Myasthenia gravis matched on baseline characteristics, Outcomes: bacterial meningitis', 'role': 'user'}]}",True,200.0,22.918012380599976,,94d005e7-32bc-461c-8736-29474a10d6bb,941.0,No published study meeting the specified PICO (retrospective EHR/claims cohorts with ≥12 months base...,2.0,F/T/T,2.0,False,True,True,"The context does not provide direct evidence from studies specifically meeting the PICO criteria (retrospective EHR/claims studies with at least 12 months of baseline, comparing rheumatoid arthritis and myasthenia gravis with outcomes of bacterial meningitis). It addresses conditions relevant to the question (i.e., risks in rheumatoid arthritis, myasthenia gravis, and data sources), but lacks direct, specific results regarding bacterial meningitis incidence in the populations specified. The AI answer accurately reflects the limitations of the context and does not introduce information not present in the context.",619,3,3,229.66666666666666,689,Rheumatoid meningitis: A systematic review and meta-analysis; Serious infections in patients with myasthenia gravis: population-based cohort study; Serious Bacterial Infections Associated with Eculizumab: A Pharmacovigilance Study,https://pubmed.ncbi.nlm.nih.gov/33966315/; https://pubmed.ncbi.nlm.nih.gov/31997519/; https://pubmed.ncbi.nlm.nih.gov/37690847/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 51, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with body mass index 30 or higher, Intervention: obesity diagnosis, Control: no obesity diagnosis, Outcomes: semaglutide or tirzepatide', 'role': 'user'}]}",True,200.0,55.05586552619934,,a06b991e-21d3-4a97-8aa3-c6351469e4c1,958.0,No published study was identified that directly compares documenting an obesity diagnosis versus not...,2.0,F/T/T,2.0,False,True,True,"The context does not provide a direct answer to whether an obesity diagnosis (versus no diagnosis) influences subsequent use of semaglutide or tirzepatide; it instead provides evidence on BMI, prescribing patterns, and comparative efficacy between the drugs. The answer correctly identifies the absence of direct evidence on the population, intervention, and control as specified in the question, while appropriately anchoring its statements to the actual context (e.g., higher BMI associates with more GLP-1 agonist prescriptions, not the effect of the diagnosis itself). The answer refrains from introducing unsupported claims and accurately references the context's information about efficacy and prescribing patterns. Thus, the response is contextual and grounded, but the context does not directly answer the original question.",832,4,4,173.0,692,"Trends in Glucagon-Like Peptide-1 Agonist Use and BMI Among Obese Adults With Type 2 Diabetes: Analysis of the 2010-2015 National Ambulatory Medical Care Survey (NAMCS), Adjusted for Cardiovascular Comorbidity; Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity - PubMed; The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials - PMC; Efficacy of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Weight Loss Management in Non-Diabetic Patients - PMC",https://pmc.ncbi.nlm.nih.gov/articles/PMC12432795/; https://pubmed.ncbi.nlm.nih.gov/38976257/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12114739/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11335185/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 56, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'does uncontrolled hypertension increase the risk of stroke', 'role': 'user'}]}",True,200.0,30.819790363311768,,853425db-a0f2-4b96-955f-863db692ebc0,837.0,Yes. Multiple cohort studies and meta-analyses show uncontrolled or higher blood pressure is associa...,3.0,T/T/T,3.0,True,True,True,"The context provides direct evidence that uncontrolled hypertension increases the risk of stroke, citing quantitative risk ratios and population-based associations. The AI's answer accurately summarizes these findings with specific data from each referenced study, including the increased risk ratios for both ischemic and hemorrhagic stroke, higher incidence rates in people with uncontrolled blood pressure, the attribution of a substantial percentage of strokes to uncontrolled hypertension, and the risk from prehypertension. It also references the protective effect of medication adherence, as documented in the sources. The answer does not introduce information beyond what is supported in the provided context. All evaluation criteria are satisfied.",756,4,4,223.75,895,Control of blood pressure and risk of stroke among pharmacologically treated hypertensive patients - PubMed; Blood pressure control and risk of stroke: a population-based prospective cohort study - PubMed; Prehypertension and the risk of stroke: a meta-analysis - PubMed; Adherence to Antihypertensive Medications and Stroke Risk: A Dose-Response Meta-Analysis - PubMed,https://pubmed.ncbi.nlm.nih.gov/10657416/; https://pubmed.ncbi.nlm.nih.gov/15746450/; https://pubmed.ncbi.nlm.nih.gov/24623843/; https://pubmed.ncbi.nlm.nih.gov/28743788/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 60, 'customer': 'Astrazeneca BBU', 'messages': [{'content': '1) How many patients are treated with at least one dose of each of the following biologics in 2024? Report the number of patients for each of the three disease areas 1) patients with asthma (without CRSwNP), 2) patients with asthma and CRSwNP, 3) Patients with CRSwNP (without asthma)\n • Patients on Dupixent\n • Patients on Nucala\n • Patients on Xolair\n • Patients on Fasenra \n • Patients on Tezspire \n  \n 2) among patients from 1), report the number of patients with a valid eosinophilic lab test value by each disease cohorts\n \n 3) among three, split the patient counts by eosinophilic lab value of a) <=150/μL, b) 150-<300/μL, c) >=300/μL', 'role': 'user'}]}",True,200.0,26.987196922302246,,49170cc6-e850-4568-9659-c355d43021af,69.0,The published literature does not contain an answer to this question.,1.0,F/F/T,1.0,False,False,True,"Since the provided context is empty, it neither answers the question directly nor addresses it. The AI's answer appropriately reflects that the context does not provide the requested data or evidence from the literature. Therefore, while the answer is grounded in the provided context (no content, no unsupported claims), the first two criteria are not met.",357,0,0,0.0,0,,,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 61, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Among hospital in-patients, does vitamin D deficiency predict fecal incontinence?', 'role': 'user'}]}",True,200.0,22.448212385177612,,8d6625eb-7377-4d97-b6e4-5b0a55f75951,454.0,"Among hospital in‑patients and large healthcare system patients, vitamin D deficiency is associated ...",3.0,T/T/T,3.0,True,True,True,"The context directly addresses the question by providing evidence from a large EHR dataset showing that vitamin D deficiency predicts a higher rate of new fecal incontinence diagnosis (HR 1.9, 95% CI 1.14–3.15) among patients, which is specifically relevant to hospital in-patients. The AI’s answer accurately summarizes these findings and cites the correct study. It also notes related findings about pelvic floor disorders, reflecting relevant context from the second reference. There is no introduction of unsupported claims; the answer remains grounded in the provided evidence.",582,2,2,225.0,450,The association between vitamin-D deficiency and fecal incontinence - PubMed; Vitamin D and pelvic floor disorders in women: results from the National Health and Nutrition Examination Survey - PubMed,https://pubmed.ncbi.nlm.nih.gov/38316640/; https://pubmed.ncbi.nlm.nih.gov/20308841/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 63, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with essential hypertension , Cohort_1: systolic blood pressure of 140 and above , Cohort_2: systolic blood pressure of less than 140, Outcomes: number of hospitalizations', 'role': 'user'}]}",True,200.0,21.894380569458008,,ef5bb494-1611-4289-9b39-48e4f2604751,441.0,Available indexed literature in NLM databases does not contain a cohort study that directly reports ...,2.0,F/T/T,2.0,False,True,True,"The context does not directly answer the question, as none of the cited studies report hospitalization counts for patients with essential hypertension stratified by systolic blood pressure ≥140 mmHg versus <140 mmHg. However, the context is relevant, as it discusses related outcomes and populations, and the AI answer accurately summarizes the gap in the literature based solely on the provided context without introducing external information.",445,3,3,306.3333333333333,919,"Admission systolic blood pressure as a prognostic predictor of acute decompensated heart failure: A report from the KCHF registry - PubMed; Comparison of Home-Based vs Center-Based Cardiac Rehabilitation in Hospitalization, Medication Adherence, and Risk Factor Control Among Patients With Cardiovascular Disease - PMC; Antihypertensive agents acting on the renin–angiotensin system and the risk of sepsis - PMC",https://pubmed.ncbi.nlm.nih.gov/34214124/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9412228/; https://pmc.ncbi.nlm.nih.gov/articles/PMC4243890/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 62, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with diagnosis of essential hypertension , Cohort_1: systolic blood pressure of 140 and above , Cohort_2: systolic blood pressure of less than 140, Outcomes: % of patients with at least 3 or more classes of antihypertensives', 'role': 'user'}]}",True,200.0,25.932781219482422,,625c0595-c532-45a6-8b29-ca526061a7b5,1154.0,"No single study was identified that directly reports, for the exact cohorts you specified (patients ...",2.0,F/T/T,2.0,False,True,True,"The provided context contains relevant information about the number of antihypertensive classes used in patients with various levels of systolic blood pressure, but none of the cited studies directly report the percentage of patients with essential hypertension and SBP ≥140 vs <140 on three or more classes, matching the specified populations precisely. However, the studies do offer data for related cohorts or summary statistics suggestive of trends in medication regimens by varying SBP. The AI answer accurately summarizes this situation, making clear the lack of a direct answer and appropriately referencing the context details. The answer does not introduce information unsupported by context.",701,4,4,154.0,616,"Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention Trial - PMC; Cross-sectional survey evaluating blood pressure control ACHIEVEment in hypertensive patients treated with multiple anti-hypertensive agents in Belgium and Luxembourg - PMC; Trends in Initial Antihypertensive Medication Prescribing Among >2.8 Million Veterans Newly Diagnosed With Hypertension, 2000 to 2019 - PMC; Prevalence and Characteristics of Systolic Blood Pressure Thresholds in Individuals Aged 60 Years and Older - PMC",https://pmc.ncbi.nlm.nih.gov/articles/PMC9931643/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6211697/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11935568/; https://pmc.ncbi.nlm.nih.gov/articles/PMC4233656/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 59, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'how many patients diagnosed with MYASTHENIA.GRAVIS', 'role': 'user'}]}",True,200.0,41.76201939582825,,6ff916a1-4eec-4ae7-8ab6-bfcc90f31dff,468.0,"Estimates vary by source and method. A 2021 US claims-based analysis estimated about 82,715 adults l...",3.0,T/T/T,3.0,True,True,True,"The AI's answer directly addresses the question by providing the number of diagnosed myasthenia gravis (MG) patients based on specific studies, particularly noting the estimate of about 82,715 adults in the US in 2021. It also includes other prevalence rates from US and global data, all clearly derived from the provided context. The answer does not introduce unsupported claims and is entirely grounded in the supplied material.",430,3,3,185.33333333333334,556,"Prevalence, Incidence, and Mortality of Myasthenia Gravis and Myasthenic Syndromes: A Systematic Review; Incidence and prevalence of myasthenia gravis in the United States: A claims-based analysis; Epidemiology of myasthenia gravis in the United States",https://pubmed.ncbi.nlm.nih.gov/39380477/; https://pubmed.ncbi.nlm.nih.gov/38040629/; https://pubmed.ncbi.nlm.nih.gov/38434198/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 65, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with hypertension , Cohort_1: BMI > 30, Cohort_2: BMI < 30, Outcomes: systolic blood pressure', 'role': 'user'}]}",True,200.0,26.561740159988403,,e84c0ae3-704d-486e-a85d-1f215eb99e86,809.0,"Among adults with hypertension, higher BMI (obesity, BMI ≥30) is associated with higher systolic blo...",3.0,T/T/T,3.0,True,True,True,"The AI's answer is well-grounded in the provided context. It explicitly states that higher BMI in hypertensive patients is associated with higher systolic blood pressure, which is supported directly by all three references given. Data is cited appropriately: the persistent positive relationship (reference 1), population-based findings for hypertensive US adults (reference 2), and specific numbers from a cross-sectional clinical sample comparing higher and lower BMI groups (reference 3). The answer does not include external or hallucinated facts, staying fully grounded in the provided evidence. All elements of the question (population, cohorts, outcome) are addressed and supported by the context.",704,3,3,280.0,840,"Changes in the body mass index and blood pressure association across time: Evidence from multiple cross-sectional and cohort studies; BMI and blood pressure control among United States adults with hypertension; Study of Body Mass Index, Blood Pressure, Serum Sodium in Newly Diagnosed Hypertensive Patients",https://pubmed.ncbi.nlm.nih.gov/34599929/; https://pubmed.ncbi.nlm.nih.gov/35001034/; https://pubmed.ncbi.nlm.nih.gov/37002745/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 64, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with essential hypertension , Cohort_1: systolic blood pressure > 140, Cohort_2: systolic blood pressure < 140, Outcomes: BMI', 'role': 'user'}]}",True,200.0,27.50873064994812,,6015ada0-1d9d-4c05-b78d-1ef9a6d0a469,277.0,"In cohorts of patients with hypertension, higher BMI is associated with poorer blood-pressure contro...",3.0,T/T/T,3.0,True,True,True,"The context directly answers the question, showing that patients with uncontrolled blood pressure (>140 mmHg) tend to have higher BMI and greater prevalence of overweight/obesity compared to those with controlled BP (<140 mmHg), as reported in the cited studies. Additionally, the context is highly relevant to the question, and the AI's answer does not introduce outside information or unsupported claims. The statements made about the relationship between BMI and blood pressure control are closely grounded in the context provided.",534,3,3,254.0,762,"Body mass index and blood pressure control among US adults with hypertension; Hypertension control and cardiometabolic risk: a regional perspective (i-SEARCH study); Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT",https://pmc.ncbi.nlm.nih.gov/articles/PMC8897212/; https://pubmed.ncbi.nlm.nih.gov/22242212/; https://pubmed.ncbi.nlm.nih.gov/24842697/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 57, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the incidence rate of bacterial meningitis in patients with rheumatoid arthritis compared to patients without rheumatoid arthritis with similar baseline characteristics?', 'role': 'user'}]}",True,200.0,56.20637536048889,,ea575a1e-f226-4ee3-a10f-3367044da617,69.0,The published literature does not contain an answer to this question.,1.0,F/F/T,1.0,False,False,True,"The provided context is empty and does not contain any evidence or information relevant to the question about the incidence rate of bacterial meningitis in patients with and without rheumatoid arthritis. The AI's answer correctly states that the literature does not contain an answer, which is grounded in the lack of context. However, since no actual context was given, this cannot be verified. Therefore, the answer is appropriately cautious, but the evaluation criteria related to directness and relevance are not met.",521,0,0,0.0,0,,,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 68, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what is the length of inpatient hospital stay for patients admitted to hospital with renal failure DRG code 682-684', 'role': 'user'}]}",True,200.0,27.708077430725098,,9c4ef328-bfd4-4fe4-b985-d10d1fe9da19,507.0,"Published literature searchable at NLM/ PubMed does not report a specific, generalizable average inp...",2.0,F/T/T,2.0,False,True,True,"The context does not provide a direct, up-to-date, or generalizable average length of inpatient hospital stay specifically for DRG codes 682–684 for renal failure. While one reference provides a mean length of stay for an ESRD cohort (10.2 days), it clearly notes this is not a DRG-wide statistic and is outdated. The context is relevant because it discusses DRG codes 682-684 and related length of stay information, but does not directly answer the precise question. The AI’s answer remains accurately grounded in the context, not making unsupported claims or introducing outside information.",593,3,3,173.33333333333334,520,Effect of Age-Friendly Care on Days at Home Post-Hospital Discharge for Traditional Medicare Patients: A Cross-Sectional Study - PMC; The impact of diagnosis-related groups on the cost of hospitalization for end-stage renal disease patients at Rhode Island Hospital from 1987 to 1990 - PubMed; Combined Use of Warfarin and Oral P2Y12 Inhibitors in Patients With Atrial Fibrillation and Acute Coronary Syndrome - PMC,https://pmc.ncbi.nlm.nih.gov/articles/PMC11898030/; https://pubmed.ncbi.nlm.nih.gov/1595699/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6649619/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 71, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma, Intervention: Symbicort or Dulera, Outcomes: % with >4 Albuterol fills', 'role': 'user'}]}",True,200.0,17.78977346420288,,38cba74d-1bd6-4213-8e3e-8b6938fa6d1d,69.0,The published literature does not contain an answer to this question.,1.0,F/F/T,1.0,False,False,True,"The context provided is empty, so there is no information directly answering the question or even addressing it. However, the AI's answer does not introduce any unsupported claims and is grounded in the (lack of) context provided.",230,0,0,0.0,0,,,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 69, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what is the length of inpatient hospital stay for patients admitted to hospital with DRG codes 682 683 or 684', 'role': 'user'}]}",True,200.0,26.546868324279785,,625148a3-c811-436e-a92e-0af3417ba951,290.0,No published articles located in the searched NLM/NCBI corpus report inpatient length-of-stay specif...,2.0,F/T/T,2.0,False,True,True,"The provided context does not include specific, relevant evidence that directly answers the question about the length of inpatient hospital stay for DRG codes 682, 683, or 684. Instead, the context explains that published studies report on length of stay variations within DRGs or for broader groups and procedures, not for these specific DRG codes. Therefore, the context addresses the general topic and supports the AI's response that specific data is not available for these codes, but it does not directly answer the question. The AI's answer is appropriately grounded in and confined to the context, accurately reflecting its limitations.",643,3,3,270.6666666666667,812,Length-of-stay variations within ICDA-8 diagnosis-related groups - PubMed; Do diagnosis-related groups appropriately explain variations in costs and length of stay of hip replacement? A comparative assessment of DRG systems across 10 European countries - PubMed; Trends in spinal surgery pre- and post-pandemic in a large metropolitan area - PMC,https://pubmed.ncbi.nlm.nih.gov/6422169/; https://pubmed.ncbi.nlm.nih.gov/22815116/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12238211/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 67, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'length of hospital stay with renal failure', 'role': 'user'}]}",True,200.0,36.85594320297241,,eb04f172-4335-4927-b5db-6c465e607306,484.0,Dialysis-requiring acute kidney injury is associated with prolonged hospitalization (median length o...,3.0,T/T/T,3.0,True,True,True,"The context provides specific information about median length of hospital stay for patients with acute kidney injury (AKI) requiring dialysis (21 days and 44.5 days), which directly addresses the question regarding hospital stay length with renal failure. The answer is grounded in this context, referencing the specific figures found in the provided studies. Additionally, the answer discusses associations between AKI and length of stay, as depicted in the third context document, without introducing unsupported claims. Therefore, all criteria are met.",555,3,3,197.66666666666666,593,"Incidence and Outcomes of Acute Kidney Injury Requiring Renal Replacement Therapy: A Retrospective Cohort Study - PubMed; Time to initiation of dialysis and length of stay in hospitalized patients with kidney damage: a cross-sectional study - PubMed; Acute kidney injury, mortality, length of stay, and costs in hospitalized patients - PubMed",https://pubmed.ncbi.nlm.nih.gov/27380264/; https://pubmed.ncbi.nlm.nih.gov/39774732/; https://pubmed.ncbi.nlm.nih.gov/16177006/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 70, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with at least 2 Asthma encounters, Intervention: Symbicort or Dulera, Outcomes: % with >4 Albuterol fills', 'role': 'user'}]}",True,200.0,31.454459190368652,,7473c6f4-e5b4-4f6e-8364-1f258e69ec96,1073.0,"No published study was found that directly reports, in a population defined as “patients with ≥2 ast...",2.0,F/T/T,2.0,False,True,True,"The AI answer correctly states that there is no published study in the context that directly answers the specific question regarding the percentage of patients with at least two asthma encounters on Symbicort or Dulera who have more than four albuterol fills. The context discusses outcomes related to albuterol/SABA use with budesonide-formoterol (Symbicort) versus other regimens, but not Dulera (mometasone-formoterol), nor does it provide the specific outcome requested (>4 albuterol fills). However, the answer is grounded in the provided context and accurately reflects the information presented therein, citing studies about budesonide–formoterol's impact on albuterol use and controller switching. The response appropriately outlines the limitations of the available evidence.",784,3,3,213.33333333333334,640,"Budesonide-Formoterol Metered-Dose Inhaler vs Fluticasone-Salmeterol Dry-Powder Inhaler - PubMed; Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial - PubMed; Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study - PubMed",https://pubmed.ncbi.nlm.nih.gov/40622686/; https://pubmed.ncbi.nlm.nih.gov/16478838/; https://pubmed.ncbi.nlm.nih.gov/16935685/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 66, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients aged 40 and older with chronic obstructive pulmonary disease, Intervention: budesonide/glycopyrrolate/formoterol fumarate, Control: fluticasone furoate/umeclidinium/vilanterol, Outcomes: % with 1 or more hospitalization', 'role': 'user'}]}",True,200.0,48.88420224189758,,4eaae776-7863-43d9-8829-76c595984c47,1322.0,No randomized trials or systematic reviews reporting the exact percentage of patients aged ≥40 with ...,2.0,F/T/T,2.0,False,True,True,"The context does not provide the exact percentage of patients with one or more hospitalizations for the treatments compared, supporting the AI's statement that this specific outcome is not directly reported. However, the context is relevant as it discusses studies comparing budesonide/glycopyrrolate/formoterol and fluticasone furoate/umeclidinium/vilanterol in COPD patients, focusing on related outcomes such as exacerbation rates and mortality. The AI's answer remains grounded in the context, accurately reflecting the limitations of the data and not introducing outside information.",588,4,4,188.75,755,Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study; Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease; Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis; Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT,https://pubmed.ncbi.nlm.nih.gov/39797646/; https://pubmed.ncbi.nlm.nih.gov/39731707/; https://pubmed.ncbi.nlm.nih.gov/35849317/; https://pubmed.ncbi.nlm.nih.gov/37583267/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 74, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Hypertension population with > 18 years of age and having at least 2 dx', 'role': 'user'}]}",True,200.0,32.56567740440369,,a6a85dcd-2170-42f0-be6b-e879b5946d22,562.0,"Common, validated electronic-health-record / claims definitions for adult (≥18 y) hypertension inclu...",3.0,T/T/T,3.0,True,True,True,"The AI's answer identifies electronic health record definitions for hypertension in adults ≥18 years old, specifying that two diagnosis codes (≥14 days apart) is a common criterion, matching the original question about a population with hypertension having ≥2 diagnoses. Context [1] and [3] support this definition directly, including age and diagnostic requirements. The answer also references additional validated EHR criteria and discusses the relative merits (PPV, sensitivity) of these definitions, in line with contextual information from source [2]. All statements made are explicitly or implicitly present in the provided context, with no unsupported claims.",666,3,3,238.66666666666666,716,The Longitudinal Epidemiologic Assessment of Diabetes Risk (LEADR): Unique 1.4 M patient Electronic Health Record cohort; Identification of Hypertension in Electronic Health Records Through Computable Phenotype Development and Validation for Use in Public Health Surveillance: Retrospective Study; Gout and the Risk of Non-vertebral Fracture,https://pmc.ncbi.nlm.nih.gov/articles/PMC11008431/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10782284/; https://pmc.ncbi.nlm.nih.gov/articles/PMC5292077/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 78, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with type 2 diabetes, Intervention: Statin, Outcomes: number of patients on statins and number of patients not on statins', 'role': 'user'}]}",True,200.0,20.848978281021118,,6753082e-5480-443e-bdcb-f9c8ef9d28b0,495.0,"Available study-level counts: In a registry of 10,226 patients with diabetes, 1,532 were included as...",3.0,T/T/T,3.0,True,True,True,"The AI's answer accurately summarizes the numbers of statin and non-statin users as described in the context. It reports the count of statin-treated and non-treated patients from the first study, the matched statin user and non-user numbers from the second study, and notes the total number of patients included in a meta-analysis comparing user/non-user groups as per the third context item. The answer neither introduces unsupported claims nor relies on information not available in the context. The context is directly relevant and answers the question regarding the number of patients on and not on statins.",611,3,3,132.0,396,"Adherence to Statin Therapy and Attainment of LDL Cholesterol Goal Among Patients with Type 2 Diabetes and Dyslipidemia; Statins for primary prevention in patients with type 2 diabetes: Can it benefit all ages? - A nationwide propensity-matched cohort study; Statin use and the risk of CVD events, stroke, and all-cause mortality in patients with diabetes: A systematic review and meta-analysis",https://pubmed.ncbi.nlm.nih.gov/31853174/; https://pubmed.ncbi.nlm.nih.gov/34508736/; https://pubmed.ncbi.nlm.nih.gov/36064686/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 72, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma, Intervention: Symbicort or Dulera, Outcomes: % with >10 Albuterol fills', 'role': 'user'}]}",True,200.0,38.652911901474,,2603ff7f-6318-4659-afa1-6f77d1847b91,318.0,The published literature searched does not report the specific outcome “percentage of asthma patient...,2.0,F/T/T,2.0,False,True,True,"The provided context explicitly states that neither study reports the percentage of asthma patients on Symbicort or Dulera with more than 10 albuterol fills. Instead, the studies provide related but not directly matching data, such as relative incidence rates or proportions with ≥5 fills. The AI answer accurately reflects this limitation by stating that the specific outcome is not reported and that only related information is available. Therefore, the context addresses the question but does not answer it directly, and the AI's answer remains grounded in the context.",572,2,2,238.5,477,Budesonide-Formoterol Metered-Dose Inhaler vs Fluticasone-Salmeterol Dry-Powder Inhaler; Medication adherence in Medicare-enrolled older adults with asthma before and during the coronavirus disease 2019 pandemic,https://pubmed.ncbi.nlm.nih.gov/40622686/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8873040/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 75, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Atherosclerotic cardiovascular disease, Cohort_1: age <18, Cohort_2: age >18, Outcomes: % patients with LDL > 70 mg/dL', 'role': 'user'}]}",True,200.0,27.970530033111572,,5c0ba8ec-83c1-4d39-90c8-2369fa6ec77f,595.0,There is no published estimate for the proportion of patients with established atherosclerotic cardi...,3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: True. The context does not provide data for patients <18 years, and the AI correctly reports this. For adults (>18), the context includes multiple estimates of the proportion with LDL ≥ 70 mg/dL and the AI summarizes these with correct references and percentages.

2. context_addresses_question: True. All sources specifically relate to the ASCVD population and LDL-C levels, precisely the topic of the question.

3. answer_grounded_in_context: True. The AI's answer is fully supported by the context, includes quoted percentages, and notes the absence of data for the pediatric cohort, which is accurate per the provided context.",668,3,3,130.66666666666666,392,Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States; Achievement of low-density lipoprotein cholesterol thresholds in very high-risk atherosclerotic cardiovascular disease - PubMed; Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study,https://pmc.ncbi.nlm.nih.gov/articles/PMC8315384/; https://pubmed.ncbi.nlm.nih.gov/40360376/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10397866/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 73, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Among COPD age > 40 years what % of patients have hospitalization on Budesonide/ Glycopyrrolate/ Formoterol Fumarate vs Fluticasone Furoate/ Umeclidinium Bromide/ Vilanterol Trifenatate', 'role': 'user'}]}",True,200.0,36.62919735908508,,baf427d0-2150-4b74-83ea-4bb597a8ff66,991.0,No randomized head-to-head trial reporting the percentage hospitalized on BUD/GLY/FOR versus FF/UMEC...,2.0,F/T/T,2.0,False,True,True,"The context does not provide a direct answer to the question regarding the absolute percentage of hospitalizations for each of the specified therapies in COPD patients over 40; neither does the AI answer. However, both the context and the AI response are fully relevant to the question, summarizing comparative and relative outcomes from studies (such as the 11% lower hospitalization rate and comparative efficacy findings), but both specifically note the absence of absolute hospitalization percentages. The AI's answer is accurately and solely grounded in the information provided in the context, without introducing extraneous information or unsupported claims.",665,3,3,259.6666666666667,779,Triple inhaled therapy of formoterol/glycopyrrolate/budesonide reduces the use of oral corticosteroids and antibiotics during COPD exacerbations in real-world conditions - PubMed; Fluticasone Furoate/Umeclidinium/Vilanterol Initiation Following a COPD Exacerbation: Benefits of Prompt Initiation on COPD Outcomes - PubMed; Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis - PubMed,https://pubmed.ncbi.nlm.nih.gov/39827764/; https://pubmed.ncbi.nlm.nih.gov/39453592/; https://pubmed.ncbi.nlm.nih.gov/33929661/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 77, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Please define a number of hypertension patients in the USA who are uncontrolled despite being treated with major anti-hypertensive medicines', 'role': 'user'}]}",True,200.0,28.203739166259766,,c29658aa-0071-40cd-8e72-a50a311462ea,286.0,An estimated 19.1 million US adults have uncontrolled blood pressure while taking antihypertensive m...,3.0,T/T/T,3.0,True,True,True,"The context provides direct, specific numbers regarding the population of US adults who have uncontrolled hypertension despite treatment: 19.1 million adults as per NHANES 2015–2018, and a subset of 5.4 million with elevated NT‑proBNP. The AI assistant accurately cited these numbers, grounded its answer in the context, and did not introduce information beyond what was provided. The context is both relevant and directly answers the question.",444,2,2,177.5,355,Reasons for uncontrolled blood pressure among US adults: Data from the US National Health and Nutrition Examination Survey; Prevalence of Elevated NT-proBNP and its Prognostic Value by Blood Pressure Treatment and Control,https://pmc.ncbi.nlm.nih.gov/articles/PMC10845887/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10570660/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 76, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with chronic obstructive pulmonary disease, Intervention: fluticasone furoate/umeclidinium/vilanterol, Control: Budesonide/glycopyrrolate/formoterol fumarate, Outcomes: % with 1 or more hospitalization', 'role': 'user'}]}",True,200.0,36.210652351379395,,77a75b51-7f68-4f5f-8e09-3226374039b7,721.0,No published randomized head-to-head trial reports the proportion of COPD patients with ≥1 hospitali...,2.0,F/T/T,2.0,False,True,True,"The AI's answer correctly states that there are no published head-to-head trials directly comparing the proportion of COPD patients with ≥1 hospitalization for the two interventions. This is supported by the context, which clarifies that available analyses do not provide this specific outcome. Thus, the context does not answer the question directly (no direct evidence or data on hospitalization rates), but it does address the broader topic relevant to the question. The AI's answer stays grounded in and accurately summarizes the context without introducing external information.",583,2,2,253.0,506,Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT; Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis,https://pubmed.ncbi.nlm.nih.gov/37583267/; https://pubmed.ncbi.nlm.nih.gov/33929661/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 80, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: systemic lupus erythematosus, Outcomes: Saphnelo', 'role': 'user'}]}",True,200.0,27.011273622512817,,2f10d44d-b2fe-4785-a355-240bf203d863,489.0,Anifrolumab (Saphnelo) 300 mg IV monthly improves clinical response rates (BICLA and SRI-based endpo...,2.0,T/T/F,1.0,True,True,False,"The provided context includes strong evidence that anifrolumab (Saphnelo) 300 mg IV improves clinical outcomes in systemic lupus erythematosus, including BICLA responses, steroid reduction, skin improvements, and reduced flare rates. Thus, the context both directly answers and addresses the question. However, the AI answer includes additional details that are not present in the provided context, such as SRI-based endpoints, long-term extension data, and specific safety information (e.g., infections and herpes zoster), which were not mentioned or discussed in any of the provided sources. Therefore, the answer is not completely grounded in the context.",658,4,4,171.5,686,"Trial of Anifrolumab in Active Systemic Lupus Erythematosus; Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials; Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial; Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus",https://pubmed.ncbi.nlm.nih.gov/31851795/; https://pubmed.ncbi.nlm.nih.gov/33216191/; https://pubmed.ncbi.nlm.nih.gov/38229377/; https://pubmed.ncbi.nlm.nih.gov/33977796/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 79, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what proportion of trelegy prescribing for asthma is by allergists, primary care, and pulmonology', 'role': 'user'}]}",True,200.0,38.57035541534424,,45d559dc-b74a-4ca8-91e7-8fcb144fe430,614.0,No published sources were found that report a nationally representative breakdown of Trelegy (FF/UME...,3.0,T/T/T,3.0,True,True,True,"The context directly answers the question regarding the proportion of Trelegy (FF/UMEC/VI) prescribing for asthma by specialty, as one cited study provides the breakdown: primary care physicians (44.2%), pulmonologists (31.8%), and allergists (11.1%). The context also addresses broader prescribing patterns in asthma overall but distinguishes them from Trelegy-specific data. The AI's answer accurately relies on and appropriately references the provided data, clearly stating what is Trelegy-specific and what is not, without introducing unsupported information.",564,2,2,117.5,235,Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI); Primary care referral patterns for patients with asthma: analysis of real-world data,https://pmc.ncbi.nlm.nih.gov/articles/PMC11787182/; https://pubmed.ncbi.nlm.nih.gov/35620831/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 46, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the distribution of IV gluccocorticoid use in SLE patients?', 'role': 'user'}]}",True,200.0,147.08255624771118,,f80e86ed-d064-49ba-ab25-b88722031d83,606.0,Available cohort data show wide variation in IV glucocorticoid (IV methylprednisolone/pulse) use in ...,3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: True. The context provides specific data regarding the proportion of SLE patients who received IV (parenteral) glucocorticoids: 26.3% in the SLICC cohort and 676/902 (~75%) in the COMOSLE-EGYPT study. These figures directly address the distribution of IV glucocorticoid use in SLE patients.

2. context_addresses_question: True. All cited studies are specifically about glucocorticoid use (including IV/pulse) in SLE, which is directly relevant to the original question.

3. answer_grounded_in_context: True. The AI answer summarizes and directly cites the statistics verbatim from the context provided, and does not introduce unsupported claims. The statement about heterogeneity in clinical practice is also supported by the third context summary.",787,3,3,132.66666666666666,398,"Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort; Cumulative pulse methylprednisolone and its relation to disease activity, damage and mortality in systemic lupus erythematosus patients: A post hoc analysis of COMOSLE-EGYPT study; Intravenous pulses of methylprednisolone for systemic lupus erythematosus",https://pmc.ncbi.nlm.nih.gov/articles/PMC5888922/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10876750/; https://pubmed.ncbi.nlm.nih.gov/12833245/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 86, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what percent of patients on ics/laba are treated with symbicort', 'role': 'user'}]}",True,200.0,21.87958288192749,,936e8253-7dd0-4320-9c48-c273dddfcb47,294.0,Reported proportions vary by population and setting: 56% of patients initiating an ICS/LABA in a Nor...,3.0,T/T/T,3.0,True,True,True,"The context provides specific percentages of ICS/LABA patients treated with Symbicort (budesonide/formoterol) from two different studies (56% and 19.2%). The AI's answer accurately reports these results, correctly referencing the populations and studies for each statistic. The answer does not introduce information not present in the context, and it clearly summarizes findings that are directly relevant to the question. Therefore, the answer meets all evaluation criteria.",475,2,2,134.5,269,"Inappropriate prescribing of combination inhalers in Northern Ireland: retrospective cross-sectional cohort study of prescribing practice in primary care; Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B2-agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study",https://pmc.ncbi.nlm.nih.gov/articles/PMC6442291/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10860111/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 88, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what proportion of asthma patients on ics/laba are on symbicort', 'role': 'user'}]}",True,200.0,19.94657015800476,,a9947b2d-2876-4d33-b502-f4181c546ec4,246.0,I cannot retrieve the needed literature right now because web searches failed. May I run a focused s...,1.0,F/F/T,1.0,False,False,True,"The provided context is empty, offering no information relevant to the question about the proportion of asthma patients on ICS/LABA who use Symbicort. Therefore, the context does not answer or address the question. The AI's answer acknowledges the lack of context and does not introduce unsupported claims, thus it remains grounded in the available (albeit nonexistent) context.",378,0,0,0.0,0,,,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 85, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Overall patients with atherosclerotic cardiovascular disease and LDL > 70 mg/dL, Intervention: Statin', 'role': 'user'}]}",True,200.0,33.45671629905701,,75506c79-1a6d-4ea0-8ffe-130797fa8a79,918.0,"In patients with established atherosclerotic cardiovascular disease and LDL‑C >70 mg/dL, randomized-...",3.0,T/T/T,3.0,True,True,True,"The context directly answers the question by providing evidence from meta-analyses about the benefit of statin therapy in reducing major vascular events and mortality among patients with atherosclerotic cardiovascular disease (ASCVD), which matches the population described in the question (ASCVD patients with LDL > 70 mg/dL). The included studies specifically discuss the effect of statins on major vascular events, all-cause and cardiovascular mortality, and confirm reduction in risk for both primary and secondary prevention. The AI's answer accurately summarizes these points, does not introduce unsupported claims, and relies on the context provided. Therefore, it fulfills all three evaluation criteria.",711,3,3,186.66666666666666,560,The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials; Adherence to Lipid-Lowering Therapies and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis; Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials,https://pubmed.ncbi.nlm.nih.gov/22607822/; https://pubmed.ncbi.nlm.nih.gov/40879042/; https://pubmed.ncbi.nlm.nih.gov/14692706/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 81, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: systemic lupus erythematosus, Outcomes: Saphnelo or Benlysta', 'role': 'user'}]}",True,200.0,45.1291823387146,,f2a92fbf-ffd7-4958-9d20-63c3c2dce826,826.0,No randomized head-to-head trials comparing anifrolumab (Saphnelo) and belimumab (Benlysta) were ide...,2.0,F/T/T,2.0,False,True,True,"The provided context includes results for anifrolumab (Saphnelo) and belimumab (Benlysta) from separate randomized trials but does not report any randomized head-to-head comparisons between the two. The AI's answer accurately reflects this, citing efficacy outcomes (BICLA for anifrolumab and SRI-4 for belimumab) and noting the separate sources and limitations of indirect comparison. While the AI answer is well-grounded in the context and relevant to the question, it does not provide a direct comparative answer, because the context lacks such direct evidence. Thus, the answer is grounded in and addresses the context, but does not directly answer the question due to limitations in the source evidence.",708,4,4,170.0,680,"Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials; Trial of Anifrolumab in Active Systemic Lupus Erythematosus; A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus; Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study",https://pubmed.ncbi.nlm.nih.gov/33216191/; https://pubmed.ncbi.nlm.nih.gov/31851795/; https://pubmed.ncbi.nlm.nih.gov/22127708/; https://pubmed.ncbi.nlm.nih.gov/28118533/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 91, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: asthma patients on advair, airduo, breo ellipta, dulera, and symbicort, Cohort_1: patients receiving Symbicort, Cohort_2: asthma patients on advair, airduo, breo ellipta, dulera,', 'role': 'user'}]}",True,200.0,11.715362071990967,,50be14b3-0680-43af-b3ed-88f0e6990bad,258.0,"Which outcome(s) do you want compared between Cohort_1 (Symbicort) and Cohort_2 (Advair, AirDuo, Bre...",0.0,F/F/F,1.0,False,False,False,"There is no context provided, so the AI's answer cannot be grounded in context or directly answer or address the question in relation to the context. The AI response simply asks for clarification on the outcome of interest but does not use any specific evidence or information from context to do so.",299,0,0,0.0,0,,,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 83, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with atherosclerotic cardiovascular disease, Cohort_1: Coronary artery bypass graft, Cohort_2: Coronary artery bypass graft, Cohort_3: Coronary artery bypass graft, Outcomes: patients with LDL > 70 mg/dL', 'role': 'user'}]}",True,200.0,36.26781630516052,,0e6498cb-237d-4144-ba78-43ae25d983be,943.0,"Among patients undergoing CABG, higher postoperative LDL-C is associated with worse clinical outcome...",3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: True. The provided context includes data on the outcomes of patients with specific LDL thresholds after CABG, directly relating to patients with LDL > 70 mg/dL. For example, study [1] reports increased MACE risk with higher LDL-C, and study [3] discusses outcomes for LDL above and below 70 mg/dL.
2. context_addresses_question: True. All cited studies focus on CABG patients and report outcomes stratified by LDL levels, directly relevant to the population and outcome of interest.
3. answer_grounded_in_context: True. The AI answer summarizes findings from the context, does not introduce unsupported information, and attributes specific claims to the referenced studies. The conclusions accurately reflect the content provided.",768,4,4,216.75,867,Impact of low-density lipoprotein cholesterol and lipoprotein(a) on mid-term clinical outcomes following coronary artery bypass grafting: A secondary analysis of the DACAB trial; Effects of intensive lipid-lowering therapy on mortality after coronary bypass surgery: A meta-analysis of 7 randomised trials; Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial; The prognostic role of the low and very low baseline LDL-C level in outcomes of patients with cardiac revascularization; comparative registry-based cohort design,https://pubmed.ncbi.nlm.nih.gov/37034344/; https://pubmed.ncbi.nlm.nih.gov/31865057/; https://pubmed.ncbi.nlm.nih.gov/21958773/; https://pubmed.ncbi.nlm.nih.gov/37507734/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 84, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'who are the prescribers for GLP1 in the latest 12 month period?', 'role': 'user'}]}",True,200.0,36.950963735580444,,09f8ee9d-0722-495c-bc62-9eaac837123d,422.0,"Limitations: no single published source explicitly reports a definitive, national list of “prescribe...",2.0,F/T/T,2.0,False,True,True,"The context does not provide a definitive, direct answer listing the prescribers for GLP-1 in the latest 12-month period, but it does provide relevant evidence about which specialties are major prescribers and their respective shares or trends (not specific for the most recent 12-month period, but up to 2020 and some broader recent data including 2021–24 in primary care). The AI's answer accurately reflects these limitations and summarizes the specialty trends based on the context, without introducing outside information. Thus, while the context is relevant and the answer is grounded in it, neither context nor answer directly and specifically answer the 'latest 12 month period' part of the question.",708,4,4,252.5,1010,"National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020; Health Care Provider Prescribing Habits and Barriers to Use of New Type 2 Diabetes Medications: A Single-System Survey Study - PMC; A system approach to improving guideline-directed therapy for cardio-renal-metabolic conditions: The “beyond diabetes” initiative - PMC; Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset - PubMed",https://pubmed.ncbi.nlm.nih.gov/35475341/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10577502/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10562667/; https://pubmed.ncbi.nlm.nih.gov/41024632/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 82, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with any prescription record for glucagon-like peptide-1 agonists in calendar year 2024, Outcomes: total number of glucagon-like peptide-1 agonist prescriptions by drug name, dose, day supply, total cost, and patient co-pay', 'role': 'user'}]}",True,200.0,40.35964894294739,,984c5950-d2d7-41eb-b66c-6414334b26a6,1582.0,"The published literature does not provide a single, publicly available dataset that lists total numb...",2.0,F/T/T,2.0,False,True,True,"The context does not directly answer the original question: there is no dataset or study listed that provides the total number of GLP-1 agonist prescriptions in 2024 by drug name, dose, day supply, total cost, and patient co-pay. The context instead presents related but not sufficient evidence: trends in prescribing and spending, prevalence estimates, and average costs, none broken down by all the requested criteria. Thus, the context does not provide a direct answer. However, the context is relevant; it addresses trends and costs for GLP-1 agonists. The AI's answer is grounded in the provided context, sticking closely to the evidence presented and explicitly noting the limitations of the available data, without introducing unsupported or external information.",770,4,4,221.75,887,"Trends in the utilization, expenditure and costs of noninsulin glucose-lowering drugs in the Medicaid population: Steady increases in glucagon-like peptide-1 receptor agonist and sodium-glucose transporter-2 inhibitor use, prices and expenditure; Trends in Newly Filled GLP-1 Receptor Agonist Prescriptions for US Patients With Versus Without Comorbid Alcohol Use Disorder, 2016-2024; GLP-1 Injectable Use Among Adults With Diagnosed Diabetes: United States, 2024 - NCHS Data Briefs - NCBI Bookshelf; Patterns and costs associated with glucagon-like peptide-1 receptor agonist use in US adults with type 2 diabetes",https://pubmed.ncbi.nlm.nih.gov/40630025/; https://pubmed.ncbi.nlm.nih.gov/41036780/; https://www.ncbi.nlm.nih.gov/books/NBK617443/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12467763/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 89, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is percentage patients with at least three different classes of anti-hypertension treatment after a diagnosis of hypertension?', 'role': 'user'}]}",True,200.0,27.7997043132782,,79b3564d-e7ef-4947-87f5-f0fd2120c761,456.0,Reported proportions vary by population and setting: 20.6% of incident hypertensive patients were pr...,3.0,T/T/T,3.0,True,True,True,"The context provides direct data points on the percentage of patients on three or more antihypertensive drug classes after a hypertension diagnosis, matching the question's requirements. The AI answer summarises these figures accurately, citing the correct numbers and appropriately referencing the studies. No unsupported claims are made and all figures used are traceable to the context. The answer is thus fully grounded in the context, directly answers the question, and is relevant throughout.",498,4,4,143.5,574,Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients - PMC; PREVALENCE OF APPARENT TREATMENT RESISTANT HYPERTENSION IN THE UNITED STATES: COMPARISON OF THE 2008 AND 2018 AMERICAN HEART ASSOCIATION SCIENTIFIC STATEMENTS ON RESISTANT HYPERTENSION - PMC; Treatment and prescribing trends of antihypertensive drugs in 2.7 million UK primary care patients over 31 years: a population-based cohort study - PMC; Antihypertensive drug treatment changes in the general population: the CoLaus study - PMC,https://pmc.ncbi.nlm.nih.gov/articles/PMC3343635/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6693520/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9189823/; https://pmc.ncbi.nlm.nih.gov/articles/PMC4021828/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 44, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: female patients with systemic lupus erythematosus, Intervention: diagnosis code for hormone replacement therapy, Control: non-hormone replacement therapy management of menopausal symptoms, Outcomes: SLE Flaire', 'role': 'user'}]}",False,,,"HTTPSConnectionPool(host='dbc-7a32c3d1-0aa9.cloud.databricks.com', port=443): Read timed out. (read timeout=180)",,,,0.0,,,,,,,0,0,0,0.0,0,,,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 87, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what proportion of GLP1 users have T2D, CKD, HF, and without any comorbidites?', 'role': 'user'}]}",True,200.0,44.92605209350586,,b38d5881-b125-4a87-9784-8362c89c9bd6,913.0,The published literature does not report a single study that directly gives the proportion of all GL...,2.0,F/T/T,2.0,False,True,True,"The context includes prevalence figures for GLP-1 RA use among adults with T2D, CKD, HF, and combinations thereof, but does not directly report the proportion of GLP-1 RA users who have each of these individual conditions or who are without comorbidities. The AI's answer correctly notes that no direct figures for the requested breakdown exist but summarizes related reported figures and stays within the bounds of the provided information. Thus, the answer is relevant, grounded in context, but the context (and so the answer) does not directly answer the original question.",576,4,4,126.5,506,"Patterns and costs associated with glucagon-like peptide-1 receptor agonist use in US adults with type 2 diabetes; Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes mellitus (NHANES 2017–2020); Utilization Trends of Dual GIP/GLP‑1 Receptor Agonist, Newer Glucose‑Lowering Medications, and Anti‑Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes; GLP‑1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries",https://pmc.ncbi.nlm.nih.gov/articles/PMC12467763/; https://pubmed.ncbi.nlm.nih.gov/35537891/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12152630/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11250228/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 90, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is percentage patients with at least one different classes of anti-hypertension treatment after a diagnosis of hypertension?', 'role': 'user'}]}",True,200.0,34.40629315376282,,4049a432-9f7f-4dbd-a762-b6ae8af7575e,397.0,Reported proportions vary by study and by how “different class/changes” is defined and the follow-up...,2.0,F/T/T,2.0,False,True,True,"The context includes several statistics regarding changes in antihypertensive therapy, such as switching, changing regimens, and therapy modifications in different cohorts and timeframes. However, none of the studies provide a direct percentage for patients who had at least one prescription from different classes of antihypertensive agents specifically after hypertension diagnosis (the question likely refers specifically to exposure to multiple classes, not just regimen change or switching). The answer summarizes the context findings accurately and doesn't introduce external information, but there is no evidence in the context strictly matching the question's specificity.",680,4,4,151.0,604,"Initial Antihypertensive Prescription and Switching: A 5 Year Cohort Study from 250,851 Patients; Antihypertensive drug treatment changes in the general population: the colaus study; Persistence to antihypertensive drug classes: A cohort study using the Swedish Primary Care Cardiovascular Database (SPCCD); Patterns and Associated Health Services Costs of Antihypertensive Drug Modifications",https://pmc.ncbi.nlm.nih.gov/articles/PMC3544913/; https://pmc.ncbi.nlm.nih.gov/articles/PMC4021828/; https://pmc.ncbi.nlm.nih.gov/articles/PMC5059050/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8109876/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 95, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with atherosclerotic cardiovascular disease, Intervention: age > 18, Outcomes: LDL result', 'role': 'user'}]}",True,200.0,22.02663564682007,,b08e08fb-f6e6-467d-a8d4-4f1a3094702e,816.0,In contemporary real-world cohorts of adults with established atherosclerotic cardiovascular disease...,3.0,T/T/T,3.0,True,True,True,"The context directly addresses the population (patients with ASCVD, age >18 implied by adult cohorts), the intervention/criteria (>18), and the outcome (LDL results). Evidence is provided that 60.1% had uncontrolled LDL‑C (≥70 mg/dL), the relation between LDL levels and CVD risk is discussed, and further stratification by imaging is mentioned. The AI's answer closely paraphrases and synthesizes data grounded in the provided sources, without introducing claims not found in the context.",489,3,3,142.66666666666666,428,"Real-world exploration of LDL-cholesterol management in patients with atherosclerotic cardiovascular disease; Association of low-density lipoprotein cholesterol levels with the risk of mortality and cardiovascular events: A meta-analysis of cohort studies with 1,232,694 participants; Low-Density Lipoprotein Cholesterol Is Predominantly Associated With Atherosclerotic Cardiovascular Disease Events in Patients With Evidence of Coronary Atherosclerosis: The Western Denmark Heart Registry",https://pubmed.ncbi.nlm.nih.gov/39423990/; https://pubmed.ncbi.nlm.nih.gov/36482567/; https://pubmed.ncbi.nlm.nih.gov/36621817/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 94, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is percentage of patients with LDL > 70 by age for patients with diagnosis of ASCVD?', 'role': 'user'}]}",True,200.0,24.181933641433716,,89151d1c-b770-4ab2-9507-678ef758bafc,609.0,Available published analyses do not report detailed age-decade strata for the proportion of patients...,2.0,F/T/T,2.0,False,True,True,"The context does not directly answer the question, as it does not provide the percentage of patients with LDL > 70 stratified specifically by age for those with ASCVD. However, the context is relevant to the question, as it discusses overall percentages and mentions data for older adults, noting the lack of detailed age breakdowns. The AI's answer accurately reflects this, summarizing the available data and correctly noting the absence of age-stratified percentages, thus the answer is well-grounded in the provided context.",528,3,3,152.66666666666666,458,"The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD; Lipid-lowering treatment among older patients with atherosclerotic cardiovascular disease; Geographic variations in lipid‑lowering therapy utilization, LDL‑C levels, and proportion retrospectively meeting the ACC/AHA very high‑risk criteria in a real‑world population of patients with major atherosclerotic cardiovascular disease events in the United States",https://pubmed.ncbi.nlm.nih.gov/34599698/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10089944/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8315617/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 98, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma patients with at least two Symbicort or Dulera prescriptions, Intervention: Fasenra, Control: Dupixent, Outcomes: asthma-related emergency department visits or hospitalizations', 'role': 'user'}]}",True,200.0,27.14873957633972,,7fc03c6e-6f40-4731-807d-08f80272b1d5,1459.0,Limitations: No identified study explicitly restricted the cohort to patients defined by “≥2 Symbico...,2.0,F/T/T,2.0,False,True,True,"The context does not directly answer the PICO question because none of the cited studies compare Fasenra (benralizumab) with Dupixent (dupilumab) in asthma patients specifically defined by ≥2 Symbicort or Dulera prescriptions. Instead, comparisons occur in broader severe/uncontrolled asthma populations. However, the context is still relevant as it discusses comparative effectiveness of dupilumab versus benralizumab regarding asthma-related outcomes, including ED visits and hospitalizations, even though the study populations are broader and sometimes the endpoint is general exacerbations rather than ED or hospitalization specifically. The AI's answer carefully remains grounded in the provided context, summarizing key points and clearly noting limitations regarding population inclusion criteria, so it does not introduce unsupported claims.",849,4,4,243.5,974,Real-world effectiveness of dupilumab versus benralizumab and mepolizumab; Comparative Effectiveness of Dupilumab Versus Mepolizumab and Benralizumab in Asthma: A Multinational Retrospective Cohort Study; Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations; Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review,https://pubmed.ncbi.nlm.nih.gov/38760161/; https://pubmed.ncbi.nlm.nih.gov/40250559/; https://pubmed.ncbi.nlm.nih.gov/38431251/; https://pubmed.ncbi.nlm.nih.gov/32019141/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 97, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma and >=2 Symbicort or Dulera prescriptions, Intervention: Fasenra, Control: Dupixent, Outcomes: Count of Steroid prescriptions', 'role': 'user'}]}",True,200.0,29.933988094329834,,a2d20d05-ef0f-478c-acb2-fa60339db928,840.0,Published trials do not report a direct head-to-head comparison of Fasenra (benralizumab) versus Dup...,2.0,F/T/T,2.0,False,True,True,"The AI's answer accurately reflects the content provided in the context. It states that there are no direct head-to-head trials comparing Fasenra (benralizumab) with Dupixent (dupilumab) regarding the count of steroid prescriptions, which is consistent with the information given. The AI appropriately describes the results of existing trials for both drugs in terms of oral corticosteroid dose reduction, the outcome actually reported in the context. Thus, the answer is grounded in the context and addresses the question, but it does not directly answer the specific outcome (count of steroid prescriptions), since the context also lacks this information. Therefore, the answer does not directly answer the question but is otherwise appropriate.",747,4,4,187.0,748,"Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma; Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma; Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma; Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial",https://pubmed.ncbi.nlm.nih.gov/28530840/; https://pubmed.ncbi.nlm.nih.gov/31859541/; https://pubmed.ncbi.nlm.nih.gov/36572184/; https://pubmed.ncbi.nlm.nih.gov/35217003/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 92, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with atherosclerotic cardiovascular disease, Cohort_1: age > 18 and age < 65, Cohort_2: age > 64, Outcomes: Percentage of patients with LDL > 70', 'role': 'user'}]}",True,200.0,41.732293367385864,,dc6a9a78-441d-48a2-8a7b-4bce9b48dcff,736.0,No published study located reports the percentage of patients with established atherosclerotic cardi...,2.0,F/T/T,2.0,False,True,True,"The context does not directly answer the question, as no provided study gives the percentage of ASCVD patients with LDL>70 mg/dL stratified by the specified age groups. However, the context is relevant since it addresses percentages of patients with LDL above or below 70 mg/dL in similar populations (high-risk CVD, ASCVD in general, and a large population cohort). The AI's answer accurately summarizes these limitations, relies solely on the context, and does not introduce additional unsupported claims.",507,3,3,181.66666666666666,545,The rate of patients at high risk for cardiovascular disease with an optimal low-density cholesterol level: a multicenter study from Thailand; Real-World Risk of Recurrent Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with LDL-C Above Guideline-Recommended Threshold: A Retrospective Observational Study; Age‐Related Associations of Low‐Density Lipoprotein Cholesterol and Atherosclerotic Cardiovascular Disease: A Nationwide Population‑Based Cohort Study,https://pmc.ncbi.nlm.nih.gov/articles/PMC6503480/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10899549/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9238630/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 93, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is percentage of patients with LDC > 70 by age for patients with diagnosis of ASCVD?', 'role': 'user'}]}",True,200.0,36.315096616744995,,10f25f8c-5e8a-4e5d-b376-2bfbfbbef74c,898.0,"Available US-based estimates do not provide a single age-stratified table in the cited literature, b...",2.0,F/T/T,2.0,False,True,True,"The context provides relevant prevalence data for the percentage of ASCVD patients with LDL-C >70 mg/dL, including overall rates and some data for older adults, but it does not offer a comprehensive age-stratified percentage breakdown. The AI's answer accurately reflects this limitation, summarizes the available data, and does not introduce any unsupported information. Thus, the context addresses the question but does not answer it directly, and the response is appropriately grounded in the context.",504,4,4,214.5,858,Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA/ACC multi-society cholesterol guideline; Bending the Cardiovascular Event Curve by Evaluating the Potential Impact of Achieving Low Density Lipoprotein-Cholesterol Goal Across a Large Health System Among Secondary Prevention Patients; Trend of Controlled Low-Density Lipoprotein Cholesterol in Older Adults With a History of Myocardial Infarction or Stroke - PMC; The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD - PubMed,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168648/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10725565/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11294686/; https://pubmed.ncbi.nlm.nih.gov/34599698/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 96, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with atherosclerotic cardiovascular disease, Intervention: age > 18, Outcomes: LDL result (DO NOT calculate change in LDL. Just provide LDL value)', 'role': 'user'}]}",True,200.0,39.240490198135376,,6bb7df67-59af-4965-a2eb-027bd656617c,307.0,Median LDL-C in a large global cohort of adults with established atherosclerotic cardiovascular dise...,3.0,T/T/T,3.0,True,True,True,"The AI answer directly provides the LDL-C value (median 77 mg/dL, IQR 58.4–101.0) from the first cited study, which directly answers the outcome of interest for the given population (patients with atherosclerotic cardiovascular disease, age > 18). The answer is further supported by relevant information from the other studies about the LDL-C levels in similar populations. All statements in the AI answer are grounded in the provided context, with no unsupported claims or hallucinations.",489,3,3,149.66666666666666,449,Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease; Cardiovascular event rates and trajectories of LDL-cholesterol levels and lipid-lowering therapy in patients with atherosclerotic cardiovascular disease: A population-based cohort study - PubMed; Characteristics of Patients With Atherosclerotic Cardiovascular Disease in Belgium and Current Treatment Patterns for the Management of Elevated LDL-C Levels,https://pubmed.ncbi.nlm.nih.gov/36252994/; https://pubmed.ncbi.nlm.nih.gov/31677592/; https://pubmed.ncbi.nlm.nih.gov/39206747/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 102, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with asthma, Intervention: Fasenra, Control: Dupixent, Outcomes: Hospitalizations or ED visits', 'role': 'user'}]}",True,200.0,26.52361488342285,,2112d48a-521f-4d01-9ab2-cbfae20f727f,1383.0,No randomized head-to-head trials compare Fasenra (benralizumab) versus Dupixent (dupilumab) for hos...,2.0,F/T/T,2.0,False,True,True,"The provided context does not contain direct head-to-head comparison RCTs of Fasenra (benralizumab) versus Dupixent (dupilumab) for hospitalizations or ED visits in asthma patients. The context addresses the question indirectly via pooled reviews, indirect treatment comparisons, network meta-analyses, and retrospective cohort studies. It notes that both agents reduce exacerbations versus placebo and that Dupixent may have advantages in some subgroups, but explicit findings regarding hospitalizations from direct comparisons are not present. The AI’s answer accurately reflects the indirect nature of the available evidence and is grounded in the provided context, without introducing unsupported claims.",708,4,4,197.0,788,"Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma; Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review; Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis; Comparative Effectiveness of Dupilumab Versus Mepolizumab and Benralizumab in Asthma: A Multinational Retrospective Cohort Study",https://pubmed.ncbi.nlm.nih.gov/40261563/; https://pubmed.ncbi.nlm.nih.gov/32019141/; https://pubmed.ncbi.nlm.nih.gov/35772597/; https://pubmed.ncbi.nlm.nih.gov/40250559/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 101, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma, Cohort_1: Fasenra, Cohort_2: Dupixent', 'role': 'user'}]}",True,200.0,31.42674446105957,,a61f6e45-e3c7-4997-9fd4-5bff0b019596,431.0,"In asthma populations, multiple comparative analyses show dupilumab (Dupixent) is associated with gr...",3.0,T/T/T,3.0,True,True,True,"The context directly compares Dupixent (dupilumab) to Fasenra (benralizumab) in asthma populations through multiple cited studies, indicating that dupilumab is associated with greater reductions in exacerbations and some improvements in FEV1, especially in patients with higher eosinophil counts. The AI's answer summarizes these findings accurately, references the relevant subgroups and outcomes, and does not introduce information beyond what the context provides. Therefore, all three criteria are fulfilled.",512,4,4,212.75,851,"Comparative Effectiveness of Dupilumab Versus Mepolizumab and Benralizumab in Asthma: A Multinational Retrospective Cohort Study; Real-world effectiveness of dupilumab versus benralizumab and mepolizumab; Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review; Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis",https://pubmed.ncbi.nlm.nih.gov/40250559/; https://pubmed.ncbi.nlm.nih.gov/38760161/; https://pubmed.ncbi.nlm.nih.gov/32019141/; https://pubmed.ncbi.nlm.nih.gov/35772597/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 103, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with asthma, Cohort_1: Fasenra, Cohort_2: Dupixent, Outcomes: Hospitalizations or ED visits', 'role': 'user'}]}",True,200.0,32.90206027030945,,bc73e7bc-aa80-413f-9ccc-a4fdc0d7ba88,893.0,No randomized head-to-head trials reporting hospitalizations or ED visits between benralizumab (Fase...,2.0,F/T/T,2.0,False,True,True,"The context provides comparative data between dupilumab and benralizumab (Fasenra) for severe asthma exacerbations, and separately, reports about the effect of benralizumab on hospitalizations and ED visits. However, no provided study directly compares the hospitalization or ED visit rates between dupilumab and benralizumab. The AI's answer correctly summarizes this limitation, notes the lack of head-to-head data on hospitalizations/ED visits, and grounds its claims in the context. Thus: 
- context_answers_question_directly: False (no direct answer to the specific outcome).
- context_addresses_question: True (studies are highly relevant).
- answer_grounded_in_context: True (the AI only uses the provided info, no hallucination or external data added).",760,3,3,206.33333333333334,619,Real-world effectiveness of dupilumab versus benralizumab and mepolizumab; Comparative Effectiveness of Dupilumab Versus Mepolizumab and Benralizumab in Asthma: A Multinational Retrospective Cohort Study; Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 Study,https://pubmed.ncbi.nlm.nih.gov/38760161/; https://pubmed.ncbi.nlm.nih.gov/40250559/; https://pubmed.ncbi.nlm.nih.gov/35247595/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 105, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype, as identified via ICD codes., Cohort_1: Dupilumab, Cohort_2: fluticasone furoate/umeclidinium/vilanterol , Outcomes: hospitalizations or ED visits', 'role': 'user'}]}",True,200.0,31.204685926437378,,131c040a-7b26-45e6-9fdd-d7fa776aef73,1619.0,Available evidence uses blood-eosinophil–defined type 2/eosinophilic COPD rather than an ICD-code ph...,2.0,F/T/T,2.0,False,True,True,"The provided context does not directly compare the outcomes (hospitalizations or ED visits) between dupilumab and fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) in COPD patients with an eosinophilic phenotype identified via ICD codes. Instead, it provides separate evidence: dupilumab reduces exacerbations (which may drive hospital/ED use) in patients with blood eosinophils ≥300, and FF/UMEC/VI reduces hospital readmissions and ED costs, but not specifically in an eosinophilic phenotype. The AI's answer is faithful to this: it explains the lack of direct head-to-head data in populations identified by ICD codes and summarizes the studied outcomes and populations. Therefore, the context does not directly answer the question but is relevant, and the AI's answer does not hallucinate or misrepresent the information.",831,4,4,201.0,804,"Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials - PubMed; Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS) - PubMed; Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation - PubMed; Fluticasone Furoate/Umeclidinium/Vilanterol Initiation Following a COPD Exacerbation: Benefits of Prompt Initiation on COPD Outcomes - PMC",https://pubmed.ncbi.nlm.nih.gov/39900091/; https://pubmed.ncbi.nlm.nih.gov/39481660/; https://pubmed.ncbi.nlm.nih.gov/38767614/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11550231/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 99, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma with >=2 Symbicort prescription, Cohort_1: Fasenra, Cohort_2: Dupixent, Outcomes: asthma-related emergency department visits', 'role': 'user'}]}",True,200.0,52.981003761291504,,027de7c9-b192-4273-8762-84ca3345602c,1366.0,There are no published studies that exactly match the cohort definition (patients defined by ≥2 Symb...,2.0,F/T/T,2.0,False,True,True,"The provided context does not include studies that directly match the exact cohort definition (asthma patients with ≥2 Symbicort prescriptions) or directly compare Fasenra (benralizumab) versus Dupixent (dupilumab) for asthma-related ED visits. Instead, the studies cited include broader cohorts of biologic initiators and report on asthma exacerbations and related healthcare resource utilization (HCRU), and not specifically on ED visits in the narrowly defined population. The AI's answer appropriately summarizes these limitations and correctly represents the findings and scope of the cited literature. Therefore, the context does not answer the question directly, but it addresses the topic and the answer is appropriately grounded in context.",749,3,3,259.3333333333333,778,Real-world effectiveness of dupilumab versus benralizumab and mepolizumab - PubMed; Comparative Effectiveness of Dupilumab Versus Mepolizumab and Benralizumab in Asthma: A Multinational Retrospective Cohort Study - PubMed; Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study - PubMed,https://pubmed.ncbi.nlm.nih.gov/38760161/; https://pubmed.ncbi.nlm.nih.gov/40250559/; https://pubmed.ncbi.nlm.nih.gov/37441729/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 109, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is percentage patients with at least three or more different classes of anti-hypertensive treatment after a diagnosis of hypertension?', 'role': 'user'}]}",True,200.0,25.061712741851807,,d9f61631-6c9f-406b-80a0-cf81b12b9e0b,542.0,Estimates vary by population and setting. In an incident‑hypertension cohort 20.6% were prescribed t...,3.0,T/T/T,3.0,True,True,True,"The AI's answer includes explicit percentages of patients on three or more classes of antihypertensive treatment after a hypertension diagnosis, citing data from multiple cohorts and studies directly referenced in the context. Each estimate matches provided context figures, and the answer refrains from introducing unsupported claims. The context thoroughly addresses the question by offering data from several relevant studies. Therefore, all evaluation criteria are met.",473,5,5,141.8,709,Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients - PMC; PREVALENCE OF APPARENT TREATMENT RESISTANT HYPERTENSION IN THE UNITED STATES: COMPARISON OF THE 2008 AND 2018 AMERICAN HEART ASSOCIATION SCIENTIFIC STATEMENTS ON RESISTANT HYPERTENSION - PMC; Blood pressure-lowering medicines implemented in 12 African countries: the cross-sectional multination EIGHT study - PMC; Effect of Different Blood-Pressure-Lowering Regimens on the Blood Pressure Control among Hypertensive Patients Treated in Hospital Conditions - PMC; Antihypertensive drug treatment changes in the general population: the colaus study - PMC,https://pmc.ncbi.nlm.nih.gov/articles/PMC3343635/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6693520/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8640662/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7596508/; https://pmc.ncbi.nlm.nih.gov/articles/PMC4021828/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 108, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with hypertension, Outcomes: receipt of at least two different classes of anti-hypertensive treatments', 'role': 'user'}]}",True,200.0,29.513919591903687,,ae7ef4be-6bbb-4163-b525-27b8f624ae18,726.0,Reported proportions of hypertensive patients receiving two (or more) different antihypertensive cla...,3.0,T/T/T,3.0,True,True,True,"The AI's answer correctly summarizes the proportions of hypertensive patients receiving at least two different classes of antihypertensive treatments based on the details provided in the context. It accurately reports the relevant figures from the original studies, refers to appropriate populations, and cites the sources given in the context. All data points (43%, 47–55%, 47.5%, 67.9%) are directly from the provided references, demonstrating the answer is grounded fully in the context. The context explicitly addresses the original question, and the answer does not introduce any unsupported claims.",604,4,4,140.25,561,"Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting - PMC; Treatment Patterns and Blood Pressure Control With Initiation of Combination Versus Monotherapy Antihypertensive Regimens - PubMed; Antihypertensive polytherapy in Australia: prevalence of inappropriate combinations, 2013-2018 - PubMed; The prevalence of monotherapy and combination therapy in hypertension in China from 2019 to 2021: A nationwide population-based cross-sectional study - PubMed",https://pmc.ncbi.nlm.nih.gov/articles/PMC7109351/; https://pubmed.ncbi.nlm.nih.gov/33190560/; https://pubmed.ncbi.nlm.nih.gov/32084043/; https://pubmed.ncbi.nlm.nih.gov/39012241/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 107, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with validated asthma diagnoses based on ICD codes, combined with evidence of clinically significant asthma such as corticosteroid prescriptions or asthma-related hospitalizations/ED visits, Outcomes: Airsupra or Albuterol', 'role': 'user'}]}",True,200.0,32.4361298084259,,fafcf2af-9405-4aa5-8adb-fa02f9036b2e,459.0,"In adults with asthma, the albuterol–budesonide combination (AIRSUPRA) reduced risk of severe exacer...",3.0,T/T/T,3.0,True,True,True,"The AI's answer is well-grounded in the provided context. It accurately summarizes that, for adults with asthma (matching the question's population), the MANDALA study found AIRSUPRA (albuterol–budesonide) reduced the risk of severe exacerbations compared to albuterol alone. This finding directly and substantially answers the question about outcomes comparing AIRSUPRA versus albuterol. The answer also references the DENALI trial's support for combination efficacy and confirms the formulation of AIRSUPRA as described in the third context document. All points are strictly derived from the context, with no unsupported claims or extrapolations. The AI's response therefore meets all three evaluation criteria.",713,3,3,211.66666666666666,635,Albuterol-budesonide fixed-dose combination rescue inhaler for asthma: a plain language summary of the MANDALA study; Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma: Results of the DENALI Double-Blind Randomized Controlled Trial; Development and validation of analytical methods for selective determination of albuterol and budesonide in Airsupra inhalation aerosol using spectrophotometry - PubMed,https://pubmed.ncbi.nlm.nih.gov/38698565/; https://pubmed.ncbi.nlm.nih.gov/37003355/; https://pubmed.ncbi.nlm.nih.gov/37789024/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 106, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients diagnosed with severe asthma (ICD-10: J45.5)\u200b with documented eosinophil count ≥300 cells/μL\u200b, Intervention: Fasenra, Control: Trelegy, Outcomes: Oral corticosteroid prescription count over 12 months\u200b', 'role': 'user'}]}",True,200.0,35.670629262924194,,a7578fdb-dd58-4b5d-8b21-9abe16302726,1167.0,No published study directly compares Fasenra (benralizumab) versus Trelegy (FF/umeclidinium/vilanter...,2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False. The context does not provide a direct, head-to-head comparison between Fasenra (benralizumab) and Trelegy (FF/UMEC/VI) for OCS prescription counts over 12 months in patients with severe eosinophilic asthma. It provides evidence of OCS-sparing effects for benralizumab and observational outcomes for FF/UMEC/VI, but not a direct comparative answer.

2. context_addresses_question: True. The context is relevant, describing clinical outcomes related to OCS use for both interventions in severe/eosinophilic asthma populations, although not directly comparing the two.

3. answer_grounded_in_context: True. The AI's answer accurately reflects the limitations and findings presented in the provided context without introducing unsupported claims. It summarizes the evidence as described and explicitly notes there is no direct comparative study found in the context.",907,3,3,183.66666666666666,551,"Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma - ZONDA trial; Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study; Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Initiation in Japanese Patients with Asthma Previously on Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: A Retrospective Cohort Study",https://pubmed.ncbi.nlm.nih.gov/28530840/; https://pubmed.ncbi.nlm.nih.gov/34619104/; https://pubmed.ncbi.nlm.nih.gov/40283397/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 100, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma, Cohort_1: Fasenra, Cohort_2: Dupixent, Outcomes: Steroid prescription', 'role': 'user'}]}",True,200.0,56.84730815887451,,a1feaff7-d2d0-4cdd-a834-7106a0979ea4,1169.0,"In patients with severe, oral corticosteroid (OCS)-dependent asthma, both benralizumab (Fasenra) and...",3.0,T/T/T,3.0,True,True,True,"The context provides direct evidence comparing benralizumab (Fasenra) and dupilumab (Dupixent) with respect to steroid (OCS) reduction and elimination, specifically referencing outcomes such as percent reduction and rates of OCS elimination. The AI's answer accurately summarizes these findings and notes that no significant differences were observed in indirect comparisons. The response is factual and supported by the context, without introducing any unsupported information. All references cited in the AI's answer are backed by the supplied context.",554,4,4,196.75,787,"Efficacy and Safety of Biologics for Oral Corticosteroid-Dependent Asthma: A Systematic Review and Network Meta-Analysis; Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics; Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma; Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study",https://pubmed.ncbi.nlm.nih.gov/37972921/; https://pubmed.ncbi.nlm.nih.gov/31943429/; https://pubmed.ncbi.nlm.nih.gov/28530840/; https://pubmed.ncbi.nlm.nih.gov/34619104/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 104, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype, as identified via ICD codes., Cohort_1: Dupixent (dupilumab), Cohort_2: Breztri or Trelegy, Outcomes: Hospitalizations or ED visits', 'role': 'user'}]}",True,200.0,44.09632420539856,,5f169a9f-69ac-4c6a-9ca8-57829a5ba11d,1564.0,Limitations: Available trials of dupilumab in “eosinophilic” COPD defined the phenotype by blood eos...,2.0,F/T/T,2.0,False,True,True,"The provided context does not contain direct, head-to-head comparison data between dupilumab and Breztri/Trelegy (single-inhaler triple therapy) for hospitalizations or ED visits among COPD patients with an eosinophilic phenotype identified by ICD codes. The AI's answer accurately notes this limitation, referencing that trials used blood eosinophil counts for selection rather than ICD codes and that no direct comparisons exist. The AI correctly summarizes the separate findings: dupilumab reduces exacerbations (some leading to hospitalizations) vs. placebo in relevant populations, and triple therapy also reduces exacerbations, with evidence for reductions in hospitalizations, though results are mixed. The context is relevant to the question as it provides efficacy data for both therapies in populations similar to those described, even if not identical (ICD-defined). The AI's answer is grounded in the context and does not assert unsupported or hallucinated information, sticking closely to the trial and review data provided. However, because there is no direct comparative data in the context or data specifically tied to ICD-identified cohorts, the context does not answer the question directly.",1209,4,4,261.5,1046,"Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts; Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials; Once‑Daily Single‑Inhaler Triple versus Dual Therapy in Patients with COPD; Triple inhaled therapy of formoterol/glycopyrrolate/budesonide reduces the use of oral corticosteroids and antibiotics during COPD exacerbations in real‑world conditions",https://pubmed.ncbi.nlm.nih.gov/37272521/; https://pubmed.ncbi.nlm.nih.gov/39900091/; https://pubmed.ncbi.nlm.nih.gov/29668352/; https://pubmed.ncbi.nlm.nih.gov/39827764/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 110, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'For patients with a diagnosis of primary hypertension treated with at least 1 or more different classes of anti-hypertension medications, what is the systolic blood pressure within 1 year of index anti-hypertension therapy?', 'role': 'user'}]}",True,200.0,29.345273971557617,,e28330e8-dbfb-4d0a-837f-419978349e5d,624.0,Limitations: available cohort studies report blood-pressure control rates or the BP target used at ≈...,2.0,F/T/T,2.0,False,True,True,"The context describes how studies assess blood pressure control at ~1 year and the targets used, and explains that pooled mean systolic BP values are not directly reported. The AI's answer accurately reflects these limitations, noting that only control rates or targets are available, not mean systolic BP. Thus, the answer is grounded in the context and the context addresses the question broadly, but does not provide a direct, specific value for systolic blood pressure within 1 year, so it does not answer the question directly.",532,2,2,273.5,547,"INITIAL MONO- AND COMBINATON THERAPY AND HYPERTENSION CONTROL THE FIRST YEAR; Ethnic differences in hypertension management, medication use and blood pressure control in UK primary care, 2006–2019: a retrospective cohort study",https://pmc.ncbi.nlm.nih.gov/articles/PMC3425944/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9929586/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 112, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the average numbers of day from diagnosis of hypertension to the first anti-hypertension treatment?', 'role': 'user'}]}",True,200.0,35.13362646102905,,1a9671ae-651f-4356-905b-1049d2cc5da2,409.0,Limitations: available data are from a single US health‑system cohort of patients with diabetes (not...,3.0,T/T/T,3.0,True,True,True,"The context provides direct data about the mean and median time from hypertension diagnosis to first antihypertensive treatment in patients with diabetes (mean: 6.9 months; median: 3.3 months). The AI's answer faithfully reports these values and clarifies it's from a diabetic population, specifying the time in both months and days. This directly answers the question for the population studied. The AI answer is grounded solely in the provided context and does not introduce outside data.",490,2,2,189.5,379,Diagnosis and Treatment of Incident Hypertension Among Patients with Diabetes: a U.S. Multi-Disciplinary Group Practice Observational Study; Treatment in the First Month After Hypertension Diagnosis Improves Blood Pressure Control,https://pmc.ncbi.nlm.nih.gov/articles/PMC4441679/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12071505/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 111, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'For patients with a diagnosis of primary hypertension treated with at least 4 or more different classes of anti-hypertension medications, what is the systolic blood pressure?', 'role': 'user'}]}",True,200.0,44.037700176239014,,187ec29b-040b-467d-9767-fbf4251c0b43,299.0,"When a patient requires ≥4 different antihypertensive drug classes to achieve control, their systoli...",1.0,F/T/F,1.0,False,True,False,"The context provides definitions of resistant hypertension, stating that resistant hypertension includes patients on four or more antihypertensive agents, and that a systolic BP (SBP) >140 mmHg (or diastolic >90 mmHg) despite three drugs constitutes resistance, while control can be achieved on four agents. However, the context does not specify the exact systolic blood pressure value for patients on ≥4 drug classes—only that control is possible ('achieves target values') on four or more drugs. The AI's answer interprets this to mean <140 mmHg is ""at goal,"" but this is inferred rather than explicitly stated in the context. Furthermore, the AI uses language about the definition of resistant hypertension correctly, but the specific claim that <140 mmHg is the target SBP relies on external guidelines or knowledge not contained directly in the context provided. Therefore, the answer is not fully grounded in context and the context does not substantially answer the question directly.",991,2,2,226.0,452,"Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association; The Global Burden of Resistant Hypertension and Potential Treatment Options - PubMed",https://pubmed.ncbi.nlm.nih.gov/30354828/; https://pubmed.ncbi.nlm.nih.gov/38983582/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 116, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the prevalence of aldosterone dysregulation in patients with hypertension?', 'role': 'user'}]}",True,200.0,27.56832790374756,,2897fb3f-859e-4d3c-9b66-dcd65a92c9e0,566.0,Estimates vary by population: most reviews report ~5–10% prevalence of primary aldosteronism among u...,3.0,T/T/T,3.0,True,True,True,"The context directly provides prevalence rates of primary aldosteronism (PA) in hypertensive populations: 5–10% in mild/moderate hypertension, 10% in general hypertensive populations, about 20% in resistant hypertension, and up to 29% in some cohorts. Additionally, the context mentions newly recognized forms of autonomous aldosterone production may increase these estimates, possibly making PA at least three times more common than previously thought. The AI's answer references these prevalence figures and accurately reflects the newer, broader understanding of aldosterone dysregulation. The answer remains grounded in the provided context and does not introduce unsupported claims, while addressing the question both directly and relevantly.",747,4,4,199.0,796,Primary aldosteronism - PubMed; Primary aldosteronism: diagnostic and therapeutic considerations - PubMed; Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension - PubMed; Primary Aldosteronism: Where Are We Now? Where to From Here? - PubMed,https://pubmed.ncbi.nlm.nih.gov/32206595/; https://pubmed.ncbi.nlm.nih.gov/16256009/; https://pubmed.ncbi.nlm.nih.gov/32384388/; https://pubmed.ncbi.nlm.nih.gov/35067069/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 115, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Obesity , Intervention: Wegovy, Control: Zepbound, Outcomes: Weight loss', 'role': 'user'}]}",True,200.0,28.64893651008606,,df9f68e2-9eb4-4646-98e6-ff4f7796feed,798.0,"In adults with overweight or obesity, tirzepatide (Zepbound) produces greater weight loss than semag...",3.0,T/T/T,3.0,True,True,True,"The provided context contains direct comparative evidence showing that tirzepatide (Zepbound) results in greater weight loss than semaglutide (Wegovy), with specific quantitative differences cited in multiple studies. The AI's answer accurately summarizes these findings, including effect sizes, weight loss percentages, and outcomes related to weight loss, closely matching the content in the references. The answer does not include unsupported or hallucinated claims, and it appropriately reflects the context. Therefore, all three criteria are met.",551,4,4,188.75,755,Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data; Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity; Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials; Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials,https://pubmed.ncbi.nlm.nih.gov/40503067/; https://pubmed.ncbi.nlm.nih.gov/38976257/; https://pubmed.ncbi.nlm.nih.gov/40978842/; https://pubmed.ncbi.nlm.nih.gov/38613667/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 113, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What percentage of patients with a diagnosis of primary hypertension and treated with at least 2 different classes of anti-hypertension therapies have elevated systolic blood pressure of 130 and above within 1 year from index anti-hypertension therapies?', 'role': 'user'}]}",True,200.0,38.5536904335022,,50b6e9a4-9ae7-4dcc-b042-205a35b5e238,998.0,No published study identified reports the exact percentage of patients with primary hypertension sta...,2.0,F/T/T,2.0,False,True,True,"The provided context does not contain the exact percentage asked in the question (patients with primary hypertension on ≥2 anti-hypertensive classes with SBP ≥130 mmHg within 1 year). The AI's answer accurately reflects this gap, stating that no published study reports the exact requested figure and referencing the available related estimates and limitations in the studies. The context as presented addresses the general topic and constraints relevant to the question, but does not answer it directly. The AI does not introduce unsupported information and grounds its claims solely in the context provided.",609,3,3,318.3333333333333,955,"PREVALENCE OF APPARENT TREATMENT RESISTANT HYPERTENSION IN THE UNITED STATES: COMPARISON OF THE 2008 AND 2018 AMERICAN HEART ASSOCIATION SCIENTIFIC STATEMENTS ON RESISTANT HYPERTENSION - PMC; Resistant Hypertension: Incidence, Prevalence and Prognosis - PMC; Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients - PMC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6693520/; https://pmc.ncbi.nlm.nih.gov/articles/PMC3350774/; https://pmc.ncbi.nlm.nih.gov/articles/PMC3343635/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 122, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with asthma, Cohort_1: Blood eosinophil levels ≥300 cells/µL, Cohort_2: Blood eosinophil levels <300 cells/µL, Outcomes: Asthma related Hospitalizations', 'role': 'user'}]}",True,200.0,22.419239044189453,,c6a8ac3d-ccc1-4afd-a1b3-f2ab2aaf1acc,1101.0,"In cohort studies and analyses, patients with blood eosinophils ≥300 cells/µL had higher rates of as...",3.0,T/T/T,3.0,True,True,True,"The context provides specific evidence that patients with asthma and blood eosinophil counts ≥300 cells/µL have a greater mean number of hospitalizations compared with those with lower counts, directly addressing the outcome of asthma-related hospitalizations in both cohorts. The AI's answer accurately summarizes this evidence and integrates relevant nuances from additional sources about admission patterns and eosinophil variability. The answer does not introduce information not found in the context, and all claims are grounded in the provided references. Thus, all three criteria are met.",595,4,4,195.5,782,Effect of clinically significant thresholds of eosinophil elevation on health care resource use in asthma - PubMed; Peripheral eosinophil count as a biomarker for asthma exacerbation severity in acute care settings - PubMed; Blood eosinophil count as predictor of asthma exacerbation. A meta-analysis - PubMed; Impact of Blood Eosinophil Variability in Asthma: A Real-Life Population Study - PubMed,https://pubmed.ncbi.nlm.nih.gov/32371242/; https://pubmed.ncbi.nlm.nih.gov/40254093/; https://pubmed.ncbi.nlm.nih.gov/33135257/; https://pubmed.ncbi.nlm.nih.gov/34534050/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 121, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients diagnosed with severe asthma (ICD-10: J45.5), Intervention: dupilumab, Control: benralizumab, Outcomes: Asthma-related hospitalizations or Asthma-related ER visits or Asthma-related urgent care visit', 'role': 'user'}]}",True,200.0,28.279438495635986,,17f659b1-40d7-4642-bd5e-eb0e49df281b,1338.0,"Available comparative evidence (real-world cohorts, indirect comparisons and systematic reviews) ind...",3.0,T/T/T,3.0,True,True,True,"The AI's answer directly addresses the question by summarizing and referencing multiple studies that compare dupilumab and benralizumab in severe asthma patients, specifically focusing on outcomes that include asthma exacerbations, hospitalizations, and ER visits. Detailed findings are presented from various studies, supporting claims about overall exacerbation risk as well as more specific outcomes like those requiring hospitalization or ED visits. The answer discusses both the comparative effectiveness for overall exacerbations and nuances regarding hospitalizations, closely reflecting the evidence in the provided context. No unsupported claims or information beyond the given context are introduced, and the answer remains fully grounded in and supported by the referenced studies.",792,5,5,231.8,1159,"Comparative Effectiveness of Dupilumab Versus Mepolizumab and Benralizumab in Asthma: A Multinational Retrospective Cohort Study; Real-world effectiveness of dupilumab versus benralizumab and mepolizumab; Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review; Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma; Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations",https://pubmed.ncbi.nlm.nih.gov/40250559/; https://pubmed.ncbi.nlm.nih.gov/38760161/; https://pubmed.ncbi.nlm.nih.gov/32019141/; https://pubmed.ncbi.nlm.nih.gov/40261563/; https://pubmed.ncbi.nlm.nih.gov/38431251/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 118, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: cirrhosis patients , Cohort_1: portal hypertension and decompensate cirrhosis, Cohort_2: portal hypertension and compensated cirrhosis , Outcomes: mortality', 'role': 'user'}]}",True,200.0,31.702610969543457,,870e6626-1714-4a71-856d-8890818f6777,1044.0,Patients with portal hypertension who are decompensated have substantially higher mortality than tho...,3.0,T/T/T,3.0,True,True,True,"The AI's answer accurately synthesizes details from the provided context to compare mortality outcomes between cirrhosis patients with portal hypertension, distinguishing between compensated and decompensated cohorts. It provides precise 1-year mortality rates (20.2% for decompensated, 5.4% for compensated), which are explicitly mentioned in the context. It also discusses long-term outcomes, including higher death rates in decompensated patients, the impact of further decompensation, and the effect of comorbidities—all reflected in the cited articles. The response introduces no external data or unsupported claims. Thus, all criteria are fulfilled.",655,4,4,191.25,765,Prognostic indicators of survival in patients with compensated and decompensated cirrhosis; Clinical outcomes of compensated and decompensated cirrhosis: A long term study; Influence of further decompensation on survival across clinical stages of decompensated cirrhosis: The role of portal hypertension and HVPG changes; Comorbid Chronic Diseases and Survival in Compensated and Decompensated Cirrhosis: A Population-Based Study,https://pubmed.ncbi.nlm.nih.gov/22679906/; https://pmc.ncbi.nlm.nih.gov/articles/PMC4110542/; https://pubmed.ncbi.nlm.nih.gov/38634685/; https://pubmed.ncbi.nlm.nih.gov/35849622/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 119, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients diagnosed with severe asthma (ICD-10: J45.5), Intervention: Allergist or Pulminologist visit within 60 days post asthma related Hospitalization, ED visit, or urgent care visit, Outcomes: Rate of subsequent asthma-related ED visits within 6 months', 'role': 'user'}]}",True,200.0,37.638787031173706,,54140510-727e-40f4-ac4e-7639bff86ce4,1774.0,No published study was identified that specifically evaluates specialist (allergist or pulmonologist...,2.0,F/T/T,2.0,False,True,True,"The provided context does not directly answer the original question because none of the studies reported outcomes specifically for severe asthma patients (ICD-10 J45.5) who saw an allergist or pulmonologist within 60 days after hospitalization/ED/urgent care, with the precise outcome of 6-month ED revisit rates. However, the context is relevant: it describes several studies examining related populations (pediatric, adult, not necessarily severe asthma), different follow-up windows (14 or 30 days), and sometimes different provider types (primary care or specialist). The AI's answer synthesizes this context carefully, noting the absence of directly relevant evidence, summarizing the related findings, and refraining from extrapolating unsupported conclusions. Thus, the answer is properly grounded in the context.",820,4,4,243.75,975,Follow-Up After Asthma Emergency Department Visits and Its Relationship With Subsequent Asthma-Related Utilization; Predictors of Outpatient Follow-Up Care after Adult Emergency Department Asthma Visits and Association with 30-Day Outcomes - PMC; Effectiveness of Educational Interventions to Increase Primary Care Follow-up for Adults Seen in the Emergency Department for Acute Asthma: A Systematic Review and Meta-analysis; Asthma outcomes in pediatric patients with 30-day follow-up after an asthma hospitalization in a Medicaid-managed care program,https://pubmed.ncbi.nlm.nih.gov/35339239/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10014489/; https://pubmed.ncbi.nlm.nih.gov/26720625/; https://pubmed.ncbi.nlm.nih.gov/36893220/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 114, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'For patients with a diagnosis of primary hypertension treated with at least 3 or more different classes of anti-hypertension medications, what is the systolic blood pressure within 1 year of index anti-hypertension therapy?', 'role': 'user'}]}",True,200.0,47.786253690719604,,6d2c357c-7f26-468d-814a-4931560a6546,637.0,No single published study clearly reports a definitive mean systolic blood pressure at 1 year for pa...,2.0,F/T/T,2.0,False,True,True,"The context does not provide a specific value for mean systolic blood pressure at 1 year in patients on three or more antihypertensive medications. Instead, it provides control rates and prevalence data regarding resistant hypertension at 1 year and the percentage of patients who achieve blood pressure control. The AI's answer accurately reflects this and is appropriately grounded only in the provided context, without introducing information external to it. The context is highly relevant but does not directly answer the original question, as it lacks a numerical systolic BP value.",587,3,3,170.66666666666666,512,Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients - PMC; Overview of resistant hypertension: A glimpse of the cardiologist’s current standpoint - PMC; Prevalence and predictors of resistant hypertension in a primary care setting: a cross-sectional study - PMC,https://pmc.ncbi.nlm.nih.gov/articles/PMC3343635/; https://pmc.ncbi.nlm.nih.gov/articles/PMC3460222/; https://pmc.ncbi.nlm.nih.gov/articles/PMC4094417/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 117, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What percentage of patients with a diagnosis of primary hypertension have elevated systolic blood pressure of 130 and above within 1 year from diagnosis?', 'role': 'user'}]}",True,200.0,43.81052112579346,,e7c1ab6d-9d98-4821-b806-eb923dc6c2d2,783.0,"Published literature does not provide a direct, generalizable percentage of patients with a new diag...",2.0,F/T/T,2.0,False,True,True,"The context does not contain a direct statistic or study result answering the precise question of what percentage of patients with a new diagnosis of primary hypertension have systolic BP ≥130 within 1 year from diagnosis. Instead, it provides related data about BP distributions in hypertensive populations and BP control rates over certain periods, but none address the exact metric or timeframe. The AI's answer accurately reflects these limitations, synthesizing and referencing the available context without making unsupported extrapolations or introducing external data. Thus, the answer is relevant and grounded in the context, but no direct answer is available in the context.",684,3,3,224.33333333333334,673,Prehypertension and hypertension in a primary care practice; Sociodemographics and Hypertension Control among Young Adults with Incident Hypertension: a Multi-Disciplinary Group Practice Observational Study; Prevalence and management of hypertension in primary care practices with electronic medical records: a report from the Canadian Primary Care Sentinel Surveillance Network,https://pmc.ncbi.nlm.nih.gov/articles/PMC2567253/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6290735/; https://pmc.ncbi.nlm.nih.gov/articles/PMC4382047/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 120, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients diagnosed with severe asthma (ICD-10: J45.5)\u200b, Cohort_1: Continuous Fasenra for ≥12 months\u200b, Cohort_2: Continuous Dulera or Trelegy for ≥12 months\u200b, Outcomes: Asthma-related hospitalization; Asthma-related ED visits; Asthma-related urgent care visits', 'role': 'user'}]}",True,200.0,42.75636386871338,,1f7b7aa8-bdc6-4229-b76f-270964165e9b,1822.0,No published head-to-head or comparative cohort study was identified that directly compares continuo...,2.0,F/T/T,2.0,False,True,True,"The provided context does not contain a direct head-to-head comparison between continuous Fasenra (benralizumab) and continuous Dulera or Trelegy for ≥12 months specifically in patients with severe asthma. Instead, the context supplies results from studies of benralizumab and inhaled corticosteroid/long-acting beta-agonist combinations in separate cohorts. The AI answer accurately recognizes the absence of direct comparative data in the context and summarizes each drug class's separate outcomes (hospitalization, ED visits, exacerbations) as provided in the context. The assessment of no conclusion being possible, due to lack of direct comparative data, is also grounded in the context. Therefore, the context does not answer the question directly, but it is relevant to it, and the answer is correctly grounded in context.",829,4,4,227.75,911,"Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 Study - PubMed; Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study - PubMed; Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate - PubMed; Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus As-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in pAtients without Optimally Controlled asThma (REACT) Study - PubMed",https://pubmed.ncbi.nlm.nih.gov/35247595/; https://pubmed.ncbi.nlm.nih.gov/37441729/; https://pubmed.ncbi.nlm.nih.gov/30537475/; https://pubmed.ncbi.nlm.nih.gov/33324041/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 125, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: asthma patients with blood eosinophil levels ≥300 cells/µL, Intervention: Asthma related hospitalizations', 'role': 'user'}]}",True,200.0,30.308412790298462,,0b16237a-99c7-455d-894a-ce91c20aa751,825.0,"In asthma patients with blood eosinophils ≥300 cells/µL, published observational evidence shows high...",3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: True. The provided context specifically states that asthma patients with blood eosinophil ≥300 cells/µL had a greater mean number of hospitalizations than those with lower counts, addressing the link between eosinophil levels and hospitalizations directly.
2. context_addresses_question: True. All context documents are related to asthma patients, blood eosinophil counts ≥300 cells/µL, and hospitalization or exacerbation outcomes, fully addressing the population and comparator in the question.
3. answer_grounded_in_context: True. The AI's answer accurately reflects the information given in the context: it cites the increased hospitalization rate, references the commonality of high eosinophils among hospitalized patients, and notes the clinical interpretation of ≥300 cells/µL, relying strictly on information from the provided sources without adding external claims.",912,3,3,206.66666666666666,620,Effect of clinically significant thresholds of eosinophil elevation on health care resource use in asthma - PubMed; Prevalence of eosinophilia in hospitalized patients with asthma exacerbation - PubMed; Measurement of Blood Eosinophils in Asthma and Chronic Obstructive Pulmonary Disease - PMC,https://pubmed.ncbi.nlm.nih.gov/32371242/; https://pubmed.ncbi.nlm.nih.gov/26198894/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9876705/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 123, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: asthma patients with blood eosinophil levels ≥300 cells/µL, Cohort_1: Dupixent, Cohort_2: Trelegy, Outcomes: Asthma related hospitalizations', 'role': 'user'}]}",True,200.0,37.937251329422,,c5892eb1-1094-4022-873d-f4d9edeb4209,1068.0,No published study directly compares Dupixent (dupilumab) versus Trelegy (FF/UMEC/VI) for asthma-rel...,2.0,F/T/T,2.0,False,True,True,"The provided context does not contain direct comparative data between Dupixent and Trelegy regarding asthma-related hospitalizations in patients with blood eosinophil levels ≥300 cells/µL. The AI's answer correctly identifies that no direct head-to-head data exists in the context and accurately summarizes the available evidence for each drug. For Dupixent, context provides data on reduced severe exacerbations and related hospitalizations for high-eosinophil patients. For Trelegy, the context says only that real-world studies show reductions in exacerbations overall, without stratification by eosinophil count or specific data on hospitalizations for this subgroup. Therefore, the context is relevant and the answer stays grounded in it, but the context does not directly answer the comparative question.",810,3,3,292.3333333333333,877,Dupilumab (Dupixent) - NCBI Bookshelf; Dupilumab: A Review in Moderate to Severe Asthma - PubMed; Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US - PubMed,https://www.ncbi.nlm.nih.gov/books/NBK601813/; https://pubmed.ncbi.nlm.nih.gov/31728838/; https://pubmed.ncbi.nlm.nih.gov/38058516/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 128, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population:\n Define severe asthma using a computable phenotype: e.g., patients aged 18+ with ≥2 asthma-related exacerbations requiring systemic corticosteroids in the past 12 months OR ≥1 asthma-related hospitalization, AND on maintenance ICS-LABA therapy.\n Intervention (Subgroups):\n Compare outcomes across patients initiating [Advair HFA | Symbicort | Dulera | etc.] as maintenance therapy for asthma.\n Outcome:\n Asthma-related hospitalizations, defined as inpatient admissions with a primary ICD-10 code of J45.x (asthma) within 12 months of index therapy start.\n Timeframe:\n Restrict analysis to Jan 1, 2019 – Dec 31, 2023.\n Setting:\n Include patients treated in outpatient settings across integrated delivery networks.\n Question:\n Among adults with severe asthma initiating different ICS-LABA or ICS-LABA-LAMA therapies, what are the rates of asthma-related hospitalization within 12 months?', 'role': 'user'}]}",True,200.0,25.68224811553955,,f98dabdc-d7ef-4948-bc55-3e1d54987046,1267.0,"No published study was found that reports, for the exact computable phenotype and setting you specif...",2.0,F/T/T,2.0,False,True,True,"The provided context includes systematic reviews, network meta-analyses, and a real-world cohort study, all examining the comparative efficacy of ICS–LABA or triple therapy regimens in asthma. However, none of the cited sources provide data specific to the question: 12-month asthma-related hospitalization rates by specific branded inhaler for the detailed computable phenotype and timeframe described. The context is relevant, as it covers comparative outcomes (e.g., exacerbation reduction) for similar interventions, but does not directly answer the question about precise hospitalization rates. The AI's answer accurately reflects these limitations, relying solely on the provided context and not making unsupported claims.",728,3,3,220.0,660,"Comparative efficacy of inhalers in mild-to-moderate asthma: systematic review and network meta-analysis; Differences in the effectiveness of single, dual, and triple inhaled corticosteroid therapy for reducing future risk of severe asthma exacerbation: A systematic review and network meta-analysis; A Comparison of the Effectiveness of Asthma Medications on Asthma Exacerbations in Real World National Cohort",https://pubmed.ncbi.nlm.nih.gov/35396495/; https://pubmed.ncbi.nlm.nih.gov/39022061/; https://pubmed.ncbi.nlm.nih.gov/36042712/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 130, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: U.S. patients with acute lymphoblastic leukemia, Cohort_1: Patients with acute lymphoblastic leukemia, Cohort_2: not applicable, Outcomes: Incidence and prevalence of patients with acute lymphoblastic leukemia, proportion of patients receiving care at academic centers, geographic distribution of patients with acute lymphoblastic leukemia', 'role': 'user'}]}",True,200.0,24.129438161849976,,d2449b48-8c55-4227-a4ed-d3b77e1edb74,1184.0,Limitations: available literature provides national incidence and regional mortality/ethnicity patte...,3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: True. The context provides direct information about the annual incidence and demographic/geographic trends for ALL in the US, as well as stating the absence of certain data (prevalence, care at academic centers) in the references. 2. context_addresses_question: True. The context is relevant to questions on incidence, prevalence, demographic trends, and treatment settings for ALL in the U.S. 3. answer_grounded_in_context: True. The AI's answer stays close to the data from the referenced sources, correctly noting the gaps (no US-wide prevalence or care setting data found), providing numeric incidence rates and trends directly from the context, and using appropriate citations.",720,5,5,163.4,817,"Acute lymphoblastic leukemia: a comprehensive review and 2017 update; Rates and Trends of Pediatric Acute Lymphoblastic Leukemia - United States, 2001-2014; Epidemiology and Etiology of Leukemia and Lymphoma (review, PMC); Trends in Acute Lymphoblastic Leukemia Incidence in the United States by Race/Ethnicity From 2000 to 2016; Trends and Disparities in Acute Lymphoblastic Leukemia-Related Mortality in the United States from 1999 to 2020",https://pmc.ncbi.nlm.nih.gov/articles/PMC5520400/; https://pubmed.ncbi.nlm.nih.gov/28910269/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7263093/; https://pubmed.ncbi.nlm.nih.gov/33034340/; https://pubmed.ncbi.nlm.nih.gov/39886753/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 127, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: COPD patient with >=1 hospitalization or >=2 OCS claims with less than 15 day supply or >= 2 Antibiotic with less than 15 day supply, Outcomes: Breztri or Trelegy', 'role': 'user'}]}",True,200.0,36.51974844932556,,02f77e68-c85a-4528-a266-6e28b2b51a2c,589.0,In patients with COPD and a recent exacerbation history (prior hospitalization and/or multiple OCS/a...,3.0,T/T/T,3.0,True,True,True,"The provided context describes two major trials (ETHOS and IMPACT) evaluating Breztri and Trelegy, respectively, in COPD patients with a prior history of exacerbations. The context includes data showing reduced exacerbations and all-cause mortality for both therapies compared to dual therapy, which directly answers the question about outcomes (exacerbations and mortality) among the specified COPD population. The AI's answer accurately summarizes these trial results, specifies the therapies and outcomes as in the context, and does not introduce information not found in the context. Thus, all criteria are met.",615,2,2,231.5,463,"Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study; Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease",https://pubmed.ncbi.nlm.nih.gov/33252985/; https://pubmed.ncbi.nlm.nih.gov/32162970/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 124, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: asthma patients with blood eosinophil levels ≥300 cells/µL, Intervention: Dupixent, Control: Trelegy, Outcomes: Asthma related hospitalizations', 'role': 'user'}]}",True,200.0,41.740227699279785,,78cd1086-bb85-42b6-9d37-4c894b02d15c,1272.0,No randomized head-to-head trials or comparative studies were identified that directly compare Dupix...,2.0,F/T/T,2.0,False,True,True,"The provided context does not include direct, head-to-head comparative data on asthma-related hospitalizations for Dupixent versus Trelegy in patients with blood eosinophils ≥300 cells/µL. The AI's answer correctly states this and accurately summarizes relevant indirect evidence: Dupilumab's effects on exacerbations in type 2-high (including high eosinophil) asthma, a comparative study among biologics (not including Trelegy), and the lack of asthma-specific hospitalization data for Trelegy in this population. Thus, while the context addresses the question and the answer is well-grounded in context, there is no direct answer to the comparative efficacy regarding the outcome of interest.",694,3,3,293.6666666666667,881,"Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline - PubMed; Differences in asthma-related outcomes by anti-IL-5 biologics, omalizumab, and dupilumab based on blood eosinophil counts - PubMed; Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction - PubMed",https://pubmed.ncbi.nlm.nih.gov/33010038/; https://pubmed.ncbi.nlm.nih.gov/38183647/; https://pubmed.ncbi.nlm.nih.gov/27767328/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 126, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: COPD patient with >=1 hospitalization or >=2 OCS claims with less than 15 day supply or >= 2 Antibiotic with less than 15 day supply, Intervention: Breztri or Trelegy', 'role': 'user'}]}",True,200.0,40.85400032997131,,1c887149-4392-4f76-aedf-cc24ae11f138,1810.0,No randomized head-to-head trial comparing Breztri (budesonide/glycopyrronium/formoterol) with Trele...,2.0,F/T/T,2.0,False,True,True,"The context does not include direct head-to-head comparative studies between Breztri and Trelegy in the specified high-risk COPD population, so it does not directly answer the original question. However, the context is relevant, as it includes evidence about the efficacy of each single-inhaler triple therapy in reducing exacerbations and improving lung function among COPD patients at risk for exacerbations. The AI's answer adheres closely to the provided sources, accurately summarizing trial findings and pointing out the absence of direct comparative evidence, without introducing unsupported claims. Therefore, the answer is well grounded in the context and addresses the question, but lacks a direct answer due to the limitations of available evidence.",760,4,4,215.0,860,Budesonide/glycopyrronium/formoterol: A Review in COPD; Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease; FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease; Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety,https://pmc.ncbi.nlm.nih.gov/articles/PMC8384783/; https://pubmed.ncbi.nlm.nih.gov/32162970/; https://pubmed.ncbi.nlm.nih.gov/28375647/; https://pubmed.ncbi.nlm.nih.gov/36065315/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 129, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the incidence and prevalence of acute lymphoblastic leukemia (ALL) patients in the United States broken down by region (Midwest, Northeast, South, West) and state? Where available, please also report on the proportion of patients who are receiving care at academic centers.', 'role': 'user'}]}",True,200.0,39.88662385940552,,974134c2-91c8-4f86-9199-6d7d0ad1aab2,2201.0,"Limitations: No single peer-reviewed US source provides a complete, state-by-state breakdown of acut...",2.0,F/T/T,2.0,False,True,True,"The context does not contain comprehensive, direct data on the incidence and prevalence of ALL by region and state for the general population, nor on the proportion of patients receiving care at academic centers. Some relevant data are present: pediatric incidence rates broken down by region (West highest) and specific states (California, New Mexico, Vermont); AYA patients regional/state diagnosis proportions; and national incidence estimates. However, the context acknowledges limitations in the data and the lack of direct answers for several aspects (state-by-state, all ages, academic center proportion). The AI answer accurately reflects these limitations, does not overstate what's in the context, and is careful to ground all claims in the evidence provided.",769,3,3,226.33333333333334,679,"Rates and Trends of Pediatric Acute Lymphoblastic Leukemia - United States, 2001-2014; Travel-time barriers to specialized cancer care for adolescents and young adults with acute lymphoblastic leukemia; Epidemiology and Etiology of Leukemia and Lymphoma (review)",https://pubmed.ncbi.nlm.nih.gov/28910269/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11229987/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7263093/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 136, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with confirmed severe asthma, defined by repeated asthma diagnoses and high-dose of any of the following - Advair, AirDuo, Breo, Dulera, Symbicort, Wixela, Intervention: Any of the following biologics - (Xolair, Nucala, Cinqair, Fasenra, Dupixent, Tezspire), Control: Not on any of the following biologic therapy (Xolair, Nucala, Cinqair, Fasenra, Dupixent, Tezspire), Outcomes: Counts of systemic corticosteroid prescriptions, asthma-related hospitalizations and emergency department visits', 'role': 'user'}]}",True,200.0,25.600022792816162,,616beb66-d2e3-4a15-a65f-91291cd8342e,716.0,"In real-world cohorts and systematic reviews of patients with severe asthma, initiation of biologic ...",3.0,T/T/T,3.0,True,True,True,"The provided context gives direct, specific evidence addressing the question. It highlights reductions in systemic corticosteroid prescriptions, asthma-related hospitalizations, and emergency department visits for severe asthma patients treated with biologics compared to periods or populations without biologic therapy. The AI's answer correctly references these findings, includes numerical reductions matching the context (e.g., incidence ratio 0.65 for hospitalizations and specific percentage reductions in corticosteroid prescriptions for mepolizumab), and does not introduce information outside the supplied material. Thus, the answer is well-grounded, directly supported, and aligned with the context.",709,3,3,201.33333333333334,604,"Real-world benefits of biologics for asthma: Exacerbation events and systemic corticosteroid use; Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis; Real-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retrospective analysis",https://pmc.ncbi.nlm.nih.gov/articles/PMC8585664/; https://pubmed.ncbi.nlm.nih.gov/35174566/; https://pubmed.ncbi.nlm.nih.gov/39786337/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 133, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype, as identified via ICD codes., Cohort_1: Use of Dupixent (dupilumab) as an add-on maintenance therapy, Cohort_2: Patients managed with breztri or trelegy, Outcomes: Decrease in the rate of moderate to severe COPD exacerbations (e.g., hospitalizations or ED visits) over a 12-month period', 'role': 'user'}]}",True,200.0,36.391841650009155,,219549f5-6a5e-46f0-9e31-993e70bc2dbc,1557.0,Limitation: the dupilumab randomized trials enrolled patients selected by blood eosinophil count (≥3...,2.0,F/T/T,2.0,False,True,True,"The AI’s answer accurately summarizes the findings from the provided context regarding the impact of dupilumab (in patients with blood eosinophils ≥300/µL) and triple inhaler therapies (Trelegy, Breztri) on COPD exacerbation rates over 12 months. It correctly notes the limitation that evidence is only for blood eosinophil-selected patients, not those selected by ICD code—a nuance supported by the context. The answer is grounded in and well-cited from the provided context. However, the context does not contain direct head-to-head evidence for the population as defined by ICD codes for eosinophilic phenotype or a direct comparison of dupilumab with Trelegy or Breztri. Thus, the answer is not directly addressed by the context (no explicit answer for those specific cohorts as defined in the question), but the context is clearly relevant.",845,4,4,215.0,860,"Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation; Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores - BOREAS analysis; Once‑Daily Single‑Inhaler Triple versus Dual Therapy in Patients with COPD; Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol among US Patients with Chronic Obstructive Pulmonary Disease",https://pubmed.ncbi.nlm.nih.gov/37272521/; https://pubmed.ncbi.nlm.nih.gov/40024335/; https://pubmed.ncbi.nlm.nih.gov/29668352/; https://pubmed.ncbi.nlm.nih.gov/39731707/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 132, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'How much percent of adult asthma patients have at least one OCS fill in 2023?', 'role': 'user'}]}",True,200.0,41.21889638900757,,d04333d1-ec96-4f05-a2c5-5cab4af636bf,188.0,The published literature searched (NCBI/NLM/PubMed) does not contain a source reporting the percenta...,1.0,F/F/T,1.0,False,False,True,"The context provided is empty, so there is no evidence to directly answer or address the question about the percentage of adult asthma patients with at least one OCS fill in 2023. The AI's answer does not introduce unsupported claims and appropriately states the lack of data, so it remains grounded in the (lack of) context.",325,0,0,0.0,0,,,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 138, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma patients on Advair, AirDuo, Breo, Dulera, Symbicort, Wixela, Fluticasone-Salmeterol, Budesonide-Formoterol, Mometasone-Formoterol, Cohort_1: Xolair, Nucala, Cinqair, Fasenra, Dupixent, Tezspire, Cohort_2: Not on Xolair, Nucala, Cinqair, Fasenra, Dupixent, Tezspire, Outcomes: ER visits, urgent care visits, asthma-related inpatient hospitalizations, systemic corticosteroid prescription initiation', 'role': 'user'}]}",True,200.0,33.73845148086548,,9cf4ceb9-9eef-404f-ba74-e6c6bac64d8a,727.0,"Limitation: the available studies are real‑world, retrospective cohorts that report pre–versus–post ...",1.0,F/T/F,1.0,False,True,False,"1. context_answers_question_directly: The context only reports the effects of mepolizumab (Nucala) on various asthma-related outcomes based on pre/post analyses, but does not provide a direct comparison between Cohort_1 (on Xolair, Nucala, etc.) and Cohort_2 (not on biologics) or outcomes across the broader population or the full set of drugs mentioned in the question. Thus, the context does not directly and substantially answer the question.
2. context_addresses_question: The context is relevant in that it discusses outcomes (ER visits, hospitalizations, corticosteroid use) in asthma patients starting a relevant biologic (Nucala), which overlaps with the question's focus on these outcomes in similar patient groups.
3. answer_grounded_in_context: The AI's answer includes language and numbers not directly present in the provided context, and makes generalized statements, such as '38%–44% reduction in all exacerbations and up to ~73% reduction in hospitalized exacerbations,' which are not precisely cited from the provided excerpts. It extrapolates beyond the context and refers to systemic/oral corticosteroid reductions in quantitative detail not exactly reflected in the context. Therefore, the answer is not fully grounded in the provided context.",1264,3,3,230.66666666666666,692,"Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs; Impact of mepolizumab in patients with high‑burden severe asthma within a managed care population; Real-World Effectiveness of Mepolizumab in Severe Asthma: Results from the Multi-country, Self-controlled Nucala Effectiveness Study (NEST)",https://pubmed.ncbi.nlm.nih.gov/32099413/; https://pubmed.ncbi.nlm.nih.gov/35853158/; https://pubmed.ncbi.nlm.nih.gov/39215767/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 131, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Incidence and prevalence of patients with acute lymphoblastic leukemia, proportion of patients with acute lymphoblastic leukemia receiving care at academic centers, geographic distribution of patients with acute lymphoblastic leukemia', 'role': 'user'}]}",True,200.0,51.09528946876526,,f8d2b37d-51ef-44ac-9631-e291930efa67,1506.0,Limitations: No peer‑reviewed sources located in the searched NCBI/NLM set report the proportion of ...,3.0,T/T/T,3.0,True,True,True,"The AI's answer accurately reflects the information provided in the context. It directly presents the incidence and prevalence data, citing specific case estimates and incidence rates for different populations (adult, pediatric), as sourced from the context. It also summarizes relevant findings on geographic and demographic disparities, as described in the referenced materials. The answer clearly states the absence of data on the proportion of ALL patients receiving care specifically at academic centers, which matches the context (no such data is presented in any context source). All information provided is directly linked to the context and citations are accurate. The response does not introduce unsupported claims or use external information.",753,5,5,158.0,790,"Acute lymphoblastic leukemia: a comprehensive review and 2017 update; Epidemiology and Etiology of Leukemia and Lymphoma (review, PMC); Epidemiology and Attributes of Specific Childhood Cancers - NCBI Bookshelf; Rates and Trends of Pediatric Acute Lymphoblastic Leukemia - United States, 2001-2014 (CDC analysis); Trends and Disparities in Acute Lymphoblastic Leukemia-Related Mortality in the United States from 1999 to 2020",https://pmc.ncbi.nlm.nih.gov/articles/PMC5520400/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7263093/; https://www.ncbi.nlm.nih.gov/books/NBK569400/; https://pubmed.ncbi.nlm.nih.gov/28910269/; https://pubmed.ncbi.nlm.nih.gov/39886753/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 137, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Puerto Rico Asthma age 12 and above, Intervention: Advair, AirDuo, Breo, Dulera, Symbicort, Wixela, Fluticasone-Salmeterol, Budesonide-Formoterol, Mometasone-Formoterol, Outcomes: Xolair, Nucala, Cinqair, Fasenra, Dupixent, Tezspire', 'role': 'user'}]}",True,200.0,35.930742502212524,,ff412821-3d65-492f-8580-fbe4dcfeb41a,716.0,No published studies were identified that directly evaluate the list of inhaled-controller regimens ...,2.0,F/T/T,2.0,False,True,True,"The provided context does not contain any data or studies specifically evaluating the listed inhaled-controller regimens (Advair, AirDuo, etc.) and their clinical outcomes related to the biologics (Xolair, Nucala, etc.) in the Puerto Rico asthma population aged 12 and above. The context instead discusses asthma prevalence, environmental triggers, and rates of uncontrolled asthma, aligning with the AI’s claim of a lack of relevant outcome data for the specified interventions. The AI answer is therefore appropriately grounded in the context: it accurately summarizes and restricts its conclusions to the available information. However, since the context does not directly answer the specific PICO question, the first criterion is not met. The context is still relevant to the general topic (asthma in Puerto Rico), thus satisfying the second criterion.",856,3,3,196.66666666666666,590,"Uncontrolled asthma and household environmental exposures in Puerto Rico; Characterizing environmental asthma triggers and healthcare use patterns in Puerto Rico; Prevalence and correlates of asthma in the Puerto Rican population: Behavioral Risk Factor Surveillance System, 2000",https://pmc.ncbi.nlm.nih.gov/articles/PMC8215078/; https://pubmed.ncbi.nlm.nih.gov/31187658/; https://pubmed.ncbi.nlm.nih.gov/14529096/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 141, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'How many patients have initiated anifrolumab?', 'role': 'user'}]}",True,200.0,28.039044618606567,,1808db1d-85e6-4d13-af1c-650311f7657d,235.0,"In the pooled TULIP‑1 and TULIP‑2 phase 3 trials, 360 patients received anifrolumab 300 mg. [1] Acro...",3.0,T/T/T,3.0,True,True,True,"The provided context specifies that, in the TULIP-1 and TULIP-2 trials, 360 patients received anifrolumab 300 mg. This information is included verbatim in the AI's answer. Furthermore, the context also mentions that a total of 1,160 SLE patients from four RCTs were included in a safety analysis (though the context doesn't specify if all these patients received anifrolumab, the AI's answer appropriately states these were patients analysed in anifrolumab trials without inferring that all received the drug). Thus, the AI's answer is entirely grounded in the provided context, directly addresses the question with the most precise number available (360), and provides additional relevant statistics without overreaching beyond the context.",741,2,2,89.5,179,Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials; Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review,https://pubmed.ncbi.nlm.nih.gov/38288923/; https://pubmed.ncbi.nlm.nih.gov/36211347/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 140, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the demographic profile and population size of patients receiving anifrolumab and belimumab?', 'role': 'user'}]}",True,200.0,36.159361362457275,,44f3369b-fa60-4e19-961a-08b77aa30892,728.0,Anifrolumab: Pooled phase‑3 (TULIP) program included 360 patients who received anifrolumab 300 mg (3...,2.0,T/T/F,1.0,True,True,False,"The AI's answer accurately summarizes the demographic breakdown and population size for both anifrolumab and belimumab based on the provided context, including gender, age, and racial composition as well as patient counts. However, the AI introduces an unsupported detail regarding the ""median/mean age in the early-to-mid 40s"" for anifrolumab patients, which is not specified in the provided context. The age data for belimumab (mean age ~38) is directly grounded in the context. The rest of the details closely match what's present in the context, so with the exception of the age detail for anifrolumab, the answer is otherwise grounded.",640,4,4,222.0,888,Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials; Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials - PMC; Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials - PMC; Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study - PMC,https://pmc.ncbi.nlm.nih.gov/articles/PMC12056589/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9538665/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9843193/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9718049/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 139, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma patients on Advair, AirDuo, Breo, Dulera, Symbicort, Wixela, Fluticasone-Salmeterol, Budesonide-Formoterol, Mometasone-Formoterol, Cohort_1: Xolair, Nucala, Cinqair, Fasenra, Dupixent, Tezspire, Cohort_2: Not on (Xolair, Nucala, Cinqair, Fasenra, Dupixent, Tezspire), Outcomes: ER visits, urgent care visits, asthma-related inpatient hospitalizations, systemic corticosteroid prescription initiation', 'role': 'user'}]}",True,200.0,37.800907373428345,,2e2a7229-2389-4971-9d8c-d49e4e8e8d7a,858.0,Limitations: evidence is from patients with severe/uncontrolled asthma initiating biologics and may ...,3.0,T/T/T,3.0,True,True,True,"The AI's answer is well-grounded in the provided context. It accurately summarizes multiple study findings about the impact of biologic therapies (e.g., Xolair, Nucala, Cinqair, Fasenra, Dupixent, Tezspire) versus non-use in asthma patients, in terms of ED visits, hospitalizations, and systemic corticosteroid use, referencing the same reductions and findings cited in the documents. It also notes limitations (severe/uncontrolled asthma), which aligns with the populations studied in the references. All outcomes listed in the original question are covered with supporting evidence from the context. No additional or hallucinated information is introduced.",658,4,4,195.0,780,"Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry - PubMed; Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma - PMC; Impact of Biologics Initiation on Oral Corticosteroid Use in the International Severe Asthma Registry and the Optimum Patient Care Research Database: A Pooled Analysis of Real-World Data - PubMed; Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations - PubMed",https://pubmed.ncbi.nlm.nih.gov/37301430/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12085395/; https://pubmed.ncbi.nlm.nih.gov/40294847/; https://pubmed.ncbi.nlm.nih.gov/38431251/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 146, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Please provide count of the number of HCPs with procedures for the following lab tests:\n Blood eosinophil count\n Blood IgE count\n FeNO', 'role': 'user'}]}",True,200.0,12.517160892486572,,1a7c1a31-2440-44ba-aa04-2c1e745a1010,455.0,I need clarification: what do you mean by “HCPs with procedures” — do you want (A) counts of healthc...,1.0,F/F/T,1.0,False,False,True,"The provided context is empty and does not contain any information relevant to the question about HCPs with procedures for the specified lab tests. The AI assistant's reply is grounded in the context (or lack thereof), as it asks for clarification based on insufficient context and does not introduce external facts or unsupported claims. However, since there is no information in the context, it neither addresses the question directly nor provides relevant evidence.",468,0,0,0.0,0,,,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 134, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with confirmed severe asthma, defined by repeated asthma diagnoses, Intervention: Any of the following biologics - (Xolair, Nucala, Cinqair, Fasenra, Dupixent, Tezspire), Outcomes: Counts of systemic corticosteroid prescriptions, asthma-related hospitalizations and emergency department visits', 'role': 'user'}]}",True,200.0,58.31709694862366,,8b802009-3c44-4ccb-a72e-81308c2d4ef8,1000.0,"Among patients with confirmed severe asthma, randomized trials and real-world studies show biologics...",3.0,T/T/T,3.0,True,True,True,"The AI's answer is well-grounded in the provided context and directly addresses the question. It presents evidence for each of the biologics where available in the context—specifically omalizumab and mepolizumab—and uses relevant study statistics (reductions in ED visits, hospitalizations, and OCS use) with appropriate references. The AI also correctly summarizes pooled and real-world analyses regarding these outcomes. While the context does not provide specific outcome statistics for every biologic mentioned in the question (e.g., benralizumab, dupilumab, tezepelumab), the AI limits the direct statistical claims to those biologics for which context evidence exists, thus avoiding unsupported statements. Therefore, the answer is directly supported and grounded in the context.",785,4,4,229.5,918,"Association between consistent omalizumab treatment and asthma control - PubMed; Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma - PubMed Central (PMC); Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma - PubMed; Real-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retrospective analysis - PubMed",https://pubmed.ncbi.nlm.nih.gov/24229822/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12085395/; https://pubmed.ncbi.nlm.nih.gov/27726946/; https://pubmed.ncbi.nlm.nih.gov/39786337/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 143, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Please provide longitudinal exacerbation rate for severe asthma patients on Tezspire.', 'role': 'user'}]}",True,200.0,27.295202016830444,,3bc72411-f0ca-47c7-84e6-7532360f9273,539.0,"In randomized trials, tezepelumab (Tezspire) reduces annualized asthma exacerbations in severe, unco...",3.0,T/T/T,3.0,True,True,True,"The AI's answer accurately extracts the longitudinal (annualized) exacerbation rates for severe asthma patients on Tezspire as reported in the provided context. It summarizes the key data points, including the AAER (0.93/year) from the NAVIGATOR trial, the 60% reduction from pooled PATHWAY + NAVIGATOR analysis, and the absolute reduction from the meta-analysis. All referenced values and statements in the answer are directly grounded in the provided context and do not rely on external or unsupported information. The context directly answers the question, is clearly relevant, and the AI's answer is faithful to it.",619,3,3,166.0,498,"Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma; Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials - PubMed; Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis - PubMed",https://pubmed.ncbi.nlm.nih.gov/33979488/; https://pubmed.ncbi.nlm.nih.gov/37015033/; https://pubmed.ncbi.nlm.nih.gov/36425526/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 144, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the estimated population of patients diagnosed with SLE in the United States, and how is this population distributed across different demographics such as age, gender, and ethnicity?', 'role': 'user'}]}",True,200.0,29.91399574279785,,9795be2c-1238-4bfd-9333-9cf4d340894b,1320.0,Limitation: the cited CDC registry meta-analyses provide sex- and race/ethnicity-stratified prevalen...,3.0,T/T/T,3.0,True,True,True,"The answer provides a direct estimate of the SLE population in the United States and breaks down the distribution by gender and ethnicity, explicitly citing prevalence rates and case estimates that match the numbers in the context. The limitation regarding the lack of age distribution data is accurately noted, reflecting what is and is not available in the provided evidence. The answer does not include unsupported claims or information not evidenced in the context. Therefore, all three criteria are met.",508,2,2,219.5,439,Prevalence of Systemic Lupus Erythematosus in the United States: Estimates from a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries - PMC; Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries - PMC,https://pmc.ncbi.nlm.nih.gov/articles/PMC8169527/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8685969/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 149, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Please count HCPs by all the medical procedure codes for these lab tests: Blood eosinophil count, Blood IgE, FeNO', 'role': 'user'}]}",True,200.0,19.57231330871582,,71da4e28-78e7-44f6-a9d4-a7055729dd07,69.0,The published literature does not contain an answer to this question.,1.0,F/F/T,1.0,False,False,True,"There is no context provided, so the AI cannot directly answer the question (the context does not contain relevant evidence), nor is the context even relevant to the question. However, the AI's answer correctly does not introduce any unsupported claims and stays grounded, acknowledging the lack of information.",311,0,0,0.0,0,,,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 142, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients initiating anifrolumab or belimumab in the United States, Cohort_1: anifrolumab, Cohort_2: belimumab, Outcomes: demographic distribution', 'role': 'user'}]}",True,200.0,41.655234575271606,,6a571681-bfff-4f81-84c2-1533e73766eb,497.0,"In US real‑world cohorts/reports, patients initiating anifrolumab are predominantly female and are m...",3.0,T/T/T,3.0,True,True,True,"The context includes direct and relevant demographic data for both anifrolumab and belimumab US patient cohorts, specifying age and sex distributions and, for belimumab, mentioning African American and Hispanic subgroups. The AI's answer accurately summarizes this data, citing relevant patient age ranges, the predominance of female patients, and presence of reported racial/ethnic subgroups for belimumab. All claims made in the answer are supported by the context, and no unsupported statements or external information are introduced.",537,3,3,218.33333333333334,655,"Post-marketing safety signals of anifrolumab in systemic lupus erythematosus: a pharmacovigilance study based on FAERS; Clinical Trials of Interferon Inhibitors in Systemic Lupus Erythematosus and Preliminary Real-World Efficacy of Anifrolumab; Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study",https://pmc.ncbi.nlm.nih.gov/articles/PMC12278508/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11345606/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10011356/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 145, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Please provide a list of procedure codes to identify the following lab test procedures in medical claims data:\n Blood eosinophil count\n Blood IgE count\n FeNO', 'role': 'user'}]}",True,200.0,33.04841995239258,,9656d15e-ef59-414e-b82b-bf8794f2139d,226.0,The published literature indexed on the NLM domains searched does not contain procedure code lists (...,1.0,F/F/T,1.0,False,False,True,"There is no relevant context provided to address the question or provide procedure code information for blood eosinophil count, blood IgE, or FeNO. The AI's answer correctly states that the literature does not contain this information, but since there is no context at all, the answer cannot be directly grounded or supported by the provided context. However, the answer does not introduce unsupported claims beyond the absence of evidence, so it is appropriately cautious.",473,0,0,0.0,0,,,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 135, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients (≥18 years) with severe asthma who initiated biologic therapy, Intervention: Continuous use of biologic therapy for ≥12 months, Control: Discontinuation of biologic therapy within 12 months of initiation, Outcomes: Differences in healthcare utilization, including asthma-related hospitalizations and emergency department visits, during the 12-month period', 'role': 'user'}]}",True,200.0,63.32750487327576,,1de521e7-923b-437f-9b4e-5799a91d4f8b,1180.0,"In severe asthma, continuing biologic therapy for ≥12 months is associated with substantial reductio...",1.0,F/T/F,1.0,False,True,False,"1. context_answers_question_directly: The context does not provide direct, robust comparison data about differences in healthcare utilization (specifically asthma-related hospitalizations and ED visits) between patients who continuously use biologics for ≥12 months and those who discontinue within 12 months. There is some indirect evidence and overall utilization rates, but no direct head-to-head comparison clearly stated for this specific control/intervention setup.

2. context_addresses_question: The context is relevant to the question, as it discusses biologic therapy duration, exacerbations, and health care utilization (ER visits, hospitalizations) in severe asthma patients. It also discusses comparisons between continuers and discontinuers, albeit not with comprehensive outcome details.

3. answer_grounded_in_context: The AI answer summarizes and references the context, but introduces some synthesis and interpretation that goes slightly beyond what is directly in the provided context. For example, it asserts 'maintained benefit with continued therapy' and makes overall comparative statements that are not directly, explicitly supported by the context, especially given the lack of direct comparative outcome data for the specific timeframes in the clinical question.",1288,3,3,216.0,648,"Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma Biologics; Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma; Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017–2022: An Analysis of the International Severe Asthma Registry",https://pubmed.ncbi.nlm.nih.gov/33652135/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12085395/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11522015/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 147, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Please provide count of the number of HCPs with HCPCS or CPT codes for the following lab tests:\n Blood eosinophil count\n Blood IgE count\n FeNO', 'role': 'user'}]}",True,200.0,37.316062211990356,,5f9505d3-ad0d-4b31-9277-6886344e47be,355.0,The published literature indexed at NLM does not report counts of HCPs who have HCPCS or CPT codes f...,3.0,T/T/T,3.0,True,True,True,"The AI's answer correctly states that the provided literature does not contain counts of HCPs with HCPCS or CPT codes for blood eosinophil count, blood IgE, or FeNO tests. It appropriately reflects the context, which states explicitly that these studies do not report this information. Therefore, the answer is directly supported by and grounded in the context, while also only referencing what is present or absent within the provided documents.",446,2,2,197.5,395,"Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis; Exhaled nitric oxide in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis",https://pubmed.ncbi.nlm.nih.gov/31900184/; https://pubmed.ncbi.nlm.nih.gov/30214187/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 151, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'How many tagrisso patients with at least 3 years follow up and in which tumor areas?', 'role': 'user'}]}",True,200.0,28.584539651870728,,b1ca5b50-6666-4c78-a56d-e6a1ce42a6f6,647.0,In the ADAURA program 682 patients were randomized and all had the opportunity for 3 years of adjuva...,1.0,F/T/F,1.0,False,True,False,"The context does not provide the explicit number of Tagrisso (osimertinib) patients with at least 3 years of follow-up, nor does it specify tumor areas where these patients were followed. The context reports 682 randomized patients and percentages completing 3 years of planned treatment, but it does not directly state how many had 3 years of follow-up. The AI's answer infers numbers based on these percentages, but this calculation is not directly supported in the context. Recurrence site information (brain, lung, bone) is mentioned in related studies, but it's unclear if this matches the follow-up cohort specifically. Therefore, the AI's answer is not fully grounded in the context provided.",699,3,3,210.66666666666666,632,Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial - PMC; ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer - PMC; Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I-III non-small cell lung cancer - PMC,https://pmc.ncbi.nlm.nih.gov/articles/PMC10082285/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9098707/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10085825/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 148, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Please list all the medical procedure codes for these lab tests: Blood eosinophil count, Blood IgE, FeNO', 'role': 'user'}]}",True,200.0,40.52363920211792,,0c7cd04c-c635-428f-8e73-a38367181cb4,363.0,The NLM/NCBI literature and MedGen pages searched do not provide authoritative procedural (CPT/HCPCS...,2.0,F/T/T,2.0,False,True,True,"The context does not provide any specific medical procedure codes for the tests mentioned. Instead, it only describes the clinical relevance of the tests and explicitly states the absence of procedural/billing codes in the sources. The AI answer correctly identifies this lack of information and directs the user to seek codes elsewhere, which aligns with the context. The context is relevant to the question because it confirms the absence of the codes. The AI answer is grounded in the context and does not introduce information not present in the context. However, the answer does not directly answer the question with the requested codes because the context does not include them.",684,3,3,173.0,519,Eosinophil count within reference range (Concept Id: C0427396) - MedGen - NCBI; Total IgE as a Marker for Chronic Spontaneous Urticaria - PubMed; Understanding the Cellular Sources of the Fractional Exhaled Nitric Oxide (FeNO) and Its Role as a Biomarker of Type 2 Inflammation in Asthma - PubMed,https://www.ncbi.nlm.nih.gov/medgen/605624; https://pubmed.ncbi.nlm.nih.gov/33474856/; https://pubmed.ncbi.nlm.nih.gov/35547356/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 153, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients on continuous 8 month of Lokelma use, Intervention: Lokelma, Outcomes: description of long term use characteristics', 'role': 'user'}]}",True,200.0,27.674062967300415,,b7101a20-3f73-404d-9f25-e4d7954bf848,1418.0,Limitations: No randomized trial specifically reports outcomes for a predefined cohort on continuous...,3.0,T/T/T,3.0,True,True,True,"The AI's answer is well grounded in the provided context. It directly draws on the cited studies to summarize long-term (including 8-month and longer) Lokelma (SZC) use characteristics, reporting duration, efficacy (potassium lowering/maintenance), and relevant safety signals including hypokalemia and cardiac/renal events, which are all supported by the referenced material. The limitations noted (absence of RCTs for EXACTLY 8 continuous months in adults) accurately reflect the context. The answer does not introduce external, unsupported information, and uses only what is justified in the context, with proper referencing of each claim to a source.",654,3,3,189.0,567,Sodium Zirconium Cyclosilicate for Renin-Angiotensin-Aldosterone System Inhibitor Optimization in Patients with Heart Failure with Reduced Ejection Fraction: A Retrospective Analysis - PubMed; Adverse drug events associated with sodium zirconium cyclosilicate: A real-world pharmacovigilance study based on the FAERS database - PubMed; Safety and efficacy of sodium zirconium cyclosilicate for the management of acute and chronic hyperkalemia in children with chronic kidney disease 4-5 and on dialysis - PubMed,https://pubmed.ncbi.nlm.nih.gov/39485602/; https://pubmed.ncbi.nlm.nih.gov/40892715/; https://pubmed.ncbi.nlm.nih.gov/37857905/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 150, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with early lung cancer, Intervention: Tagrisso, Outcomes: death', 'role': 'user'}]}",True,200.0,32.69336676597595,,98b78306-3f8d-4fd1-ac07-bab08a95cb56,396.0,"In patients with resected, early-stage (IB–IIIA) EGFR‑mutated non–small-cell lung cancer, adjuvant o...",3.0,T/T/T,3.0,True,True,True,"The provided context reports that adjuvant osimertinib (Tagrisso) in resected, early-stage (IB–IIIA) EGFR-mutated non–small-cell lung cancer leads to a significant reduction in risk of death, including a quantified 51% risk reduction and specific 5-year overall survival improvements (85% vs 73%). The AI's answer accurately reflects these findings, citing the appropriate patient population, intervention, outcome, and statistics. No information is added beyond what is present in the context, and the answer is grounded wholly in the evidence supplied. Thus, the response is fully supported by the context under all three evaluation criteria.",644,2,2,219.5,439,Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC - PubMed; Overall Survival for Osimertinib Wows - PubMed,https://pubmed.ncbi.nlm.nih.gov/37272535/; https://pubmed.ncbi.nlm.nih.gov/37276331/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 154, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients on continuous 8 month of Lokelma use, Intervention: Lokelma, Outcomes: Serum Potassium Change measured by the difference in serum potassium levels from baseline to 8 months using laboratory EHR data; Hypokalemia Incidence determined by identifying diagnosis codes for hypokalemia occurrences over the 8-month period; all-cause hospital admission rate during 12 month follow-up; hyperkalemia-related hospital admission rate during 12 month follow-up; mortlaity during 12 month follow-up, MACE during 12 month follow-up; number of encounters where serum potassium level is measured greater than 5.0 mmol/l; number of encounters where serum potassium level is measured greater or equal to 5.5 mmol/l; time to first serum potassium greater than 5.0 mmol/l after index day; time to first serum potassium greater or equal to 5.5 mmol/l after index day; rate of edema', 'role': 'user'}]}",True,200.0,29.03210997581482,,a4fe701f-5162-4f05-84a3-30ed0af60eec,976.0,No published study was identified that specifically reports all requested EHR-derived outcomes for a...,2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False. The provided context does not supply all of the specific outcome data (e.g., detailed EHR data on all the endpoints listed such as number of hyperkalemic encounters, time to first potassium elevation, detailed hospitalization, and mortality data for continuous 8-month users) as requested in the question. The contextual studies provide only partial outcome data (maintenance of normokalemia, hypokalemia incidence, adverse events, mortality not related to medication, and lack of effect on MACE), but not the full set of granular endpoints specified in the prompt.

2. context_addresses_question: True. The context is relevant to the question, as it describes studies on Lokelma/SZC with similar patient populations and outcome measures, including potassium levels, hypokalemia, adverse events, deaths, and MACE, though it doesn't address the question fully or directly.

3. answer_grounded_in_context: True. The AI answer does not introduce unsupported claims and accurately summarizes the limitations of the context, appropriately reflecting on what is and isn't reported in the referenced studies.",1146,2,2,323.5,647,Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study - PubMed; The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis - PubMed,https://pubmed.ncbi.nlm.nih.gov/31110051/; https://pubmed.ncbi.nlm.nih.gov/40618849/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 156, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with 12 month of continuous outpatient use of Lokelma during a 12-month follow-up period, with a clearly defined baseline period of the 12 months immediately prior to Lokelma initiation to capture patient comorbidities and relevant characteristics, Intervention: Lokelma, Outcomes: Assessment of patient characteristics including baseline comorbidities (e.g., heart failure, hypertension, diabetes, chronic kidney disease identified via diagnosis codes); risk of acute myocardial infarction and stroke determined using specific diagnosis codes from EHR data (operationalizing MACE); risk of hyperkalemia recurrence defined as one or more serum potassium measurements above 5.0 mmol/L using laboratory result data, supplemented by hyperkalemia-related diagnostic codes from claims or EHRs to capture events potentially missed by lab draw timing; risk of edema defined based on specific diagnostic codes for peripheral or fluid retention edema; risk of all-cause inpatient admission.', 'role': 'user'}]}",True,200.0,31.3456392288208,,4766a156-09f6-45eb-bd31-c004d09d3552,789.0,No published study was identified that exactly matches the requested design (patients with 12 months...,2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False. The provided context does not include evidence directly matching the precise study design requested (patients with 12 months continuous outpatient Lokelma use, with a 12-month pre-initiation baseline, and detailed outcomes). The AI's answer correctly states that no such study is identified among the sources, so the context does not contain data that directly answers the very specific question regarding that population and timeframe.

2. context_addresses_question: True. The context is relevant insofar as it provides studies involving sodium zirconium cyclosilicate (Lokelma), its outcomes, and associated risks such as heart failure, edema, and relevant adverse events, aligning broadly with the topics and outcomes of interest specified in the question.

3. answer_grounded_in_context: True. The AI answer limits itself to summarizing findings directly supported by the cited contextual literature, makes clear that the ideal study was not found, and does not introduce unsupported claims or external data.",1058,3,3,194.66666666666666,584,The Association of Heart Failure and Edema Events between Patients Initiating Sodium Zirconium Cyclosilicate or Patiromer; Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial; Post-marketing safety associated with sodium zirconium cyclosilicate: a pharmacovigilance study based on the FDA reporting system,https://pubmed.ncbi.nlm.nih.gov/39303023/; https://pubmed.ncbi.nlm.nih.gov/25402495/; https://pubmed.ncbi.nlm.nih.gov/40151141/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 158, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients who were diagnosed with hyperkalemia during the index hospitalization and discharged from hospital, no history of lokelma, patrimer, or SPS use prior to hyperkalemia hospitalization; report baseline mean serum potassium level , Intervention: Lokelma outpatient initiation and continued use as documented in structured EHR or claims data, Control: no lokelma, patrimer, SPS treatment during the follow-up period, Outcomes: serum potassium control defined by specific metrics such as the mean serum potassium level and the proportion of patients achieving a target potassium range (e.g., 3.5-5.0 mEq/L) during follow-up', 'role': 'user'}]}",True,200.0,30.164990425109863,,40b66200-5dbc-445f-810f-e7667c1bad94,1075.0,"No studies matching the exact real-world design (patients hospitalized with hyperkalemia, discharged...",2.0,F/T/T,2.0,False,True,True,"The context provides results from randomized clinical trials and open-label extension studies regarding the baseline and follow-up serum potassium levels with SZC (Lokelma), but not for the precise population described in the question (patients discharged after hospitalization for hyperkalemia, with no prior K-binder use, and with EHR/claims-based outpatient initiation vs an untreated control group). The AI answer accurately reflects this gap, notes the limitation, and restricts its claims to what the context offers. Thus, the answer is well-grounded in the given context and appropriately cautious, but the context does not provide a direct answer to the specific population, intervention, control, and outcomes requested.",729,3,3,190.33333333333334,571,Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial - PubMed; Sodium zirconium cyclosilicate in hyperkalemia - PubMed; Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE - PubMed,https://pubmed.ncbi.nlm.nih.gov/25402495/; https://pubmed.ncbi.nlm.nih.gov/25415807/; https://pubmed.ncbi.nlm.nih.gov/31658466/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 152, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with transthyretin amyloid neuropathy (ATTR-PN), Cohort_1: patients with V122I genetic mutation subtype, Cohort_2: patients with V30M mutation subtype, Outcomes: ATTR treatment choices', 'role': 'user'}]}",True,200.0,44.62888050079346,,6b2f37b2-ac8c-4c41-8584-46cc8086b16a,1397.0,Direct head-to-head comparisons of treatment selection by V122I versus V30M subtypes are not availab...,3.0,T/T/T,3.0,True,True,True,"The AI’s answer directly summarizes the context provided, offering a mutation-specific synthesis of available clinical evidence for treatment choices in ATTR-PN patients with V122I and V30M mutations. It accurately notes that tafamidis has proven benefit in V30M (supported by a randomized trial in early-stage patients) and that patisiran is supported by clinical trial data in both genotypes, including V122I (with outcome improvements reported in the APOLLO and phase IV multicenter studies). The discussion of tafamidis’s mechanism in V122I and the lack of firm clinical outcome data for this subtype is based on referenced biochemical findings and the absence of clinical trial outcomes, as per the context. The clinical implication drawn aligns tightly with the references supplied. The answer does not rely on external knowledge or unreferenced claims, strictly grounding itself in the text. Thus, all assessment criteria are fulfilled.",943,4,4,252.0,1008,"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial; Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade; Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis; Impact of patisiran on polyneuropathy of hereditary transthyretin amyloidosis in patients with a V122I or T60A variant: a phase IV multicenter study",https://pubmed.ncbi.nlm.nih.gov/22843282/; https://pubmed.ncbi.nlm.nih.gov/22645360/; https://pubmed.ncbi.nlm.nih.gov/29972753/; https://pubmed.ncbi.nlm.nih.gov/40974604/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 155, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with at least 8 month of continous outpatient use of Lokelma in a 12 month follow-up period, Intervention: Lokelma, Outcomes: description patient characteristics, risk of MACE; risk of hyperkalemia recurrence as measured as having serium potesasium level above 5.0 mmol/l during the follow-up period; risk of edema; risk of all-cause inpatient admission;', 'role': 'user'}]}",True,200.0,40.92548966407776,,35deda8f-0f7a-4847-95af-76198b8df642,1829.0,Limitations: No published study was identified that reports outcomes specifically for a cohort defin...,3.0,T/T/T,3.0,True,True,True,"The AI assistant's answer is well-grounded in the provided context, transparently discussing the limitations due to lack of studies matching the exact population criteria but appropriately summarizing findings from the most relevant and closely matching studies reported in the context. Each outcome requested in the original question is addressed with supporting data: patient characteristics, recurrence of hyperkalemia (reporting percentages from the 12-month phase-3 study), risk of edema (citing both trial and observational data), risk of major adverse cardiovascular events (providing relevant events and clarifying causality), and all-cause hospitalizations (using claims data from long-term users as defined in the context). The answer is appropriately cautious, highlights approximation due to study design differences, and avoids introducing unsupported external information. Therefore, all three criteria are met.",925,3,3,240.0,720,Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study - PubMed; Impact on hospitalizations of long-term versus short-term therapy with sodium zirconium cyclosilicate during routine outpatient care of patients with hyperkalemia: the RECOGNIZE I study - PubMed; The Association of Heart Failure and Edema Events between Patients Initiating Sodium Zirconium Cyclosilicate or Patiromer - PubMed,https://pubmed.ncbi.nlm.nih.gov/31110051/; https://pubmed.ncbi.nlm.nih.gov/36576213/; https://pubmed.ncbi.nlm.nih.gov/39303023/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 160, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with at least one SABA (albuterol) rescue inhaler fill in 2023, a documented asthma diagnosis during the study period, and no documented COPD diagnosis, Cohort_1: commercially insured, Cohort_2: Medicare, Cohort_3: Medicaid, Outcomes: count of asthma-related exasperation events by hospitalization, ER and outpatient visits and count of corticosteroids fills', 'role': 'user'}]}",True,200.0,30.123399019241333,,e6cd9c56-2f64-425b-8988-83f24f30f666,636.0,The published literature does not contain cohort-level counts in 2023 for patients meeting the exact...,2.0,F/T/T,2.0,False,True,True,"The context does not directly answer the question, which asks for cohort-level counts by insurance type (commercial, Medicare, Medicaid) for the specified population and outcomes in 2023. However, the context is relevant because it discusses associations between SABA fills and asthma exacerbation events, and corticosteroid use in populations with asthma, and broadly addresses the relationship between high SABA use and morbidity. The AI answer is faithful to the context, correctly noting the absence of direct cohort counts and summarizing findings from relevant studies without introducing external information or unsupported claims.",638,3,3,225.33333333333334,676,Short-acting beta-agonist prescription fills as a marker for asthma morbidity - PubMed; Real-world patterns and implications of short-acting β2-agonist use in patients with asthma in the United States - PubMed; Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America - PubMed,https://pubmed.ncbi.nlm.nih.gov/16100144/; https://pubmed.ncbi.nlm.nih.gov/33515710/; https://pubmed.ncbi.nlm.nih.gov/35364341/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 163, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the average annual number of doses of mepolizumab?', 'role': 'user'}]}",True,200.0,26.779650926589966,,c9f1dae8-08e5-419f-b6f1-b62402af240f,149.0,Recommended adult dosing is 100 mg subcutaneously every 4 weeks [1]; that dosing interval correspond...,3.0,T/T/T,3.0,True,True,True,"The AI's answer is fully grounded in the provided context. The context states mepolizumab is administered every 4 weeks, which equals 13 doses in a 52-week year. The calculation of annual doses (52/4 = 13) is a direct and logical inference from this information and does not rely on external knowledge. Both context pieces confirm the dosing interval, and the answer is entirely based on that information.",405,2,2,120.5,241,"Mepolizumab - PMC; Asthma Biologics: Comparing Trial Designs, Patient Cohorts and Study Results - PMC",https://pmc.ncbi.nlm.nih.gov/articles/PMC4896350/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6911637/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 162, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the average treatment duration of mepolizumab?', 'role': 'user'}]}",True,200.0,27.259522199630737,,811ccc4c-c232-49fd-a719-ac30da71acae,469.0,Published studies report variable mean/median durations depending on cohort and follow-up: about 11....,3.0,T/T/T,3.0,True,True,True,"The context provides data from multiple studies reporting mean and median durations of mepolizumab treatment (e.g., 340.4 days, 789.34 days, median 2.2 years, up to 10 years). The AI's answer summarizes each of these findings accurately with appropriate values, references the apparent variability, and does not introduce unsupported information. Thus: (1) The context does directly answer the question about average duration; (2) The context is highly relevant; (3) The AI's answer is firmly grounded in the provided context.",526,4,4,127.75,511,Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis - PMC; Efficacy and Safety of Mepolizumab in the Management of Severe Eosinophilic Asthma: A Systematic Review - PMC; REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study - PMC; Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study - PMC,https://pmc.ncbi.nlm.nih.gov/articles/PMC7559868/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10757760/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8550660/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11520089/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 161, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with severe eosinophilic asthma, Intervention: mepolizumab, Control: none, Outcomes: asthma exacerbations', 'role': 'user'}]}",True,200.0,29.567365884780884,,81f6cf0b-cdb5-4f24-8199-6910ff7a2661,478.0,"In patients with severe eosinophilic asthma, mepolizumab significantly reduces asthma exacerbations:...",3.0,T/T/T,3.0,True,True,True,"The provided context directly answers the question by supplying specific data on mepolizumab's effect on asthma exacerbations in patients with severe eosinophilic asthma. The context is highly relevant, featuring multiple studies (including randomized controlled trials) that detail reduction rates in exacerbations and hospitalization due to mepolizumab use. The AI's answer accurately summarizes these findings with correct numbers and percentages, and does not introduce information outside the context. All statements are grounded in the documents provided.",561,3,3,199.66666666666666,599,"Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis; Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial; Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma",https://pubmed.ncbi.nlm.nih.gov/30533206/; https://pubmed.ncbi.nlm.nih.gov/22901886/; https://pubmed.ncbi.nlm.nih.gov/27726946/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 159, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'long term trajectory of hyperkalemia recurrence in non-ESRD or dialysis adult patients newly diagnosed with hyperkalemia with confirmed lab measurement of serum potassium level greater than 5.0 mmol/L with greater than 5 years of continuous enrollment. primary oucome is chronic hyperkalemia defined as greater than 3 episodes of serium potassium greater than 5.0 mmol/L with greater than 30 days apart of each episode. also report on time to recurrence, frequency, and proportion of time with elevated potassium level.', 'role': 'user'}]}",True,200.0,56.00524973869324,,93d5d63c-ef6c-4b8f-b218-a5cd2fda602c,2326.0,Limitations: No identified studies matched the exact cohort (non-ESRD adults newly diagnosed with K+...,2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False. The provided context does not contain direct evidence for the long-term (≥5 years) trajectory of hyperkalemia recurrence in non-ESRD adult patients, using the chronic hyperkalemia outcome definition requested. None of the cited studies provide results for ≥5 years follow-up or specifically address three or more episodes >30 days apart within ≥5 years, nor do they report on the proportion of time with elevated K+ for this cohort.
2. context_addresses_question: True. The context presents studies on hyperkalemia recurrence, relevant patient populations (non-ESRD, CKD, CHF), relevant measurements (K+>5.0 mmol/L), and outcomes such as recurrence rates, time-to-recurrence, and predictors. While the studies do not exactly meet the inclusion criteria of the original question, they address related outcomes over shorter durations and with somewhat similar populations.
3. answer_grounded_in_context: True. The AI’s answer accurately summarizes the findings from each referenced study, carefully notes the lack of direct evidence for the primary outcome, and transparently communicates evidence limitations. There are no unsupported or hallucinated claims; all synthesized points are grounded in the provided context.",1263,4,4,225.0,900,Liver Disease Is a Risk Factor for Recurrent Hyperkalemia: A Retrospective Cohort Study; Inpatient management and post-discharge outcomes of hyperkalemia; Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients - A population-based cohort study; Hyperkalemia Recurrence Following Medical Nutrition Therapy in Patients with Stage 3-4 Chronic Kidney Disease: The REVOLUTIONIZE I Real-World Study,https://pubmed.ncbi.nlm.nih.gov/37510679/; https://pubmed.ncbi.nlm.nih.gov/34038312/; https://pubmed.ncbi.nlm.nih.gov/31226134/; https://pubmed.ncbi.nlm.nih.gov/38687454/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 166, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Among Asthma patients in 2023 what is the healthcare resource utilization among 3 cohorts of systemic steroid usage:\n - No Systemic steroid usage\n - <500mg in a year\n - 500mg - 1000mg a year\n - >1000mg a year', 'role': 'user'}]}",True,200.0,32.20326566696167,,71b758e3-ce6f-4d17-9067-fdd07394afe8,1368.0,Published literature does not report 2023-era asthma cohort healthcare-resource‑use (HCRU) broken do...,2.0,F/T/T,2.0,False,True,True,"The provided context does not contain direct data for healthcare resource utilization (HCRU) in 2023 among the specific four cohorts of systemic steroid usage (<500 mg, 500–1000 mg, >1000 mg, and no usage). However, it is relevant to the question as it discusses dose–response relationships between corticosteroid use and healthcare utilization/morbidity, generally supporting that increased steroid use is associated with higher healthcare burden. The AI assistant accurately reflects this, stating no data is available for the exact requested breakdown but summarizing the available relevant findings. The answer is well-grounded in the provided context and avoids introducing unsupported information.",703,3,3,219.0,657,"Oral corticosteroid stewardship: key insights from the Australasian Severe Asthma Registry - PubMed; Low-dose oral corticosteroids in asthma associates with increased morbidity and mortality - PubMed; Oral corticosteroid use, morbidity and mortality in asthma: A nationwide prospective cohort study in Sweden - PubMed",https://pubmed.ncbi.nlm.nih.gov/38622806/; https://pubmed.ncbi.nlm.nih.gov/35144997/; https://pubmed.ncbi.nlm.nih.gov/31095758/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 164, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with chronic obstructive pulmonary disease, Intervention: proportion of patients on spiriva, Outcomes: spiriva', 'role': 'user'}]}",True,200.0,46.07860016822815,,afd4f887-9da0-4119-9e08-686e10180136,838.0,"Published literature does not provide a single, generalizable population-wide proportion of COPD pat...",3.0,T/T/T,3.0,True,True,True,"The AI's answer accurately reflects the provided context. It mentions that population-wide proportions are not universally reported in the literature, but cites a nationwide cohort study indicating LAMA (including tiotropium/Spiriva) prescription rates of about 22.8–24.1%, which directly answers the question about the proportion of patients on Spiriva. It also correctly references other studies included in the context, noting their focus on initiator cohort sizes or trial enrollment rather than population-level prevalence, matching what is in the context without introducing extraneous information. The answer is grounded solely in the provided material.",660,3,3,200.0,600,Effects of tiotropium on the risk of coronary heart disease in patients with COPD: a nationwide cohort study; Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease; Results - Clinical Review Report: tiotropium bromide monohydrate (Spiriva Respimat) for oral inhalation,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535029/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150166/; https://www.ncbi.nlm.nih.gov/books/NBK581869/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 167, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with hypertension defined by either two or more separate SBP readings >130 mmHg or the presence of documented hypertension diagnosis codes in the EHR/claims data to minimize misclassification., Cohort_1: Patients receiving exactly three hypertensive medications with detailed identification of medication classes based on available EHR/claims data. For example, specify if the medications are from classes such as ACE inhibitors, ARBs, beta blockers, or thiazide diuretics (with individual agent names noted when possible)., Cohort_2: Patients receiving exactly four hypertensive medications with explicit identification of each medication class or agent. For instance, document use of combinations potentially including ACE inhibitors, ARBs, beta blockers, thiazide diuretics, and/or calcium channel blockers, with specific agents noted if available., Outcomes: Outcomes operationalized using validated EHR/claims definitions. Stroke is defined by differentiating ischemic (e.g., ICD codes I63) and hemorrhagic subtypes (e.g., ICD codes I61), MI is identified using acute myocardial infarction hospitalization codes (e.g., ICD-10 I21/I22), and heart failure is defined based on robust diagnostic criteria and hospital admission records (e.g., ICD codes I50 with confirmatory hospitalization).', 'role': 'user'}]}",True,200.0,35.289058208465576,,045799e6-9425-49a5-a549-94531f4e0f83,413.0,"In observational EHR/registry and claims-based analyses, patients requiring three antihypertensive a...",1.0,F/T/F,1.0,False,True,False,"The context includes studies relevant to patients with hypertension on three or more antihypertensive agents, their classification, and associated cardiovascular outcomes, including those using EHR/claims data. However, none of the provided context passages explicitly differentiates the outcomes between patients on exactly three medications versus exactly four medications with the required level of class- or agent-specific detail specified in the question. The AI's answer generalizes about higher cardiovascular risk for patients on three or more agents, citing the context, but does not specifically address or differentiate the distinct cohorts defined in the question (Cohort_1: three drugs, Cohort_2: four drugs with class detail). Furthermore, the answer refers to multiple outcomes as elevated but does not provide evidence directly from the context that exactly these outcomes are measured and stratified by those precise cohorts or according to the operational definitions stated in the question. Thus: 
- context does not answer the question directly, 
- but it is relevant, 
- and the answer is not strictly grounded in the context, as it extrapolates beyond what is explicitly stated.",1200,4,4,246.25,985,Resistant hypertension and cardiovascular disease mortality in the US: results from the National Health and Nutrition Examination Survey (NHANES) - PMC; Risk of Cardiovascular Outcomes and Antihypertensive Triple Combination Therapy Among Elderly Patients with Hypertension Enrolled in a Medicare Advantage Plan (MAP) - PubMed; Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients - PMC; The comparative effectiveness of fourth‑line drugs in resistant hypertension: An application in electronic health record data - PMC,https://pmc.ncbi.nlm.nih.gov/articles/PMC6485047/; https://pubmed.ncbi.nlm.nih.gov/32043245/; https://pmc.ncbi.nlm.nih.gov/articles/PMC3343635/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6771826/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 165, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the overlap of HCPs who are treating Hypertension and Dyslipidemia among Cardiologists?', 'role': 'user'}]}",True,200.0,44.68124723434448,,e1b0f01f-62d1-4f37-965a-40d8529ab56b,760.0,No published study was found that directly reports the proportion of cardiologists (HCPs) who treat ...,2.0,F/T/T,2.0,False,True,True,"The provided context does not include any specific data or explicit percentage regarding the overlap of HCPs (specifically cardiologists) treating both hypertension and dyslipidemia. None of the cited articles report HCP-level treatment overlap; instead, they provide data on patient-level comorbidity and general recommendations for combined management. Thus, the context does not answer the question directly. However, the context is relevant to the question as it pertains to hypertension and dyslipidemia management, and the answer given by the AI accurately reflects the limitations found in the context and does not go beyond the provided information.",657,3,3,199.33333333333334,598,Adherence to Cardiovascular Prevention Guidelines in an Academic Centre - PMC; Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease - PubMed; Evidence for a combined approach to the management of hypertension and dyslipidemia - PubMed,https://pmc.ncbi.nlm.nih.gov/articles/PMC10366625/; https://pubmed.ncbi.nlm.nih.gov/15617368/; https://pubmed.ncbi.nlm.nih.gov/16245413/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 168, 'customer': 'Astrazeneca BBU', 'messages': [{'content': ""Population: patients with hypertension in the United States, Intervention: Prescriptions filled will be analyzed to compute an objective medication adherence metric, such as the proportion of days covered (PDC) or medication possession ratio (MPR), to better assess patients' actual use of prescribed therapies using claims or electronic health records data., Outcomes: Aggregated SBP computed as the average of multiple SBP readings from routine clinical visits, stratified by age to minimize measurement error and better reflect patients’ typical blood pressure levels"", 'role': 'user'}]}",True,200.0,39.52579402923584,,b2495cbf-49db-4840-8a16-f4cf388ca31e,1483.0,The published literature identified here does not report a single study that directly pairs claims- ...,2.0,F/T/T,2.0,False,True,True,"The AI assistant's answer accurately states that no single study in the provided context directly pairs objective adherence metrics (PDC/MPR) from claims or EHR data with age-stratified, aggregated SBP from routine clinical visits; therefore, the context does not directly answer the question. However, the answer clearly addresses the question by summarizing the relevant studies: showing that adherence measurement using PDC/MPR is common and linked to outcomes, BP control and demographic stratification are regularly reported, and large datasets use multiple SBP readings to estimate average BP, supporting the feasibility of the proposed methodology. The AI's answer is fully grounded in the context, does not add unsupported claims, and accurately cites referenced studies. Thus, the response meets criteria 2 and 3, but not criterion 1.",843,4,4,217.0,868,"Antihypertensive Medication Adherence and Medical Costs, Health Care Use, and Labor Productivity Among People With Hypertension; Use and outcomes of antihypertensive medication treatment in the US hypertensive population: A gender comparison; Hypertension Prevalence, Awareness, Treatment, and Control Among Adults Age 18 and Older: United States, August 2021–August 2023 - NCHS Data Briefs; The control rate of hypertension across months of year and hours of day in a large real-world database",https://pubmed.ncbi.nlm.nih.gov/39494551; https://pmc.ncbi.nlm.nih.gov/articles/PMC10439450/; https://www.ncbi.nlm.nih.gov/books/NBK612761/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11534683/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 171, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what is the prevalence of nighttime symptoms in patients with asthma', 'role': 'user'}]}",True,200.0,29.8930561542511,,d05ece13-0012-4e0f-a34d-a626c0f6a49f,360.0,Estimates vary by study: overall prevalence of nocturnal/nighttime asthma symptoms is commonly repor...,3.0,T/T/T,3.0,True,True,True,"The provided context contains specific prevalence figures for nighttime/nocturnal symptoms in patients with asthma, ranging from 44–61%, 60%, and up to 75% for weekly awakenings, with 39–40% experiencing nightly symptoms. The AI assistant accurately summarizes these data points and gives an appropriately cited range for prevalence, making specific reference to weekly and nightly symptoms as presented in the context. No extraneous information or unsupported claims are introduced. Thus, all three evaluation criteria are met.",528,4,4,119.5,478,Nocturnal asthma; Nocturnal asthma - PubMed; Underdiagnosis of nocturnal symptoms in asthma in general practice; Nocturnal asthma: a study in general practice,https://pubmed.ncbi.nlm.nih.gov/34174807/; https://pubmed.ncbi.nlm.nih.gov/16337443/; https://pubmed.ncbi.nlm.nih.gov/16754521/; https://pubmed.ncbi.nlm.nih.gov/2556517/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 169, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Severe asthma patients in Puerto Rico, Outcomes: asthma‐related hospitalization (hospital admissions with a primary diagnosis of asthma)', 'role': 'user'}]}",True,200.0,39.46036672592163,,b878cbe3-3dd0-4d9d-a239-7e966534652e,845.0,No published study was found that reports asthma-related hospitalization rates specifically for a de...,2.0,F/T/T,2.0,False,True,True,"The context does not directly answer the question regarding asthma-related hospitalization rates specifically among severe asthma patients in Puerto Rico; rather, it provides general asthma hospitalization data and information about associations with environmental triggers, as well as some data on uncontrolled asthma. The context is relevant to the question, as it discusses asthma hospitalizations in Puerto Rico, but it does not provide the specific information sought (severe asthma population rates). The AI's answer remains grounded in the provided context, accurately reflecting the scope and limitations of the data available and not introducing unsupported claims.",674,3,3,215.33333333333334,646,Characterizing environmental asthma triggers and healthcare use patterns in Puerto Rico; Uncontrolled asthma and household environmental exposures in Puerto Rico; Association between Health Care Utilization with Asthma Control Levels among a Sample of Adult Patients in Puerto Rico,https://pmc.ncbi.nlm.nih.gov/articles/PMC8225466/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8215078/; https://pubmed.ncbi.nlm.nih.gov/27232869/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 173, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'I want to know how many metastasis breast patients have BRCAm', 'role': 'user'}]}",True,200.0,31.816251516342163,,a6b50f26-3c6f-4364-b57f-c29b8eac7d5a,528.0,"Published literature does not provide a clear, directly reported prevalence of BRCA1/2 pathogenic va...",2.0,F/T/T,2.0,False,True,True,"The context does not directly answer the question of how many metastatic breast cancer patients have BRCAm; instead, it provides prevalence data among all breast cancer patients, those with triple-negative breast cancer, and those referred for BRCA testing. However, the context is relevant to the question, as it deals with BRCA mutation prevalence in various breast cancer subgroups and discusses metastasis in relation to BRCA mutations. The AI's answer correctly summarizes the context and explicitly states the lack of direct evidence regarding the prevalence among metastatic breast cancer patients, without introducing unsupported information.",650,3,3,234.66666666666666,704,Patterns of recurrence and metastasis in BRCA1/BRCA2‐associated breast cancers; A systematic review of the international prevalence of BRCA mutation in breast cancer; Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel,https://pmc.ncbi.nlm.nih.gov/articles/PMC7003745/; https://pubmed.ncbi.nlm.nih.gov/31372057/; https://pubmed.ncbi.nlm.nih.gov/25186627/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 170, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Severe asthma patients in Puerto Rico on intervention, Intervention: Advair HFA, Symbicort, Dulera, Breo Ellipta, AirDuo RespiClick, Wixela Inhub, Trelegy Ellipta, Enerzair Breezhaler, Trimbow pMDI, Outcomes: asthma‐related hospitalization (hospital admissions with a primary diagnosis of asthma)', 'role': 'user'}]}",True,200.0,35.60007691383362,,5341761d-b67b-4998-9f08-557ac683b8b3,1029.0,No published studies were found that evaluate the effect of the specific ICS/LABA or triple-inhaler ...,2.0,F/T/T,2.0,False,True,True,"The context does not provide direct evidence about the effect of specific inhaler products (Advair HFA, Symbicort, etc.) on asthma-related hospitalization in severe asthma patients in Puerto Rico; it reports overall asthma hospitalization rates and notes that outcome data are not stratified by product or severity. The general efficacy of ICS–LABA therapy on exacerbations is mentioned in a non-Puerto Rico, non-product-specific study. The context is relevant, discussing asthma hospitalizations, uncontrolled asthma, and treatment patterns, but it falls short of a direct answer. The AI answer accurately reflects these limitations, remains grounded in the provided context, and does not introduce unsupported information.",724,3,3,241.66666666666666,725,Characterizing environmental asthma triggers and healthcare use patterns in Puerto Rico; Real-Life Patterns of Exacerbations While on Inhaled Corticosteroids and Long-Acting Beta Agonists for Asthma over 15 Years; Uncontrolled asthma and household environmental exposures in Puerto Rico,https://pmc.ncbi.nlm.nih.gov/articles/PMC8225466/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7141292/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8215078/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 177, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Proportion of COPD patients with comorbid Asthma', 'role': 'user'}]}",True,200.0,18.86046051979065,,6f17ebbd-a0a3-4a67-8a2f-7f97c9019bb3,290.0,Unable to provide an evidence‑grounded proportion because the required literature search (NCBI/NLM/P...,1.0,F/F/T,1.0,False,False,True,"There is no context provided, so the response cannot be evaluated for directly answering or addressing the question. The AI's answer does not attempt to make unsupported claims and transparently explains that it cannot answer the question without additional information, so it is grounded in the (absent) context.",313,0,0,0.0,0,,,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 172, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Severe asthma patients in Puerto Rico, Intervention: Advair HFA, Symbicort, Dulera, Breo Ellipta, AirDuo RespiClick, Wixela Inhub, Trelegy Ellipta, Enerzair Breezhaler, Trimbow pMDI, Outcomes: asthma‐related hospitalization (hospital admissions with a primary diagnosis of asthma)', 'role': 'user'}]}",True,200.0,44.54089832305908,,258281d6-973f-47e6-8769-0dd9b0bb77ba,986.0,No published study was identified that directly compares the listed inhaled combination products (Ad...,2.0,F/T/T,2.0,False,True,True,"The provided context contains information about asthma-related hospitalizations and healthcare utilization in Puerto Rico, but it clearly states that hospitalizations were not stratified or compared by specific inhaled medication products. The context is relevant to the question, as it discusses the general topic and outcomes of interest, but does not directly answer the question by providing head-to-head comparisons of the listed interventions among severe asthma patients. The AI assistant's answer correctly reflects this lack of direct evidence and accurately summarizes what is and isn't available in the provided context. The answer is grounded in the context, does not introduce information from outside the context, and does not fabricate any findings.",764,3,3,223.33333333333334,670,Burden of illness among patients with asthma prescribed inhaled corticosteroids/long-acting  - PubMed; Characterizing environmental asthma triggers and healthcare use patterns in Puerto Rico - PMC; Association between Health Care Utilization with Asthma Control Levels among a Sample of Adult Patients in Puerto Rico - PubMed,https://pubmed.ncbi.nlm.nih.gov/40011538/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8225466/; https://pubmed.ncbi.nlm.nih.gov/27232869/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 175, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients diagnosed with advanced biliary tract cancers between March 2022 - February 2024, Outcomes: first-line treatment regimens', 'role': 'user'}]}",True,200.0,27.399831295013428,,a4ca18cf-15dd-4924-81a4-eb1f2930a172,863.0,"Among patients with advanced biliary tract cancer diagnosed between March 2022 and February 2024, fi...",3.0,T/T/T,3.0,True,True,True,"The provided context includes specific evidence about the first-line treatment regimens for advanced biliary tract cancers during the relevant timeframe (March 2022 - February 2024), mentioning gemcitabine plus cisplatin, and the addition of immunotherapy agents such as pembrolizumab or durvalumab based on major phase III trials. The AI's answer accurately summarizes these points, referencing both real-world practice and clinical trial evidence, and is fully grounded in the given content without introducing unsupported claims. The context addresses, and directly answers, the question. Therefore, all three criteria are fulfilled.",636,3,3,285.6666666666667,857,Chemoimmunotherapy in Advanced Biliary Tract Cancers: A Meta-Analysis of Clinical Outcomes - PMC; Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study - PubMed; Treatment Patterns and Outcomes in Patients with Advanced Biliary Tract Cancers Treated with Gemcitabine-Based Chemotherapy: A Retrospective Study - PubMed,https://pmc.ncbi.nlm.nih.gov/articles/PMC12467448/; https://pubmed.ncbi.nlm.nih.gov/40387725/; https://pubmed.ncbi.nlm.nih.gov/39858087/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 174, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with stage I breast cancer, Cohort_1: hormone receptor positive, Cohort_2: human epidermal growth factor receptor 2 positive, Cohort_3: BRCA positive, Cohort_4: germline BRCA positive , Cohort_5: human epidermal growth factor receptor 2 negative, Outcomes: prevalence rate', 'role': 'user'}]}",True,200.0,38.55936121940613,,f05a71e7-200b-499f-9842-53b2e5e1cd34,873.0,Estimated prevalence among patients with stage I (early) invasive breast cancer: Cohort_1 (hormone r...,3.0,T/T/T,3.0,True,True,True,"The AI's answer accurately extracts relevant prevalence data for all the requested cohorts directly from the provided context. For hormone receptor-positive (Cohort 1), it provides the 70–75% estimate from the referenced article. For HER2-positive and HER2-negative (Cohorts 2 and 5), it uses the SEER-based 16% (with age breakdown) and calculates the complementary rate for HER2-negative appropriately. For BRCA and germline BRCA-positive (Cohorts 3 and 4), it presents prevalence from both the systematic review and genomic cohort papers, accurately quoting values for BRCA1/2. All figures are grounded in the provided context and do not rely on any external or unsupported data. Thus, every criterion is met.",711,4,4,172.5,690,Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US - PMC; Clinical and Pathological Features and Survival Outcomes of Breast Cancers with Intermediate ER Expression - Cancers (Basel) (2025) - PMC; A systematic review of the international prevalence of BRCA mutation in breast cancer - PubMed; Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants - PMC,https://pmc.ncbi.nlm.nih.gov/articles/PMC5094051/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12248481/; https://pubmed.ncbi.nlm.nih.gov/31372057/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7567851/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 181, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with chronic obstructive pulmonary disease, Cohort_1: patients identified as White, Cohort_2: patients identified as African American, Cohort_3: patients identified as other races, Outcomes: age at incident diagnosis', 'role': 'user'}]}",True,200.0,22.26276922225952,,23531342-acc7-4cfa-b669-76402314389d,518.0,"In COPDGene data, African American patients had a higher proportion of early-onset (age <55) severe ...",3.0,T/T/T,3.0,True,True,True,"The AI's answer is well-grounded in the provided context. It reports direct comparison data for the age of incident diagnosis (as reflected by early-onset COPD rates) between African American and White patients, matching the figures from the cited study. It also conveys that African American race was independently associated with early-onset COPD, accurately quoting the odds ratio and confidence interval from the context. Regarding other races, the AI correctly notes that the studies do not provide direct comparisons for this group but rather focus on African American and non-Hispanic White patients—this is consistent with what's found in the context. Therefore, all criteria are satisfied.",698,2,2,191.5,383,"Early-onset chronic obstructive pulmonary disease is associated with female sex, maternal factors, and African American race in the COPDGene Study; A Polygenic Risk Score and Age of Diagnosis of Chronic Obstructive Pulmonary Disease",https://pubmed.ncbi.nlm.nih.gov/21562134/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9969342/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 176, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients under the care of a nephrologist, Outcomes: disease distribution lupus nephritis vs other CKD conditions', 'role': 'user'}]}",True,200.0,34.220685958862305,,0c629a86-e3c9-47f4-845e-7bc7d87aa0ce,1113.0,Available nephrology- and registry-based evidence indicates lupus nephritis (LN) is an important but...,3.0,T/T/T,3.0,True,True,True,"The AI's answer directly uses the provided context to answer the question about disease distribution among nephrology patients—specifically contrasting lupus nephritis (LN) with other CKD etiologies. The Swedish registry data is used to present the ratio of LN to other-CKD (317 vs 34,778), directly addressing disease distribution. Incidence and prevalence figures from US population-based studies and demographic details are incorporated with appropriate reference, staying strictly within the scope of the provided context. The answer does not introduce external information or unsupported claims and accurately reflects the depths and limitations of the cited data. The context is both relevant and directly informative to the original question.",749,4,4,200.25,801,"Long-term Outcomes of Lupus Nephritis in Comparison to Other CKD Etiologies; Incidence, Prevalence, and Mortality of Lupus Nephritis: A Population-Based Study Over Four Decades—The Lupus Midwest Network (LUMEN); Prevalence, Risk Factors, and Outcomes of Chronic Kidney Disease in Patients With Systemic Lupus Erythematosus With and Without Lupus Nephritis; Insights into the epidemiology and management of lupus nephritis from the US rheumatologist's perspective",https://pubmed.ncbi.nlm.nih.gov/39810755/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10065880/; https://pubmed.ncbi.nlm.nih.gov/40592551/; https://pmc.ncbi.nlm.nih.gov/articles/PMC5679458/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 179, 'customer': 'Astrazeneca BBU', 'messages': [{'content': '% of Asthma patients who also have COPD', 'role': 'user'}]}",True,200.0,27.409270763397217,,4e96d28d-363d-4017-91bc-7115ead5bc6e,354.0,About 26–28% of patients with asthma have coexisting COPD (asthma–COPD overlap). A systematic review...,3.0,T/T/T,3.0,True,True,True,"The context provides specific prevalence numbers: 26.5% of asthma patients have asthma–COPD overlap according to a systematic review and meta-analysis, which directly answers the question regarding what percentage of asthma patients also have COPD. The AI's answer uses these data points precisely, specifying the relevant numbers and correctly attributing them to the context, without introducing external or unsupported information. The context is highly relevant to the question, as it addresses the prevalence of asthma–COPD overlap among asthma and COPD patients. Overall, the answer is well-grounded in the provided context and accurately reflects the evidence presented there.",683,2,2,167.5,335,Global prevalence of asthma-COPD overlap (ACO) in the general population: a systematic review and meta-analysis; Asthma and COPD Overlap Syndrome (ACOS): A Systematic Review and Meta Analysis,https://pubmed.ncbi.nlm.nih.gov/31647021/; https://pubmed.ncbi.nlm.nih.gov/26336076/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 180, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: metastatic non-small cell lung cancer patients, Intervention: first-line use of pembrolizumab, Control: first-line use of nivolumab, Outcomes: duration of thearpy', 'role': 'user'}]}",True,200.0,28.179009437561035,,4a26e304-54b3-4228-b70c-b7a34546b9ee,1145.0,No randomized head-to-head trial reports exist that directly compare duration of first-line pembroli...,2.0,F/T/T,2.0,False,True,True,"The context does not directly answer the question, as there are no head-to-head studies or direct duration-of-therapy data comparing first-line pembrolizumab with first-line nivolumab monotherapy in metastatic NSCLC. However, the context does address the question by summarizing relevant studies: KEYNOTE-042 provides pembrolizumab regimen information and follow-up, while studies involving nivolumab+ipilimumab or retrospective real-world analyses do not offer direct duration data for first-line nivolumab monotherapy. The AI's answer is well grounded in the context and accurately reflects these limitations without introducing unsubstantiated claims.",654,4,4,269.0,1076,"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score 6 1% in the KEYNOTE-042 Study; Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer; Indirect comparison of pembrolizumab monotherapy versus nivolumab + ipilimumab in first-line metastatic lung cancer; Duration of nivolumab for pretreated, advanced non-small-cell lung cancer",https://pubmed.ncbi.nlm.nih.gov/36306479/; https://pubmed.ncbi.nlm.nih.gov/32508007/; https://pubmed.ncbi.nlm.nih.gov/35073727/; https://pubmed.ncbi.nlm.nih.gov/32412157/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 178, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Can you give me a comparison of demographic summary of breast cancer HER2+ patients with enhertu in the second line vs third line?', 'role': 'user'}]}",True,200.0,41.28042650222778,,787dcc7f-d8a4-4de4-b618-9ae3d0a8f2f8,1580.0,Key limitation: DESTINY‑Breast03 is a randomized phase 3 second‑line trial; DESTINY‑Breast01 is a si...,3.0,T/T/T,3.0,True,True,True,"The context provides specific demographic details from both DESTINY-Breast03 (second-line) and DESTINY-Breast01 (later-line) studies, including age, sex, prior treatments, ECOG status, race, presence of visceral and CNS metastases, and hormone-receptor status. The AI's answer uses these data to directly compare the demographics between the two trials, corresponding to the second-line and third-line or later settings respectively. No external or unsupported information is introduced, and the summary accurately reflects the context. Thus, all criteria are met.",564,3,3,217.33333333333334,652,Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial; Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer; FDA Approval Summary: Fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer,https://pmc.ncbi.nlm.nih.gov/articles/PMC11333275/; https://pubmed.ncbi.nlm.nih.gov/31825192/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8570919/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 157, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: New users of Lokelma, defined as patients who initiate Lokelma therapy during the study period with no evidence of Lokelma prescriptions during the 12-month baseline period, and who have continuous outpatient lokelma prescriptions post-initiation with less than 30 day gaps and a minimal of 12 month follow-up data for outcome assessment. The baseline period (the 12 months immediately prior to Lokelma initiation) is used to capture patient comorbidities and relevant clinical characteristics., Intervention: Lokelma, Outcomes: Assessment of patient characteristics including baseline comorbidities (e.g., heart failure, hypertension, diabetes, chronic kidney disease identified via diagnosis codes); risk of MACE+; risk of hyperkalemia associated events defined as inpatient or ED visits with hyperkalemia associated diagnosis code on the principle position; risk of edema defined inpatient or ED visits with specific diagnostic codes for peripheral or fluid retention edema at the principle position; risk of all-cause inpatient admission.', 'role': 'user'}]}",True,200.0,112.62157344818115,,f26e16e9-9206-46b2-a16e-030b3b33f9f2,1391.0,Limitations: No single identified study exactly matches the cohort definition and all outcomes reque...,2.0,F/T/T,2.0,False,True,True,"The provided context includes relevant studies on the risks (edema, heart failure, hyperkalemia events) and patient characteristics associated with sodium zirconium cyclosilicate (Lokelma) use. However, none of the cited sources exactly match the highly specific cohort and all outcome measures described in the question; rather, they address related outcomes in somewhat different populations or time frames. The AI's answer appropriately acknowledges this gap and summarizes the main, related findings without overreaching or introducing external information. Thus: (1) the context does NOT directly and fully answer the question, (2) it does address the question by providing evidence related to key outcomes, and (3) the answer is well-grounded in the context provided.",773,4,4,186.5,746,"The Association of Heart Failure and Edema Events between Patients Initiating Sodium Zirconium Cyclosilicate or Patiromer - PubMed; Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial - PubMed; Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level 1 5.5 mmol/L: pooled analysis from two phase 3 trials - PubMed; The anti-hyperkalemic, sodium zirconium cyclosilicate: Adverse events and analysis of the FAERS database - PubMed",https://pubmed.ncbi.nlm.nih.gov/39303023/; https://pubmed.ncbi.nlm.nih.gov/25402495/; https://pubmed.ncbi.nlm.nih.gov/31791288/; https://pubmed.ncbi.nlm.nih.gov/40116199/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 182, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with RSV and hMPV, Outcomes: count', 'role': 'user'}]}",True,200.0,39.37134790420532,,b444eb92-58f6-4166-b10b-08a1b20292dc,395.0,Selected reported counts from representative studies: Adults presenting to ED/hospital: RT‑PCR ident...,3.0,T/T/T,3.0,True,True,True,"The AI's answer directly provides the count of patients with RSV and hMPV from each referenced study, exactly matching the data within the context. The details about the patient populations and outcome counts (for both RSV and hMPV) are extracted accurately from the sources. Each count is also referenced back to the specific context item, with no additional or unsupported claims introduced. The response is relevant, precise, and entirely grounded in the provided context.",475,3,3,116.0,348,"Respiratory syncytial virus- and human metapneumovirus-associated emergency department and hospital burden in adults - PubMed; Bronchiolitis Due to RSV and HMPV-Epidemiology, Clinical Course, and Prognosis: Experience of a Single Tertiary Center - PubMed; Human Metapneumovirus: Epidemiology and genotype diversity in children and adult patients with respiratory infection in Córdoba, Argentina - PMC",https://pubmed.ncbi.nlm.nih.gov/24512531/; https://pubmed.ncbi.nlm.nih.gov/36744682/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7769284/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 183, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with de novo, unresectable Stage III or Stage IV non-small cell lung cancer, Intervention: osimertinib monotherapy in Stage III non-small cell lung cancer, Control: osimertinib monotherapy in Stage IV non-small cell lung cancer, Outcomes: duration of therapy', 'role': 'user'}]}",True,200.0,41.77063035964966,,3f9185d1-7f71-4d0c-a0c6-665359224443,419.0,In patients receiving osimertinib monotherapy after definitive chemoradiotherapy for unresectable St...,3.0,T/T/T,3.0,True,True,True,"The provided context gives specific data on the duration of osimertinib therapy in both Stage III and Stage IV EGFR-mutated NSCLC patients: 39.1 months progression-free survival in Stage III (used in the context as a proxy for duration on therapy), and 18.9 months median PFS and 20.7 months median exposure (treatment duration) in Stage IV. The AI's answer accurately summarizes and draws from these details, directly comparing the durations as per the question's PICO structure. The answer remains grounded in the context without introducing external information.",565,2,2,190.5,381,Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC - PubMed; Retrospective analysis of independent predictors of progression‑free survival in patients with EGFR mutation‑positive advanced non‑small cell lung cancer receiving first‑line osimertinib - PMC,https://pubmed.ncbi.nlm.nih.gov/38828946/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9527177/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 192, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What % patients with V122 (Val122I or Val142I) variant of ATTR develop PN (Polyneuropathy) symptoms?', 'role': 'user'}]}",True,200.0,26.19368314743042,,ae2a6595-787f-4c98-856e-0decd603d524,694.0,Reported frequencies vary widely by cohort and ascertainment: population biobank analyses found poly...,3.0,T/T/T,3.0,True,True,True,"The AI's answer directly states the polyneuropathy (PN) prevalence among V122I (Val122I or Val142I) variant carriers, citing specific numbers from each referenced cohort: 2.1%, 9.0%, 4.8% in population biobanks, 40% in a UK national ATTRv cohort, and majority (data: 74% with sensory loss, 60% with weakness) in a US clinical series. These values are explicitly supported by the provided context, and no external or hallucinated information is added. The answer is well-grounded in the context, directly responds to the exact prevalence question, and all content is relevant and sourced from the context provided.",613,3,3,148.33333333333334,445,Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry; Peripheral Neuropathy in p.Val142Ile (Val122Ile) Variant Hereditary Transthyretin-Mediated Amyloidosis: United Kingdom Experience; Peripheral Nervous System Involvement of Hereditary Transthyretin Amyloidosis in the United States: A Multi-Center Perspective,https://pmc.ncbi.nlm.nih.gov/articles/PMC8172853/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12462426/; https://pubmed.ncbi.nlm.nih.gov/40395027/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 193, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'does terzepitide or semaglutide lead to greater changes in bmi', 'role': 'user'}]}",True,200.0,24.412044525146484,,5f2f4bb3-dd3f-4e6a-9170-cba1461c37af,826.0,"Across indirect comparisons, network meta-analyses, and systematic reviews, tirzepatide (especially ...",3.0,T/T/T,3.0,True,True,True,"The provided context includes several studies and meta-analyses, all of which directly address whether tirzepatide or semaglutide leads to greater changes in BMI. In particular, reference [2] explicitly states that tirzepatide 10 and 15 mg lead to greater reductions in percent body weight and BMI versus semaglutide 2.4 mg. The AI's answer accurately summarizes the findings from these references and does not introduce unsupported claims. The context and answer both directly address the question, and the answer is grounded in the provided evidence.",552,4,4,197.5,790,Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials - PubMed; Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison - PubMed; Tirzepatide for managing overweight and obesity - NCBI Bookshelf; Tirzepatide Versus Semaglutide for Weight Loss in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Direct Comparative Studies - PMC,https://pubmed.ncbi.nlm.nih.gov/40978842/; https://pubmed.ncbi.nlm.nih.gov/37344384/; https://www.ncbi.nlm.nih.gov/books/NBK611612/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12263181/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 194, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What % patients with V122I (Val122Ile or Val142Ile) variant of ATTR develop PN (Polyneuropathy) symptoms?', 'role': 'user'}]}",True,200.0,20.69791865348816,,359246e2-551e-4c2f-bab6-867e19276c94,547.0,Estimates vary by study and setting. Large biobank-based analyses report polyneuropathy prevalence a...,3.0,T/T/T,3.0,True,True,True,"The context provides direct prevalence percentages from large biobank studies (2.1%, 9.0%, and 4.8%) as well as from a UK national amyloidosis clinic cohort (40%), which specifically addresses the percentage of patients with the V122I variant developing polyneuropathy. The AI's answer accurately cites these figures and appropriately notes variation across cohorts and definitions. There is no evidence of unsupported information or hallucinated data; the answer is completely based on the provided context. The context also includes relevant clarification about ascertainment differences, which the AI summarizes correctly.",625,3,3,197.66666666666666,593,Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry - PubMed; Peripheral Neuropathy in p.Val142Ile (Val122Ile) Variant Hereditary Transthyretin-Mediated Amyloidosis: United Kingdom Experience - PMC; Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays - PubMed,https://pubmed.ncbi.nlm.nih.gov/34079032/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12462426/; https://pubmed.ncbi.nlm.nih.gov/35253562/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 184, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with de novo Stage III unresectable, and Stage IV, EGFR-mutated non-small cell lung cancer diagnosed between April 2022 and Dec 2024, Intervention: first line osimertinib monotherapy, Outcomes: death, duration of therapy', 'role': 'user'}]}",True,200.0,55.72285509109497,,93b90b3e-3fce-40db-80a0-7612f6e45d64,617.0,"No study was identified that reports outcomes specifically for patients diagnosed between April 1, 2...",1.0,F/T/F,1.0,False,True,False,"The context provides data on median overall survival (OS) and progression-free survival (PFS) for first-line osimertinib in broad cohorts of patients with EGFR-mutated advanced NSCLC, including median OS (38.6–42.0 months) and median exposure or PFS (20.0–20.7 months). The question asks specifically about patients diagnosed between April 2022 and December 2024; however, the context only covers patients treated in earlier periods (e.g., 2018–2019). Thus, the context does not directly answer the question, though it is relevant. The AI's answer appropriately notes the absence of data for the specific date range but accurately summarizes available outcomes for similar populations. However, the AI introduces ""median time to treatment discontinuation (mTTD) 25.3 months"" and the ""FLOWER cohort,"" which are not found in the provided context, making the answer not fully grounded in the supplied material.",907,3,3,153.0,459,"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC - PubMed; The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study) - PubMed; Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS) - PubMed",https://pubmed.ncbi.nlm.nih.gov/31751012/; https://pubmed.ncbi.nlm.nih.gov/39416709/; https://pubmed.ncbi.nlm.nih.gov/40582919/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 188, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the duration of therapy among patients diagnosed with de novo Stage III unresectable, and separately, de novo Stage IV, EGFR-mutated non-small cell lung cancer who initiated first line osimertinib monotherapy between April 2018 and Dec 2022?', 'role': 'user'}]}",True,200.0,43.00186061859131,,58d849a1-3fa3-43b8-aebf-4cdd58b059d6,881.0,Published studies do not report the duration of therapy specifically for patients stratified as (a) ...,2.0,F/T/T,2.0,False,True,True,"The provided context does not directly answer the question about the duration of therapy for de novo Stage III unresectable and de novo Stage IV EGFR-mutated NSCLC patients starting first-line osimertinib between April 2018 and Dec 2022. It only reports median progression-free survival (PFS) in overall advanced EGFR-mutant NSCLC cohorts, without the requested stratification. However, the context is relevant as it discusses related populations and outcomes. The AI's answer accurately summarizes the lack of directly relevant data, offers the closest matching published results, and does not introduce unsupported claims.",624,3,3,166.0,498,"The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study) - PubMed; First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic - PubMed Central (full text); Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC - PubMed",https://pubmed.ncbi.nlm.nih.gov/39416709/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10413024/; https://pubmed.ncbi.nlm.nih.gov/38828946/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 186, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the duration of therapy and overall survival among patients diagnosed with de novo Stage III unresectable, and Stage IV, EGFR-mutated non-small cell lung cancer, who were diagnosed between April 2018 and Dec 2022, and initiated first line osimertinib monotherapy after diagnosis?', 'role': 'user'}]}",True,200.0,52.107455015182495,,528fcbdc-c376-44c8-8e99-497b1ae7a853,905.0,Limitation: no single published report was found that reports both median duration of first-line osi...,2.0,F/T/T,2.0,False,True,True,"The context provides relevant real-world data on overall survival (median 28.6 and 36.8 months) and median time-to-treatment discontinuation (27.9 months) for patients initiating first-line osimertinib, but it does not state with certainty that both statistics apply strictly to the precise subpopulation described in the question (i.e., specifically de novo unresectable Stage III and IV, EGFR-mutant NSCLC diagnosed between April 2018-Dec 2022). The AI answer accurately describes this limitation and grounds its response in the context provided. Thus, the answer is grounded in the context and the context is relevant, but the context does not directly answer the question with specific data for the exact patient group or period asked.",739,2,2,186.0,372,"Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States; Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World",https://pubmed.ncbi.nlm.nih.gov/40320171/; https://pubmed.ncbi.nlm.nih.gov/38520745/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 187, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the duration of therapy among patients diagnosed with de novo Stage III unresectable, and Stage IV, EGFR-mutated non-small cell lung cancer between April 2018 and Dec 2022 who began first line osimertinib monotherapy?', 'role': 'user'}]}",True,200.0,45.481077909469604,,5d963ae3-51e9-4cdb-811a-3e7ddc7ec2d7,869.0,Limitation: No single published source was found that reports duration of therapy specifically for p...,2.0,F/T/T,2.0,False,True,True,"The provided context does not include data specifically for duration of therapy among de novo Stage III unresectable and Stage IV EGFR-mutant NSCLC patients; it only gives data for overall populations that may include such patients. Therefore, the context does not directly answer the question, but it is highly relevant to the question. The AI answer accurately reflects this limitation and summarizes the data from the context without introducing information not found in the cited sources.",492,3,3,197.66666666666666,593,"Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors; Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC; Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States",https://pubmed.ncbi.nlm.nih.gov/35702932/; https://pubmed.ncbi.nlm.nih.gov/31751012/; https://pubmed.ncbi.nlm.nih.gov/40320171/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 190, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What are the first-line treatment regimens of patients with biliary tract cancers diagnosed between March 2022 - February 2024.', 'role': 'user'}]}",True,200.0,43.03827691078186,,ac928237-fd5c-4658-bd66-1deeeda0bb0a,470.0,First-line systemic regimens used for patients diagnosed with unresectable or metastatic biliary tra...,2.0,T/T/F,1.0,True,True,False,"The provided context includes specific, relevant evidence to answer the question, listing gemcitabine/cisplatin, gemcitabine/cisplatin/durvalumab, and gemcitabine/cisplatin/pembrolizumab as first-line regimens, as well as contextual referencing to recent clinical trials and guidelines during the requested time period. The answer is broadly consistent with the context.

However, the AI's answer introduces additional details not fully supported by the context: it specifies the historical use of gemcitabine/cisplatin as a first-line treatment and mentions FDA approval dates, neither of which are directly cited in the provided extracts. The context supports the legitimacy of these regimens as first-line options (via study results and guidelines), but does not directly mention FDA approval dates or the historical context of the regimens. Therefore, while the answer is accurate, it is not entirely grounded solely in the provided context.",945,3,3,223.66666666666666,671,"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial - PubMed; Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer - PubMed (TOPAZ-1); Corrigendum to ""Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer"": [ESMO Open 9 (2024) 103647] - PubMed",https://pubmed.ncbi.nlm.nih.gov/37075781/; https://pubmed.ncbi.nlm.nih.gov/38319896/; https://pubmed.ncbi.nlm.nih.gov/39864890/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 195, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with hereditary transthyretin amyloidosis (E85.0, E85.1, E85.2), Outcomes: polyneuropathy symptoms', 'role': 'user'}]}",True,200.0,30.205835580825806,,80932a6a-52e2-4820-9cdd-fcd39cf94295,645.0,"In patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy, RNAi therapy with...",3.0,T/T/T,3.0,True,True,True,"The context specifically addresses the outcomes (polyneuropathy symptoms) in patients with hereditary transthyretin amyloidosis. It includes direct evidence from clinical trials about the impact of patisiran and tafamidis on neuropathy, quality of life, and neurological measures. The AI's answer is closely aligned with the information in the context, appropriately referencing both the results of patisiran (improvement and sustained benefits) and tafamidis (failure to meet coprimary endpoints but some benefit in secondary/subgroup analyses). No information outside the provided context is included, and the answer avoids unsupported claims.",645,4,4,234.25,937,"Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy; Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin‑mediated amyloidosis; Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial; Five‑Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open‑Label Extension",https://pubmed.ncbi.nlm.nih.gov/28893208/; https://pubmed.ncbi.nlm.nih.gov/32131641/; https://pubmed.ncbi.nlm.nih.gov/22843282/; https://pubmed.ncbi.nlm.nih.gov/39804640/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 189, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the time to discontinuation among patients diagnosed with de novo Stage III unresectable, and separately, de novo Stage IV, EGFR-mutated non-small cell lung cancer who initiated first line osimertinib monotherapy between April 2018 and Dec 2022?', 'role': 'user'}]}",True,200.0,59.882664918899536,,d2f77dc3-0114-4ba0-8f0e-a7d0148a433f,698.0,No published study was found that reports time-to-discontinuation (TTD) separately for patients with...,2.0,F/T/T,2.0,False,True,True,"The context provides median time-to-treatment discontinuation (TTD) values for real-world osimertinib use in EGFR-mutant NSCLC, but it does not offer TTD separated by de novo unresectable Stage III versus de novo Stage IV. The AI answer correctly notes the lack of stage-specific data and accurately summarizes the available overall estimates without adding unsupported claims. Thus, the answer is well-grounded in context and addresses the question, but the context itself does not directly answer the stage-specific breakdown requested.",538,3,3,120.33333333333333,361,"A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice - PubMed; Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World - PubMed; First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study - PubMed",https://pubmed.ncbi.nlm.nih.gov/38539415/; https://pubmed.ncbi.nlm.nih.gov/38520745/; https://pubmed.ncbi.nlm.nih.gov/35641222/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 191, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with systemic lupus erythematosus, Outcomes: time from diagnosis to treatment with on label biologics', 'role': 'user'}]}",True,200.0,60.44031810760498,,2a76c902-42f5-441e-bf24-1e4caa809595,794.0,"Published studies do not report a clear, consistent estimate of time from SLE diagnosis specifically...",2.0,F/T/T,2.0,False,True,True,"The context provides information about time-to-treatment from diagnosis (2.09 months) in general, but does not specify this interval specifically for on-label biologic therapies. It also describes diagnostic delays and the lack of pooled population-level data for time from diagnosis to biologic initiation. The AI's answer accurately reflects this, noting the lack of direct data and summarizing what is available, without introducing information not present in the context. Therefore, the answer does not directly answer the question, but does address it with contextual relevance and is grounded in the provided information.",627,4,4,209.0,836,Factors associated with delay in the diagnosis and treatment of systemic lupus erythematosus in adult patients: a systematic review; Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort; Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature Review; Changing paradigms in the treatment of systemic lupus erythematosus,https://pubmed.ncbi.nlm.nih.gov/40644617/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7933718/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9314515/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6519431/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 203, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: COPD patients aged 40 and above, Cohort_1: White on Breztri or Trelegy, Cohort_2: White not on Breztri or Trelegy, Cohort_3: Black on Breztri or Trelegy, Cohort_4: Black not on Breztri or Trelegy, Outcomes: Hospitalization', 'role': 'user'}]}",True,200.0,22.13376498222351,,90fc484f-1ebd-4e9a-b8b2-dbceaad14dab,1300.0,Limitations: No published studies were identified that directly compare hospitalization rates by rac...,2.0,F/T/T,2.0,False,True,True,"The provided context consists of studies and reviews regarding the impact of triple therapy (ICS+LAMA+LABA) on COPD-related hospitalization and exacerbation rates. However, none of the context directly compares hospitalization outcomes stratified by both race (Black vs. White) and specific medications (Breztri or Trelegy) as requested in the question. The context is relevant as it provides background on triple therapy and its effectiveness in reducing hospitalizations, but it does not answer the specific four-cohort question. The AI assistant's answer accurately reflects this limitation, outlining that no such direct comparison is available in the literature and basing its summary solely on information present in the provided context. No claims outside the context are presented.",789,3,3,220.66666666666666,662,Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis; Triple therapy for the management of COPD: a review - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews - NCBI Bookshelf; Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study - PubMed,https://pubmed.ncbi.nlm.nih.gov/30401700/; https://www.ncbi.nlm.nih.gov/books/NBK80817/; https://pubmed.ncbi.nlm.nih.gov/36427341/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 197, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what is the difference in efficacy of breztri on exacerbations in patients with copd between pateints with blood eosinophil values greater than 150 and less than 150.', 'role': 'user'}]}",True,200.0,30.66982412338257,,93e340b6-2328-43f0-9c7f-b09e00964dac,1221.0,There are no published COPD trials that report the effect of Breztri (budesonide/glycopyrronium/form...,2.0,F/T/T,2.0,False,True,True,"The context does not provide a direct numeric comparison of Breztri efficacy on exacerbations in COPD patients with blood eosinophils >150 vs <150 cells/µL. However, it addresses the question by noting trends of increasing benefit with higher eosinophil counts and explaining that most studies do not use the 150 cells/µL cutoff specifically. The AI answer accurately reflects these points, stating the lack of direct data for a 150 cells/µL cutoff and summarizing the evidence as given in the context. There are no hallucinations or claims unsupported by the context. Thus, the answer is relevant and grounded, but the question is not directly answered by the information provided.",682,3,3,268.6666666666667,806,Budesonide/glycopyrronium/formoterol: A Review in COPD; Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials; Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts,https://pmc.ncbi.nlm.nih.gov/articles/PMC8384783/; https://pubmed.ncbi.nlm.nih.gov/32943047/; https://pubmed.ncbi.nlm.nih.gov/34182998/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 201, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with systemic lupus erythematosus, Cohort_1: Saphnelo or Benlysta, Cohort_2: Not on Saphnelo or benlysta', 'role': 'user'}]}",True,200.0,30.637343406677246,,36a99d07-49cd-4676-9ce1-2874a1841147,630.0,"In patients with active SLE, anifrolumab (Saphnelo) improved composite disease activity (higher BICL...",3.0,T/T/T,3.0,True,True,True,"The AI's answer correctly summarizes the findings from the provided context: Anifrolumab (Saphnelo) and Belimumab (Benlysta) were each superior to placebo in RCTs for patients with SLE regarding clinical response measures (BICLA, SRI), steroid reduction, and skin improvement. The AI also notes, appropriately, that there are no direct randomized head-to-head trials comparing the efficacy or safety of Saphnelo and Benlysta, which matches the context (the studies referenced compared each drug to placebo, not to each other). No claims are made beyond the context. Thus, all three criteria are met.",599,3,3,164.66666666666666,494,"Trial of Anifrolumab in Active Systemic Lupus Erythematosus; Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials; A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus",https://pubmed.ncbi.nlm.nih.gov/31851795/; https://pubmed.ncbi.nlm.nih.gov/33216191/; https://pubmed.ncbi.nlm.nih.gov/22127708/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 202, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with chronic obstructive pulmonary disease aged 40 and above, Cohort_1: White, Cohort_2: African American, Cohort_3: other races, Outcomes: Breztri and Trelegy', 'role': 'user'}]}",True,200.0,30.77445101737976,,aa4bedac-51c7-4253-912c-c6176b76fb2b,1058.0,There are no randomized trials or meta-analyses that report Breztri (budesonide/glycopyrrolate/formo...,3.0,T/T/T,3.0,True,True,True,"The provided context clearly states that the relevant clinical trials and meta-analyses predominantly enrolled White participants and do not provide race-stratified outcomes or robust adjustments for race as a modifier. The AI's answer closely follows the evidence in the context, accurately stating the lack of race-stratified outcome data for Breztri versus Trelegy in COPD patients ≥40 years, and it correctly refers to the limitations highlighted in the referenced studies. There are no unsupported claims or extraneous information introduced by the AI. Therefore, all evaluation criteria are met.",601,3,3,227.33333333333334,682,"DailyMed - BREZTRI- budesonide, glycopyrrolate, and formoterol fumarate aerosol, metered; Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other ICS/LAMA/LABA Triple Combinations in COPD: A Systematic Literature Review and Network Meta‑analysis; Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease",https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467454/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11787206/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 196, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: systolic blood pressure is 130 mmHg or higher, Cohort_1: plasma aldosterone is 10 ng/dL or higher (excess), Cohort_2: plasma aldosterone is less than 10 ng/dL (no excess), Outcomes: prevalence of excess aldosterone', 'role': 'user'}]}",True,200.0,54.14574933052063,,4e204cc6-92cd-4b09-a834-49e739820ac2,848.0,Available published studies do not report prevalence specifically using a plasma aldosterone cutoff ...,2.0,F/T/T,2.0,False,True,True,"The context provided does not specifically report the prevalence of excess aldosterone using a plasma aldosterone cutoff of 10 ng/dL, which was the definition required by the question. Instead, the context describes prevalence estimates for primary aldosteronism in hypertensive patients based on various criteria and testing methods. The AI's answer accurately reflects this, stating that available studies do not use the requested cutoff and summarizing prevalence ranges from the literature, as given in the context. Thus, while the context is relevant and the answer remains grounded in it, it does not directly answer the precise question regarding prevalence using plasma aldosterone of 10 ng/dL as the threshold.",719,3,3,169.0,507,The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study; Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects - PubMed; The Prevalence of Primary Aldosteronism and Evolving Approaches for Treatment - PMC,https://pubmed.ncbi.nlm.nih.gov/32449886/; https://pubmed.ncbi.nlm.nih.gov/20927116/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7442120/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 198, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with COPD defined as having 2 or more COPD ICD diagnosis codes at least 30 days apart, Intervention: Breztri, Control: Trelegy, Outcomes: COPD exacerbations requiring emergency room or inpatient admission', 'role': 'user'}]}",True,200.0,51.735379695892334,,0e96bc42-156a-4239-8758-7f9eb5dcc0ce,879.0,No randomized head‑to‑head trial comparing Breztri (budesonide/glycopyrronium/formoterol) with Trele...,2.0,F/T/T,2.0,False,True,True,"The provided context does not directly answer the question, as there is no head-to-head comparison of Breztri versus Trelegy for COPD exacerbations requiring ER or inpatient admission. The context is relevant and addresses the question by summarizing evidence from trials of each triple therapy versus dual regimens, as well as a network meta-analysis, but no direct comparative outcome between Breztri and Trelegy is provided. The AI's answer accurately summarizes these limitations and is well-grounded in the context without introducing unsupported claims.",559,4,4,234.25,937,"Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study; Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts; Once‑Daily Single‑Inhaler Triple versus Dual Therapy in Patients with COPD (IMPACT); Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis",https://pubmed.ncbi.nlm.nih.gov/33252985/; https://pubmed.ncbi.nlm.nih.gov/34182998/; https://pubmed.ncbi.nlm.nih.gov/29668352/; https://pubmed.ncbi.nlm.nih.gov/35849317/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 199, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients >=18 years of age with asthma defined by enhanced diagnostic validity, requiring at least two separate asthma diagnostic codes over a 12-month period along with concurrent asthma medication fills recorded within the EHR., Intervention: inhaled triple therapy , Outcomes: Frequency of short-acting beta-agonist (SABA) refills or emergency department visits for asthma exacerbations (operationalized as events accompanied by an ICD code for asthma exacerbation), oral corticosteroid (OCS) utilization operationalized by categorizing prescription fills into short-term bursts for acute management versus patterns suggestive of chronic use (using metrics such as number of prescriptions filled, cumulative dose, and timing criteria), and asthma control measured by validated ACT scores obtained at standardized intervals (e.g., every 3 months) with predefined thresholds for clinically significant changes.', 'role': 'user'}]}",True,200.0,49.68160796165466,,8f077929-7958-4a46-b5ee-206d473ec6cd,1395.0,Limitations: available systematic reviews and real-world studies report effects on exacerbations and...,2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False. The context does not provide direct evidence for all specified outcomes (SABA refill frequency and ACT scores at 3-month intervals), as these are explicitly noted in both the context and the answer to be infrequently or not consistently reported. The available evidence primarily pertains to steroid-requiring exacerbations, OCS use, and general measures of asthma control.

2. context_addresses_question: True. The context is highly relevant to the question, covering systematic reviews and real-world studies on triple therapy in asthma with discussions about the outcomes of interest (exacerbations, OCS, asthma control), even if not all specified outcome measures are directly addressed.

3. answer_grounded_in_context: True. The AI answer faithfully represents the information from the context and correctly communicates the gaps in evidence related to specific outcomes (SABA refill and ACT scores per the specified criteria) while summarizing reported findings on exacerbation, OCS use, and asthma control improvement.",1070,4,4,259.75,1039,Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis; Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma: A Systematic Review and Meta-analysis; Asthma management with triple ICS/LABA/LAMA combination to reduce the risk of exacerbation: an umbrella review compliant with the PRIOR statement; A Brief Report on a Systematic Review of Real-World Effectiveness Studies of ICS/LAMA/LABA for Treatment of Adults with Asthma in the US,https://pubmed.ncbi.nlm.nih.gov/36472162/; https://pubmed.ncbi.nlm.nih.gov/34009257/; https://pubmed.ncbi.nlm.nih.gov/38864834/; https://pubmed.ncbi.nlm.nih.gov/40050459/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 200, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Amongst asthma patients (>=18 years) on high dose or medium dose ICS/LABA, what are annual rates of OCS use and symptoms reported, ACQ scores, AIRQ scores?', 'role': 'user'}]}",True,200.0,50.30370759963989,,72573f68-6420-4356-815c-7ed3533cecba,889.0,Key findings from published studies of adults on medium/high‑dose ICS/LABA: annual oral corticostero...,3.0,T/T/T,3.0,True,True,True,"The AI assistant's answer accurately extracts relevant annual OCS use rates, rates of poorly controlled symptoms (via ACQ), and AIRQ control distributions from the provided context, referencing the appropriate studies for each metric without introducing unsupported information. The answer addresses all parts of the original question directly, including the annual OCS use rates, symptom control by ACQ, and AIRQ score distributions. It also cites the relevant references, supporting each data point with the provided context. Therefore, the response fulfills all evaluative criteria.",585,4,4,145.25,581,"Prevalence of oral corticosteroid use in the German severe asthma population; Oral Corticosteroid Treatment Patterns of Patients in the United States with Persistent Asthma - PubMed; Suboptimally controlled asthma in patients treated with inhaled ICS/LABA: prevalence, risk factors, and outcomes; The Asthma Impairment and Risk Questionnaire (AIRQ) Control Level Predicts Future Risk of Asthma Exacerbations",https://pmc.ncbi.nlm.nih.gov/articles/PMC6819991/; https://pubmed.ncbi.nlm.nih.gov/32569754/; https://pubmed.ncbi.nlm.nih.gov/37156824/; https://pubmed.ncbi.nlm.nih.gov/35998877/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 185, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with de novo Stage III unresectable and Stage IV, EGFR-mutated non-small cell lung cancer , Intervention: osimertinib monotherapy, Outcomes: death, duration of therapy', 'role': 'user'}]}",True,200.0,105.8576180934906,,edc98d8e-60eb-47a8-9465-7b6c7f98eaba,556.0,"In patients with previously untreated, advanced (de novo stage IIIB/IV) EGFR‑mutated NSCLC, first‑li...",3.0,T/T/T,3.0,True,True,True,"The context provides direct data on death (overall survival) and duration of therapy (median exposure, duration of response, and time to treatment discontinuation) in patients with advanced EGFR-mutated NSCLC treated with first-line osimertinib. The AI's answer accurately summarizes these outcomes using figures explicitly given in the provided context. There is no evidence of information introduced from outside the context; all data points are supported. Thus, all three criteria are satisfied.",498,4,4,160.75,643,"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC; Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer; First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study; Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)",https://pubmed.ncbi.nlm.nih.gov/31751012/; https://pubmed.ncbi.nlm.nih.gov/29151359/; https://pubmed.ncbi.nlm.nih.gov/35641222/; https://pubmed.ncbi.nlm.nih.gov/40582919/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 206, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients diagnosed with advanced biliary tract cancer between January 2016 and March 2022, Outcomes: first-line treatment regimens', 'role': 'user'}]}",True,200.0,34.04014229774475,,eef5cd38-4fbd-4198-8204-921840c69536,770.0,"In patients with advanced biliary tract cancer diagnosed between January 2016 and March 2022, real‑w...",3.0,T/T/T,3.0,True,True,True,"The context directly answers the question by specifying that gemcitabine plus cisplatin (GemCis) was the most common first-line regimen for advanced biliary tract cancer during the specified period, providing percentages for de novo and recurrent cases (73.8% and 57.7%, respectively). It also addresses related outcomes such as median cycles and median OS. The context further mentions the emergence of immunotherapy and targeted therapy as potential first-line treatments by early 2022. The AI's answer is appropriately grounded in this context, accurately reflecting the details in the source material without introducing unsupported claims.",644,3,3,181.33333333333334,544,Treatment Patterns and Outcomes in Patients with Advanced Biliary Tract Cancers Treated with Gemcitabine-Based Chemotherapy: A Retrospective Study; Efficacy and Safety of First-Line Targeted Treatment and Immunotherapy for Patients with Biliary Tract Cancer: A Systematic Review and Meta-Analysis; Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients,https://pubmed.ncbi.nlm.nih.gov/39858087/; https://pubmed.ncbi.nlm.nih.gov/36612035/; https://pubmed.ncbi.nlm.nih.gov/28597043/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 208, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with advanced biliary tract cancer diagnosed between January 2018 and March 2022, Outcomes: first-line treatment regimens', 'role': 'user'}]}",True,200.0,32.46548366546631,,9b83bbef-18d3-4013-9ef1-598cc00c310f,830.0,"Among patients with advanced biliary tract cancer diagnosed between January 2018 and March 2022, fir...",3.0,T/T/T,3.0,True,True,True,"The AI's answer directly reports that first-line treatment regimens for advanced biliary tract cancer during the study period were predominantly gemcitabine-based chemotherapy, specifically gemcitabine + cisplatin, which aligns with the data in the context ([1] and [2]). The answer cites real-world numbers (73.8%–84.5%) for use of these regimens and mentions median survival and duration of therapy, all of which are present in the context. The answer also correctly notes, based on reference [3], that targeted therapies and immunotherapy were being evaluated in trials but had not yet supplanted chemotherapy as standard first-line treatment during this period. The entire response is well-grounded in the cited context, uses relevant, specific data points, and does not introduce unsupported claims. Therefore, all criteria are met.",837,3,3,195.0,585,"Real-world treatment patterns, resource utilization and costs in biliary tract cancers in the USA - PubMed; Treatment Patterns and Outcomes in Patients with Advanced Biliary Tract Cancers Treated with Gemcitabine-Based Chemotherapy: A Retrospective Study - PubMed; Efficacy and Safety of First-Line Targeted Treatment and Immunotherapy for Patients with Biliary Tract Cancer: A Systematic Review and Meta-Analysis - PubMed",https://pubmed.ncbi.nlm.nih.gov/39155836/; https://pubmed.ncbi.nlm.nih.gov/39858087/; https://pubmed.ncbi.nlm.nih.gov/36612035/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 204, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: COPD aged 40 and above, Intervention: Breztri or Trelegy, Outcomes: Hospitalization', 'role': 'user'}]}",True,200.0,48.85411524772644,,ad9e8de3-c9d6-404e-98f2-f73338cedf38,1085.0,Limitations: searched literature did not return trials reporting hospitalization (hospital admission...,2.0,F/T/T,2.0,False,True,True,"The provided context contains results from large, randomized trials (IMPACT, TRILOGY, and INTREPID) comparing single-inhaler triple therapy with dual therapy in COPD, primarily reporting outcomes related to moderate and severe exacerbations. The AI's answer accurately notes that hospitalization-specific outcomes are not directly reported in these trials nor in the context. It correctly interprets that severe exacerbations may include hospitalization but clarifies that direct data on hospitalization for Breztri or Trelegy is not presented. 

1. context_answers_question_directly: False – The context does not include specific, direct evidence about hospitalization rates for Breztri or Trelegy.
2. context_addresses_question: True – The context is highly relevant (trials of the relevant drugs, outcomes of exacerbations including some requiring hospitalization).
3. answer_grounded_in_context: True – The AI's answer does not make unsupported claims and stays within the limitations of the provided data.",1010,3,3,200.66666666666666,602,"Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD; Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial; Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design",https://pubmed.ncbi.nlm.nih.gov/29668352/; https://pubmed.ncbi.nlm.nih.gov/27598678/; https://pubmed.ncbi.nlm.nih.gov/31720293/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 209, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with unresectable hepatocellular carcinoma, Intervention: received STRIDE regimen after diagnosis of uHCC, Outcomes: characteristics', 'role': 'user'}]}",True,200.0,30.58898115158081,,bdc6bb7a-682a-4c60-aa2f-ab9e08ecf2f1,1269.0,Key characteristics of patients who received the STRIDE regimen (tremelimumab single dose + regular-...,3.0,T/T/T,3.0,True,True,True,"The AI's answer is well-supported by the provided context. It summarizes key characteristics of patients receiving STRIDE in the HIMALAYA study, directly citing trial details such as patient numbers, treatment-naïve status, survival outcomes, common adverse events, pharmacodynamic findings, and the diversity of long-term survivors. Each point aligns with specific evidence presented in the context. The answer does not introduce information not found in the sources and remains grounded in and faithful to the referenced studies. All criteria are met: the context directly answers the question, is relevant to the question, and the AI's answer is grounded solely in the information provided.",693,4,4,267.75,1071,Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma; Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma; FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma; Modeling of Proliferating CD4 and CD8 T-Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma,https://pubmed.ncbi.nlm.nih.gov/38319892/; https://pubmed.ncbi.nlm.nih.gov/38382875/; https://pubmed.ncbi.nlm.nih.gov/37676259/; https://pubmed.ncbi.nlm.nih.gov/37422678/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 210, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: uHCC, Cohort_1: IO treatment , Cohort_2: STRIDE regiment , Outcomes: overall survival', 'role': 'user'}]}",True,200.0,30.409276008605957,,3ed409ee-e1cc-4174-9493-040b10420008,712.0,Limitation: the query is ambiguous because “IO treatment” is not specified; no sourced head-to-head ...,2.0,F/T/T,2.0,False,True,True,"The context provides detailed outcomes for the STRIDE regimen (tremelimumab plus durvalumab) versus sorafenib in terms of overall survival in unresectable HCC, citing median OS, long-term OS rates, and HRs. However, there is no evidence provided for outcomes in a general IO (immuno-oncology) treatment cohort as implied by Cohort 1, nor is there a direct head-to-head comparison between IO and STRIDE regimens. The AI answer acknowledges this limitation and only reports STRIDE outcomes, which is accurate and grounded in the context. Thus, the context is relevant and the answer does not overreach the evidence provided, but the context does not directly answer the original comparative question.",698,4,4,167.75,671,Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma; Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma; Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC; FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma,https://pubmed.ncbi.nlm.nih.gov/38382875/; https://pubmed.ncbi.nlm.nih.gov/38319892/; https://pubmed.ncbi.nlm.nih.gov/40222621/; https://pubmed.ncbi.nlm.nih.gov/37676259/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 207, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What are the first-line treatment regimens administered to patients with advanced biliary tract cancer, diagnosed between January 2018 through March 2022.', 'role': 'user'}]}",True,200.0,39.1450572013855,,cff71a3e-f150-45fb-9501-27e100c26cd4,760.0,For patients diagnosed with advanced biliary tract cancer between January 2018 and March 2022 the fi...,3.0,T/T/T,3.0,True,True,True,"The context provides direct and relevant evidence about first-line regimens for advanced biliary tract cancer between Jan 2018 and Mar 2022, detailing the standard cisplatin+gemcitabine (supported explicitly), gemcitabine monotherapy, alternative doublets, investigational nab-paclitaxel combinations, and the emergence of immune checkpoint inhibitors and targeted agents in trials. The AI's answer closely reflects and cites these context points without overreaching; every regimen or practice mentioned can be traced to the provided sources. The answer neither fabricates nor relies on unsupported information, and addresses the question thoroughly. Therefore, all criteria are met.",684,4,4,210.0,840,"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer; Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First‑Line Gemcitabine Plus Cisplatin; First‑line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC‑02 Trial: ""And Yet It Moves!""; Nab‑paclitaxel plus capecitabine as a first‑line regimen for advanced biliary tract cancers: Feasible or not feasible?",https://pubmed.ncbi.nlm.nih.gov/20678012/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6639240/; https://pubmed.ncbi.nlm.nih.gov/33592561/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11886530/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 212, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'How many SLE patients are on Saphnelo or Benlysta', 'role': 'user'}]}",True,200.0,18.829556465148926,,5e3cee6d-926e-413b-8dc3-b03df0ab25df,519.0,The published literature does not provide population-level counts of how many SLE patients are curre...,2.0,F/T/T,2.0,False,True,True,"The context specifies that neither the Saphnelo (anifrolumab) nor Benlysta (belimumab) sources provide population-level counts of SLE patients on these therapies. It instead discusses trial exposure data and trial sizes, but clearly states that data on the overall number of treated patients is not available in the referenced material. The AI's answer accurately reflects this limitation and is grounded in the context provided. The context does not directly answer the original question (it does not provide numbers of SLE patients on these therapies), but it is highly relevant and the answer accurately reports the limits of the available evidence.",652,2,2,206.5,413,Anifrolumab (Saphnelo) - NCBI Bookshelf; Belimumab (Benlysta) - NCBI Bookshelf,https://www.ncbi.nlm.nih.gov/books/NBK601816/; https://www.ncbi.nlm.nih.gov/books/NBK601812/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 205, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: COPD aged 40 and above, Intervention: Breztri, Control: Trelegy, Outcomes: Hospitalization', 'role': 'user'}]}",True,200.0,48.86723279953003,,8086213e-fcad-49a2-9c39-95b3dbf83721,498.0,"In COPD patients aged ≥40, real-world comparative cohort data show budesonide/glycopyrrolate/formote...",3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: True – The context includes direct comparative cohort data regarding hospitalization (first admission to hospital with pneumonia and hazard for severe exacerbation) between Breztri and Trelegy, meeting the PICO criteria specified in the question.

2. context_addresses_question: True – The provided context is relevant, focusing on the comparative safety and efficacy (including hospitalization outcomes) of Breztri vs Trelegy in COPD patients.

3. answer_grounded_in_context: True – The AI assistant’s answer accurately describes the outcomes (no difference in pneumonia admission, higher hazard of severe COPD exacerbation for Breztri) as reported in the context, and appropriately references the network/meta-analyses discussing comparable efficacy for exacerbation outcomes, staying within the boundaries of the given context. No unsupported claims are present.",903,3,3,240.0,720,Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study; Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis; Safety and efficacy of budesonide/glycopyrrolate/formoterol fumarate compared with glycopyrrolate/formoterol fumarate for the treatment of COPD: A systematic review and meta-analysis,https://pubmed.ncbi.nlm.nih.gov/39797646/; https://pubmed.ncbi.nlm.nih.gov/33929661/; https://pubmed.ncbi.nlm.nih.gov/40840693/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 218, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'How many SLE patients who initiated newly on Saphnelo or Benlysta were not on an immunosuppressant in 12 months prior to the initiation on Saphnelo or Benlysta.', 'role': 'user'}]}",True,200.0,15.900257110595703,,5541eb29-1ebc-40bd-97c9-4052908ccaf8,69.0,The published literature does not contain an answer to this question.,1.0,F/F/T,1.0,False,False,True,"The context provided is empty, so there is no information available that directly answers or even addresses the question about the number of SLE patients initiating Saphnelo or Benlysta without prior immunosuppressant use. The AI's answer is grounded in the context (which is to say, it acknowledges the absence of information), but it does not and cannot answer or address the question due to the lack of source material.",422,0,0,0.0,0,,,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 214, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: SLE, Intervention: Saphnelo or Benlysta', 'role': 'user'}]}",True,200.0,29.89552927017212,,3d0f1e69-7081-4344-bcee-e961601dd88f,893.0,Indirect evidence indicates broadly similar clinical effectiveness of anifrolumab (Saphnelo) and bel...,3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: True. The AI answer directly references study results comparing Saphnelo (anifrolumab) and Benlysta (belimumab) in SLE, including details from the trials about SRI-4 responses and the limits of indirect evidence. 
2. context_addresses_question: True. All cited context documents are relevant to the question of comparing Saphnelo and Benlysta in SLE, discussing either direct or indirect evidence of efficacy. 
3. answer_grounded_in_context: True. The AI answer is based entirely on the provided context, accurately citing differences and findings from the included studies, and does not introduce outside or unsupported information.",671,4,4,193.0,772,"Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks; Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus; Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial; Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus",https://pubmed.ncbi.nlm.nih.gov/37147022/; https://pubmed.ncbi.nlm.nih.gov/35546484/; https://pubmed.ncbi.nlm.nih.gov/38229377/; https://pubmed.ncbi.nlm.nih.gov/33977796/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 213, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: SLE, Intervention: Saphnelo or Benlysta, Outcomes: Flares', 'role': 'user'}]}",True,200.0,32.59534955024719,,ed93dc98-673e-4b25-ad6e-da53599c749d,1023.0,No head-to-head randomized trial comparing Saphnelo (anifrolumab) versus Benlysta (belimumab) for SL...,3.0,T/T/T,3.0,True,True,True,"The context provides results from trials and real-world studies on both anifrolumab (Saphnelo) and belimumab (Benlysta), demonstrating reduced flare rates for each in SLE. The AI's answer accurately summarizes these findings and specifies that evidence comes from separate studies without head-to-head comparisons, which aligns with the context. The AI also appropriately references the limitations regarding comparative interpretation. The answer is directly supported by the provided context, is relevant, and does not introduce information not present in the supplied material.",580,3,3,230.33333333333334,691,Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus - PubMed; Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus - PubMed; Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature Review - PubMed,https://pubmed.ncbi.nlm.nih.gov/33977796/; https://pubmed.ncbi.nlm.nih.gov/27390293/; https://pubmed.ncbi.nlm.nih.gov/35596922/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 215, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with advanced non-small cell lung cancer, Cohort_1: Black patients, Cohort_2: Hispanic patients, Cohort_3: White patients, Outcomes: receipt of Erlotinib, Gefitinib, Afatinib, Osimertinib, Pembrolizumab, Nivolumab, Durvalumab, or Atezolizumab', 'role': 'user'}]}",True,200.0,32.33614206314087,,f0e10e14-ff96-40e0-b395-39f10a4e41f0,1142.0,Available US cohort analyses report that Black patients with advanced NSCLC are less likely to recei...,2.0,F/T/T,2.0,False,True,True,"The context provides strong evidence that Black and Hispanic patients with advanced NSCLC are less likely than White patients to receive immunotherapy or immune checkpoint inhibitors overall, and that overall guideline-concordant treatment is less likely for non-Hispanic Black patients. However, it does not specifically provide drug-level data (for erlotinib, gefitinib, afatinib, osimertinib, pembrolizumab, nivolumab, durvalumab, atezolizumab) stratified for Black, Hispanic, and White patients. The AI response reflects this limitation and does not introduce unsupported claims, citing lower overall ICI and immunotherapy receipt among Black and Hispanic individuals, and specifically noting a lack of granular drug-level data. Thus: 
1) The context does not answer the question directly at the level of individual drugs. 
2) The context is relevant, as it addresses disparities in treatment receipt for the specified cohorts and therapies. 
3) The answer is grounded in the context and accurately reflects its findings and limitations.",1041,4,4,210.75,843,"Unequal racial distribution of immunotherapy for late-stage non-small cell lung cancer - PubMed; Racial and socioeconomic disparities in survival among patients with metastatic non-small cell lung cancer - PubMed; Racial Disparities in Cancer Guideline-Concordant Treatment Using Surveillance, Epidemiology, and End Results Data for Patients With NSCLC - PubMed; Racial Differences in Survival Among Advanced-stage Non-small-Cell Lung Cancer Patients Who Received Immunotherapy: An Analysis of the US National Cancer Database (NCDB) - PubMed",https://pubmed.ncbi.nlm.nih.gov/37421405/; https://pubmed.ncbi.nlm.nih.gov/38830035/; https://pubmed.ncbi.nlm.nih.gov/39758596/; https://pubmed.ncbi.nlm.nih.gov/34747372/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 211, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with intrahepatic hepatocellular carcinoma who receive systematic treatment , Intervention: atezolizumab, bevacizumab, cabozantinib, durvalumab, ipilimumab, lenvatinib, nivolumab, pembrolizumab, ramucirumab, regorafenib, selpercatinib, sorafenib, tremelimumab, Outcomes: overall survival', 'role': 'user'}]}",True,200.0,40.58120107650757,,bbc5e10f-94a0-45f4-9763-5490ea97de8d,799.0,"In patients with unresectable/intrahepatic hepatocellular carcinoma receiving systemic therapy, rand...",3.0,T/T/T,3.0,True,True,True,"The AI's answer is directly supported by the provided context and references specific median overall survival (OS) figures—such as those for atezolizumab + bevacizumab from the IMbrave150 trial and STRIDE regimen (durvalumab+tremelimumab) from HIMALAYA STRIDE—matching the cited studies. The mention that atezolizumab+cabozantinib failed to show OS benefit is also substantiated by context. The general observation about meta-analyses ranking ICI + anti-VEGF combinations highest for OS and variability among other regimens is also represented in the summaries from the context. The answer avoids introducing unsupported or external information and stays well-grounded in reported trial results. Therefore, all criteria are met.",728,4,4,206.75,827,"Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis based on randomized controlled trials; Efficacy and safety of PD-1/PD-L1 inhibitor-based immune combination therapy versus sorafenib in the treatment of advanced hepatocellular carcinoma: a meta-analysis; Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials; Current perspectives on the pharmacological treatment of advanced hepatocellular carcinoma: a narrative review - PMC",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413926/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11096553/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501787/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093610/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 217, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with chronic lymphocytic leukemia, Cohort_1: patients of lower socio-economic status, Cohort_2: patients of higher socio-economic status, Outcomes: access to targeted therapies', 'role': 'user'}]}",True,200.0,30.592165231704712,,d8a5b93a-760e-47ca-a475-5faa2873167e,1014.0,Published literature documents substantial cost and economic barriers to oral targeted therapies for...,2.0,F/T/T,2.0,False,True,True,"The provided context discusses the high costs and financial toxicity associated with targeted therapies for CLL, which is relevant to economic barriers to access. It also addresses disparities by race and mentions factors such as socioeconomic status (SES) in relation to access to therapies. However, the context does not include a study that directly compares access to targeted therapies between CLL patients of lower versus higher SES, which is the specific comparison the question requires. The AI's answer accurately reflects this limitation and stays grounded in the context, summarizing what is known and pointing out the lack of direct data regarding SES-based comparison.",681,4,4,218.5,874,"Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents; Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States; Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US; Health disparity in use of novel agents for first-line therapy in Black and White patients with chronic lymphocytic leukemia in the Department of Veterans Affairs",https://pubmed.ncbi.nlm.nih.gov/32634056/; https://pubmed.ncbi.nlm.nih.gov/27870563/; https://pubmed.ncbi.nlm.nih.gov/38280190/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10387978/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 219, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: systemic lupus erythematosus patients newly initiated on anifrolumab or belimumab, Cohort_1: Not on an immunosuppressant such as “ Methotrexate, Azathioprine, Mycophenolate Mofetil, Tacrolimus, Cyclosporine, Cyclophosphamide, Baricitinib, Sirolimus” in the 12 months prior to initiation, Cohort_2: on an immunosuppressant such as “ Methotrexate, Azathioprine, Mycophenolate Mofetil, Tacrolimus, Cyclosporine, Cyclophosphamide, Baricitinib, Sirolimus” in the 12 months prior to initiation', 'role': 'user'}]}",True,200.0,30.62827730178833,,67127697-53d1-42d0-af61-bbe2cf5b4713,1046.0,Published studies do not directly report outcomes for the exact cohorts defined (anifrolumab- or bel...,2.0,F/T/T,2.0,False,True,True,"The context supports that the available studies do not directly address the requested cohorts (anifrolumab- or belimumab-initiators stratified by immunosuppressant use in the prior 12 months). The studies either look at overall outcomes, compare belimumab cohorts with and without prior immunosuppressant use (but not for anifrolumab), or conduct indirect comparisons without stratification by immunosuppressant exposure. The AI's answer accurately reports the scope and limitations of the evidence as presented in the context, relying only on what is documented and not introducing unsupported claims. Thus, the answer is relevant and grounded in the context, but the context does not directly answer the original question.",724,3,3,231.66666666666666,695,"Real-world effectiveness of belimumab and anifrolumab in systemic lupus erythematosus: comparable trends in disease activity and glucocorticoid reduction; Clinical Outcomes of Patients with SLE Treated with Belimumab, Without Versus With Prior Immunosuppressant Use: a US Claims Database Study; Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus",https://pubmed.ncbi.nlm.nih.gov/40625101/; https://pubmed.ncbi.nlm.nih.gov/40528076/; https://pubmed.ncbi.nlm.nih.gov/35546484/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 221, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with systemic lupus erythematosus initiating biologic therapy (Saphnelo, or Benlysta) between January 2017 and December 2024 and no immunosuppressant use in the 12 months before starting biologics, Cohort_1: Non-Hispanic White, Hispanic, Black or African American, Asian, and Other racial/ethnic groups, Cohort_2: baseline disease activity levels', 'role': 'user'}]}",True,200.0,34.05722689628601,,4b9b7655-6ccf-4d3f-b9f0-b5627763d4d8,1765.0,Direct published evidence specifically limited to SLE patients who initiated belimumab (Benlysta) or...,2.0,F/T/T,2.0,False,True,True,"The provided context includes studies on the efficacy and real-world outcomes of belimumab and anifrolumab in SLE patients, with some focus on racial/ethnic subgroups and baseline disease activity. However, none of the studies report specifically on patients who had no immunosuppressant use in the 12 months prior to starting biologic therapy. The AI's answer accurately states this limitation and summarizes the relevant evidence on racial/ethnic groups and baseline disease activity. The answer is well-grounded in the context, does not introduce unsupported facts, and maintains appropriate caution about the cohort limitations. However, because the precise, narrowly defined patient population in the question (no immunosuppressant use in prior 12 months) is not directly addressed by the context, the answer cannot be considered directly supported by the context.",869,4,4,253.0,1012,"Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study; Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus; Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria - PubMed; Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials",https://pubmed.ncbi.nlm.nih.gov/36652052/; https://pubmed.ncbi.nlm.nih.gov/34164944/; https://pubmed.ncbi.nlm.nih.gov/40274305/; https://pubmed.ncbi.nlm.nih.gov/33216191/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 222, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'In patients with systemic lupus erythematosus (SLE) who newly initiated on biologic therapy between Jan-2017 to Dec-2024, what proportion had no immunosuppressant use in the 12 months before starting biologics, and how does this vary across different racial/ethnic groups?', 'role': 'user'}]}",True,200.0,33.588693618774414,,4ce40b2c-4555-44ac-9f26-1514b6300ce8,349.0,Among US patients with SLE initiating belimumab (a biologic) between January 2017 and the study peri...,3.0,T/T/T,3.0,True,True,True,"The context directly provides numbers for patients with and without immunosuppressant use in the 12 months prior to starting belimumab (2,190 non-IS out of 4,723 total), matching the figure (~46.4%) cited by the AI. The context also explicitly states that race/ethnicity-stratified data are not available, which the answer accurately notes. The details presented in the answer are fully supported by the context, and no unsupported information is introduced.",458,2,2,216.0,432,"Clinical Outcomes of Patients with SLE Treated with Belimumab, Without Versus With Prior Immunosuppressant Use: a US Claims Database Study; Improved Health Outcomes in Patients with Systemic Lupus Erythematosus Following Early Belimumab Initiation Without Prior Immunosuppressant Use: A Real-World Descriptive Study",https://pubmed.ncbi.nlm.nih.gov/40528076/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11264657/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 220, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'In patients with systemic lupus erythematosus (SLE) who are newly initiated on biologic therapy (P), what proportion had no immunosuppressant use (O) in the 12 months before starting biologics (T), and how does this vary across different racial/ethnic groups (C) and baseline disease activity levels categorized by SLEDAI score (C)?', 'role': 'user'}]}",True,200.0,37.346370697021484,,401e609a-23c1-4b72-89de-6effb6a43dbd,1082.0,No published study identified reports the proportion of patients with SLE who were newly initiated o...,2.0,F/T/T,2.0,False,True,True,"The provided context does not include any study that directly reports the proportion of SLE patients newly initiated on biologic therapy who had no immunosuppressant use in the 12 months before initiation, nor does it report this stratified by race/ethnicity and SLEDAI score. However, the context is relevant, presenting related data (such as baseline immunosuppressive use by race and predictors of immunomodulatory prescription by childhood-onset and race/ethnicity), but it does not give the precise figures or stratification requested. The AI's answer accurately reflects these limitations, only citing findings that are present in the context and refraining from making unsupported claims. Therefore, the answer is not directly answered by the context, is relevant, and is grounded in the context.",803,3,3,292.6666666666667,878,Immunomodulatory Medication Use in Newly Diagnosed Youth With Systemic Lupus Erythematosus - PMC; Racial Differences in Persistent Glucocorticoid Use Patterns Among Medicaid Beneficiaries with Incident Systemic Lupus Erythematosus - PMC; Association of disease-modifying antirheumatic drug selection with hospitalised infection among youth with childhood-onset systemic lupus erythematosus - PMC,https://pmc.ncbi.nlm.nih.gov/articles/PMC9212072/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9976620/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12458716/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 216, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with non-small cell lung cancer, Intervention: durvalumab, Outcomes: treatment duration', 'role': 'user'}]}",True,200.0,44.2919065952301,,abcbe709-7f14-49ed-b058-0fbf2f2e8db7,386.0,"In pivotal phase 3 PACIFIC, durvalumab was given 10 mg/kg IV every 2 weeks for up to 12 months. [1] ...",3.0,T/T/T,3.0,True,True,True,"The context provides detailed and specific information about durvalumab treatment duration in various studies (PACIFIC, PACIFIC-R, and PACIFIC-6) involving patients with non-small cell lung cancer. The AI's answer accurately summarizes the treatment schedules and durations as described in the context, including references to the different protocols and median durations. There are no unsupported or external claims in the response. All details in the answer are directly grounded in the provided context.",506,3,3,116.66666666666667,350,"Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC; Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study; Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial - PubMed",https://pubmed.ncbi.nlm.nih.gov/31622733/; https://pubmed.ncbi.nlm.nih.gov/36307040/; https://pubmed.ncbi.nlm.nih.gov/35961520/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 224, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'In patients with systemic lupus erythematosus who are newly initiated on Saphnelo or Benlysta, what proportion had no immunosuppressant use in the 12 months before starting biologics, and how does this vary across different racial/ethnic groups (Non-Hispanic White, African American, Hispanic, Asian)?', 'role': 'user'}]}",True,200.0,35.18990111351013,,d9e50fb0-73a6-4d69-8fea-384a845c73b6,69.0,The published literature does not contain an answer to this question.,0.0,F/F/F,1.0,False,False,False,"There is no context provided for the question. Therefore, the AI's answer cannot be grounded in the context, does not address the question directly, and the context itself does not address the question. The answer given by the AI is not supported or derived from any supplied evidence.",285,0,0,0.0,0,,,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 225, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with systemic lupus erythematosus newly initiated on anifrolumab or belimumab, Cohort_1: Non-Hispanic White, Cohort_2: African American, Cohort_3: Hispanic, Cohort_4: Asian, Cohort_5: Others, Outcomes: no immunosuppressant use in the 12 months before starting biologics', 'role': 'user'}]}",True,200.0,39.17890930175781,,9e22141b-b83e-4a6c-9c61-3b2eb8a6453a,817.0,Limitations: available published reports do not provide race-stratified proportions for “no immunosu...,2.0,F/T/T,2.0,False,True,True,"The context does not provide direct, specific evidence or data on race-stratified proportions of patients with systemic lupus erythematosus who had no immunosuppressant use in the 12 months prior to initiation of anifrolumab or belimumab. However, it is relevant to the question because it mentions the studies attempted to stratify or report such information; they just do not include the outcome as requested. The AI's answer accurately conveys these limitations and does not introduce any unsupported claims, relying completely on what is stated in the context. Therefore, the answer is grounded in the provided context and acknowledges the lack of directly relevant data.",675,2,2,205.0,410,Improved Health Outcomes in Patients with Systemic Lupus Erythematosus Following Early Belimumab Initiation Without Prior Immunosuppressant Use: A Real-World Descriptive Study; Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials,https://pmc.ncbi.nlm.nih.gov/articles/PMC11264657/; https://pubmed.ncbi.nlm.nih.gov/38288923/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 223, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'In patients with systemic lupus erythematosus who are newly initiated on biologic therapy (Saphnelo or Benlysta), what proportion had no immunosuppressant use in the 12 months before starting biologics, and how does this vary across different racial/ethnic groups (Non-Hispanic White, African American, Hispanic, Asian)?', 'role': 'user'}]}",True,200.0,58.40467166900635,,a7d15cb4-d177-4fdd-9e2f-787ac1f33508,870.0,Limitations: the located studies do not report the proportion with no immunosuppressant in the 12 mo...,2.0,F/T/T,2.0,False,True,True,"The provided context does not supply the specific proportion of systemic lupus erythematosus patients with no immunosuppressant use in the 12 months before starting biologics (Saphnelo or Benlysta), nor does it show how this varies by racial/ethnic group. The Komodo Health study provides a proportion (35.8%) over a 24-month period, not 12 months, and the OBSErve study gives a non-race-stratified percentage for 'no immunosuppressant at baseline'. The context is relevant in that it reports related but not precisely matching data, and the AI's answer correctly reflects these gaps, staying grounded in the provided sources and not introducing external information.",667,2,2,207.5,415,Improved Health Outcomes in Patients with Systemic Lupus Erythematosus Following Early Belimumab Initiation Without Prior Immunosuppressant Use: A Real-World Descriptive Study; Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study,https://pmc.ncbi.nlm.nih.gov/articles/PMC11264657/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9716789/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
2025-10-29 14:54:30,"{'organization_id': 1093, 'qidx': 226, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Number of patients who were on Osimertinib treatment by year-quarter from Jan 1, 2023:\n 1) FLAURA: Osi mono in 1L among metastatic NSCLC\n 2) FLAURA2: Osi combo in 1L among metastatic NSCLC\n 3) ADAURA: Adjuvant Osi among early stage resectable NSCLC', 'role': 'user'}]}",True,200.0,48.130857706069946,,7dae15dc-cbeb-4ce0-8cd8-dc3529fcb2e2,525.0,The published literature does not report per-calendar-quarter counts of patients actively receiving ...,2.0,F/T/T,2.0,False,True,True,"The context provides the total number of patients randomized in each of the three respective trials (FLAURA, FLAURA2, ADAURA), but does not provide per-year or per-quarter breakdowns, nor the number of patients actively on osimertinib treatment at specific times (such as since Jan 1, 2023). The AI's answer accurately reflects this, noting the limitations in the available data and giving the total randomization numbers directly from the context. However, because no per-quarter data is provided or inferred, the context does not directly answer the question, though it is relevant. The AI's answer remains well-grounded in the context and does not introduce unsupported or external information.",697,3,3,140.66666666666666,422,Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer; Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC; Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial,https://pubmed.ncbi.nlm.nih.gov/31439584/; https://pubmed.ncbi.nlm.nih.gov/41104938/; https://pubmed.ncbi.nlm.nih.gov/36720083/,gpt-5-mini-lowreasoning,gpt-4.1,Astrazeneca BBU
